Abcam Plc000380204US000380204007/12/2023THAT Peter Allen be removed from office as a director of the Company with immediate effect.DIRECTOR ELECTIONSSECURITY HOLDER0.0000000S000002106Abcam Plc000380204US000380204007/12/2023THAT Michael S. Baldock be removed from office as a director of the Company with immediate effect.DIRECTOR ELECTIONSSECURITY HOLDER0.0000000S000002106Abcam Plc000380204US000380204007/12/2023THAT Sally W. Crawford be removed from office as a director of the Company with immediate effect.DIRECTOR ELECTIONSSECURITY HOLDER0.0000000S000002106Abcam Plc000380204US000380204007/12/2023THAT in the event any director of the Company is appointed after the Company's receipt of the general meeting request dated May 30, 2023 and prior to this meeting, each such director be removed from office as a director of the Company with immediate effect.DIRECTOR ELECTIONSSECURITY HOLDER0.0000000S000002106Abcam Plc000380204US000380204007/12/2023THAT Dr. Jonathan Milner, having consented to act, be appointed as Director of the Company with immediate effect.DIRECTOR ELECTIONSSECURITY HOLDER0.0000000S000002106Abcam Plc000380204US000380204007/12/2023THAT Dr. Jonathan Milner, having been appointed a Director of the Company, be further appointed to the position of Executive Chairman of the Company with immediate effect.CORPORATE GOVERNANCESECURITY HOLDER0.0000000S000002106Abcam Plc000380204US000380204007/12/2023THAT it is the consensus of the shareholders that, promptly after the conclusion of this meeting, the Board of Directors shall conduct a thorough search for candidates and shall appoint at least two additional, independent, highly qualified Directors to the Board whose qualifications will include significant capital allocation and biotechnology company operating experience.CORPORATE GOVERNANCESECURITY HOLDER0.0000000S000002106Abcam Plc000380204US000380204007/12/2023THAT the expenses incurred by Dr. Milner and those acting on his behalf in connection with his engagement with the Company in respect of the request to convene a general meeting be reimbursed by the Company.CORPORATE GOVERNANCESECURITY HOLDER0.0000000S000002106Abcam Plc000380204US000380204007/12/2023That Peter Allen be removed from office as a director of the Company with immediate effect.DIRECTOR ELECTIONSSECURITY HOLDER0.0000000S000002106Abcam Plc000380204US000380204007/12/2023That Michael S. Baldock be removed from office as a director of the Company with immediate effect.DIRECTOR ELECTIONSSECURITY HOLDER0.0000000S000002106Abcam Plc000380204US000380204007/12/2023That Sally W. Crawford be removed from office as a director of the Company with immediate effect.DIRECTOR ELECTIONSSECURITY HOLDER0.0000000S000002106Abcam Plc000380204US000380204007/12/2023That in the event any director of the Company is appointed after the Company's receipt of the general meeting request dated May 30, 2023 and prior to this meeting, each such director be removed from office as a director of the Company with immediate effect.DIRECTOR ELECTIONSSECURITY HOLDER0.0000000S000002106Abcam Plc000380204US000380204007/12/2023That Dr. Jonathan Milner, having consented to act, be appointed as a Director of the Company with immediate effect.DIRECTOR ELECTIONSSECURITY HOLDER0.0000000S000002106Abcam Plc000380204US000380204007/12/2023That Dr. Jonathan Milner, having been appointed a Director of the Company, be further appointed to the position of Executive Chairman of the Company with immediate effect.CORPORATE GOVERNANCESECURITY HOLDER0.0000000S000002106Abcam Plc000380204US000380204007/12/2023That it is the consensus of the shareholders that, promptly after the conclusion of this meeting, the Board of Directors shall conduct a thorough search for candidates and shall appoint at least two additional, independent, highly qualified Directors to the Board whose qualifications will include significant capital allocation and biotechnology company operating experience.CORPORATE GOVERNANCESECURITY HOLDER0.0000000S000002106Abcam Plc000380204US000380204007/12/2023That the expenses incurred by Dr. Milner and those acting on his behalf in connection with his engagement with the Company in respect of the request to convene a general meeting be reimbursed by the Company.CORPORATE GOVERNANCESECURITY HOLDER0.0000000S000002106Booz Allen Hamilton Holding Corporation099502106US099502106207/26/2023Election of Directors: Ralph W. ShraderDIRECTOR ELECTIONSISSUER5183972.0000000FOR5183972.000000FORS000002106Booz Allen Hamilton Holding Corporation099502106US099502106207/26/2023Election of Directors: Horacio D. RozanskiDIRECTOR ELECTIONSISSUER5183972.0000000FOR5183972.000000FORS000002106Booz Allen Hamilton Holding Corporation099502106US099502106207/26/2023Election of Directors: Joan Lordi C. AmbleDIRECTOR ELECTIONSISSUER5183972.0000000FOR5183972.000000FORS000002106Booz Allen Hamilton Holding Corporation099502106US099502106207/26/2023Election of Directors: Melody C. BarnesDIRECTOR ELECTIONSISSUER5183972.0000000FOR5183972.000000FORS000002106Booz Allen Hamilton Holding Corporation099502106US099502106207/26/2023Election of Directors: Michele A. FlournoyDIRECTOR ELECTIONSISSUER5183972.0000000FOR5183972.000000FORS000002106Booz Allen Hamilton Holding Corporation099502106US099502106207/26/2023Election of Directors: Mark GaumondDIRECTOR ELECTIONSISSUER5183972.0000000FOR5183972.000000FORS000002106Booz Allen Hamilton Holding Corporation099502106US099502106207/26/2023Election of Directors: Ellen JewettDIRECTOR ELECTIONSISSUER5183972.0000000FOR5183972.000000FORS000002106Booz Allen Hamilton Holding Corporation099502106US099502106207/26/2023Election of Directors: Arthur E. JohnsonDIRECTOR ELECTIONSISSUER5183972.0000000FOR5183972.000000FORS000002106Booz Allen Hamilton Holding Corporation099502106US099502106207/26/2023Election of Directors: Gretchen W. McClainDIRECTOR ELECTIONSISSUER5183972.0000000FOR5183972.000000FORS000002106Booz Allen Hamilton Holding Corporation099502106US099502106207/26/2023Election of Directors: Rory P. ReadDIRECTOR ELECTIONSISSUER5183972.0000000FOR5183972.000000FORS000002106Booz Allen Hamilton Holding Corporation099502106US099502106207/26/2023Election of Directors: Charles O. RossottiDIRECTOR ELECTIONSISSUER5183972.0000000FOR5183972.000000FORS000002106Booz Allen Hamilton Holding Corporation099502106US099502106207/26/2023Ratification of the appointment of Ernst & Young LLP as the Company's registered independent public accountants for fiscal year 2024.AUDIT-RELATEDISSUER5183972.0000000FOR5183972.000000FORS000002106Booz Allen Hamilton Holding Corporation099502106US099502106207/26/2023Advisory vote to approve the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER5183972.0000000FOR5183972.000000FORS000002106Booz Allen Hamilton Holding Corporation099502106US099502106207/26/2023Advisory vote on the frequency of future advisory votes on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER5183972.0000000ONE YEAR5183972.000000FORS000002106Booz Allen Hamilton Holding Corporation099502106US099502106207/26/2023Approval of the adoption of the Seventh Amended and Restated Certificate of Incorporation to, among other things, limit the liability of certain officers of the Company as permitted by recent amendments to Delaware law.CORPORATE GOVERNANCEISSUER5183972.0000000FOR5183972.000000FORS000002106Booz Allen Hamilton Holding Corporation099502106US099502106207/26/2023Approval of the 2023 Equity Incentive Plan.COMPENSATIONISSUER5183972.0000000FOR5183972.000000FORS000002106monday.com Ltd.M7S64H106IL001176213007/31/2023Reelect Eran Zinman as DirectorDIRECTOR ELECTIONSISSUER2193038.0000000FOR2193038.000000FORS000002106monday.com Ltd.M7S64H106IL001176213007/31/2023Reelect Aviad Eyal as DirectorDIRECTOR ELECTIONSISSUER2193038.0000000FOR2193038.000000FORS000002106monday.com Ltd.M7S64H106IL001176213007/31/2023Reappoint Brightman, Almagor and Zohar as Auditors and Authorize Board to Fix Their RemunerationAUDIT-RELATEDISSUER2193038.0000000FOR2193038.000000FORS000002106Dynatrace, Inc.268150109US268150109208/23/2023Election of Class I Directors Nominees: Rick McConnellDIRECTOR ELECTIONSISSUER1150067.0000000FOR1150067.000000FORS000002106Dynatrace, Inc.268150109US268150109208/23/2023Election of Class I Directors Nominees: Michael CaponeDIRECTOR ELECTIONSISSUER1150067.0000000FOR1150067.000000FORS000002106Dynatrace, Inc.268150109US268150109208/23/2023Election of Class I Directors Nominees: Stephen LifshatzDIRECTOR ELECTIONSISSUER1150067.0000000FOR1150067.000000FORS000002106Dynatrace, Inc.268150109US268150109208/23/2023Ratify the appointment of Ernst & Young LLP as Dynatrace's independent registered public accounting firm for the year ending March 31, 2024.AUDIT-RELATEDISSUER1150067.0000000FOR1150067.000000FORS000002106Dynatrace, Inc.268150109US268150109208/23/2023Non-binding, advisory vote on the compensation of Dynatrace's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1150067.0000000FOR1150067.000000FORS000002106e.l.f. Beauty, Inc.26856L103US26856L103508/24/2023To elect three Class I directors to serve a three-year term expiring at our 2026 annual meeting of stockholders: Kenny MitchellDIRECTOR ELECTIONSISSUER553685.0000000FOR553685.000000FORS000002106e.l.f. Beauty, Inc.26856L103US26856L103508/24/2023To elect three Class I directors to serve a three-year term expiring at our 2026 annual meeting of stockholders: Gayle TaitDIRECTOR ELECTIONSISSUER553685.0000000FOR553685.000000FORS000002106e.l.f. Beauty, Inc.26856L103US26856L103508/24/2023To elect three Class I directors to serve a three-year term expiring at our 2026 annual meeting of stockholders: Maureen WatsonDIRECTOR ELECTIONSISSUER553685.0000000FOR553685.000000FORS000002106e.l.f. Beauty, Inc.26856L103US26856L103508/24/2023To approve, on an advisory basis, the compensation paid to the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER553685.0000000FOR553685.000000FORS000002106e.l.f. Beauty, Inc.26856L103US26856L103508/24/2023To ratify the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending March 31, 2024.AUDIT-RELATEDISSUER553685.0000000FOR553685.000000FORS000002106Replimune Group, Inc.76029N106US76029N106309/06/2023Election of Directors: Paolo PucciDIRECTOR ELECTIONSISSUER2444994.0000000FOR2444994.000000FORS000002106Replimune Group, Inc.76029N106US76029N106309/06/2023Election of Directors: Veleka Peeples-DyerDIRECTOR ELECTIONSISSUER2444994.0000000FOR2444994.000000FORS000002106Replimune Group, Inc.76029N106US76029N106309/06/2023To ratify the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for Replimune Group, Inc. for the fiscal year ending March 31, 2024.AUDIT-RELATEDISSUER2444994.0000000FOR2444994.000000FORS000002106RBC Bearings Incorporated75524B104US75524B104409/07/2023Election of two directors in Class III to serve a term of three years: Dr. Michael J. HartnettDIRECTOR ELECTIONSISSUER1322394.0000000FOR1322394.000000FORS000002106RBC Bearings Incorporated75524B104US75524B104409/07/2023Election of two directors in Class III to serve a term of three years: Dolores J. EnnicoDIRECTOR ELECTIONSISSUER1322394.0000000AGAINST1322394.000000AGAINSTS000002106RBC Bearings Incorporated75524B104US75524B104409/07/2023To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for fiscal year 2024.AUDIT-RELATEDISSUER1322394.0000000FOR1322394.000000FORS000002106RBC Bearings Incorporated75524B104US75524B104409/07/2023To vote, on a non-binding advisory basis, regarding the frequency of the stockholder advisory vote on named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1322394.0000000ONE YEAR1322394.000000FORS000002106RBC Bearings Incorporated75524B104US75524B104409/07/2023To consider a resolution regarding the stockholder advisory vote on named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1322394.0000000FOR1322394.000000FORS000002106Legend Biotech Corporation52490G102US52490G102209/21/2023To receive the audited consolidated financial statements of the Company for the fiscal year ended December 31, 2022.CORPORATE GOVERNANCEISSUER391230.0000000FOR391230.000000FORS000002106Legend Biotech Corporation52490G102US52490G102209/21/2023To ratify the appointment of Ernst & Young LLP as independent auditor of the Company (the "Independent Auditor") for the fiscal year ending December 31, 2023.AUDIT-RELATEDISSUER391230.0000000FOR391230.000000FORS000002106Legend Biotech Corporation52490G102US52490G102209/21/2023To re-elect Dr. Li Zhu, whose term of office will expire pursuant to article 88(b) of the Company's memorandum of association, to serve as a Class III director of the Company for a full term of three (3) years.DIRECTOR ELECTIONSISSUER391230.0000000FOR391230.000000FORS000002106Legend Biotech Corporation52490G102US52490G102209/21/2023To re-elect Dr. Corazon D. Sanders, whose term of office will expire pursuant to article 88(b) of the Company's memorandum of association, to serve as a Class III director of the Company for a full term of three (3) years.DIRECTOR ELECTIONSISSUER391230.0000000FOR391230.000000FORS000002106Legend Biotech Corporation52490G102US52490G102209/21/2023To re-elect Dr. Li Mao, whose term of office will expire pursuant to article 88(b) of the Company's memorandum of association, to serve as a Class III director of the Company for a full term of three (3) years.DIRECTOR ELECTIONSISSUER391230.0000000FOR391230.000000FORS000002106Legend Biotech Corporation52490G102US52490G102209/21/2023To authorize each of the directors and officers of the Company to take any and every action that might be necessary to effect the foregoing resolutions as such director or officer, in his or her absolute discretion, thinks fit.CORPORATE GOVERNANCEISSUER391230.0000000FOR391230.000000FORS000002106Bio-Techne Corporation09073M104US09073M104510/26/2023To set the number of Directors at nine.CORPORATE GOVERNANCEISSUER2156005.0000000FOR2156005.000000FORS000002106Bio-Techne Corporation09073M104US09073M104510/26/2023Election of Directors: Robert V. BaumgartnerDIRECTOR ELECTIONSISSUER2156005.0000000FOR2156005.000000FORS000002106Bio-Techne Corporation09073M104US09073M104510/26/2023Election of Directors: Julie L. BushmanDIRECTOR ELECTIONSISSUER2156005.0000000FOR2156005.000000FORS000002106Bio-Techne Corporation09073M104US09073M104510/26/2023Election of Directors: John L. HigginsDIRECTOR ELECTIONSISSUER2156005.0000000FOR2156005.000000FORS000002106Bio-Techne Corporation09073M104US09073M104510/26/2023Election of Directors: Joseph D. KeeganDIRECTOR ELECTIONSISSUER2156005.0000000FOR2156005.000000FORS000002106Bio-Techne Corporation09073M104US09073M104510/26/2023Election of Directors: Charles R. KummethDIRECTOR ELECTIONSISSUER2156005.0000000FOR2156005.000000FORS000002106Bio-Techne Corporation09073M104US09073M104510/26/2023Election of Directors: Roeland NusseDIRECTOR ELECTIONSISSUER2156005.0000000FOR2156005.000000FORS000002106Bio-Techne Corporation09073M104US09073M104510/26/2023Election of Directors: Alpna SethDIRECTOR ELECTIONSISSUER2156005.0000000FOR2156005.000000FORS000002106Bio-Techne Corporation09073M104US09073M104510/26/2023Election of Directors: Randolph SteerDIRECTOR ELECTIONSISSUER2156005.0000000FOR2156005.000000FORS000002106Bio-Techne Corporation09073M104US09073M104510/26/2023Election of Directors: Rupert VesseyDIRECTOR ELECTIONSISSUER2156005.0000000FOR2156005.000000FORS000002106Bio-Techne Corporation09073M104US09073M104510/26/2023Approve, on an advisory basis, the compensation of our executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER2156005.0000000FOR2156005.000000FORS000002106Bio-Techne Corporation09073M104US09073M104510/26/2023Approve, on an advisory bass, the frequency of advisory votes on executive compensation to occur every (1) year.SECTION 14A SAY-ON-PAY VOTESISSUER2156005.0000000ONE YEAR2156005.000000FORS000002106Bio-Techne Corporation09073M104US09073M104510/26/2023Ratify the appointment of KPMG, LLP as the Company's independent registered public accounting firm for the 2024 fiscal year.AUDIT-RELATEDISSUER2156005.0000000FOR2156005.000000FORS000002106Revolution Medicines, Inc.76155X100US76155X100011/08/2023To approve the issuance of shares of Revolution Medicines common stock (including securities convertible into or exercisable for shares of Revolution Medicines common stock) to certain equityholders of EQRX, Inc., which is referred to as EQRX, pursuant to the Agreement and Plan of Merger, dated as of July 31, 2023 (as it may be amended from time to time), by and among Revolution Medicines, Equinox Merger Sub I, Inc., Equinox Merger Sub II LLC, and EQRX, which proposal is referred to as the Revolution Medicines share issuance proposal; andEXTRAORDINARY TRANSACTIONSISSUER1734294.0000000FOR1734294.000000FORS000002106Revolution Medicines, Inc.76155X100US76155X100011/08/2023To approve the adjournment of the Revolution Medicines special meeting, to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are not sufficient votes at the time of the Revolution Medicines special meeting to approve the Revolution Medicines share issuance proposal.CORPORATE GOVERNANCEISSUER1734294.0000000AGAINST1734294.000000AGAINSTS000002106Paylocity Holding Corporation70438V106US70438V106111/30/2023Election of Directors: Steven R. BeauchampDIRECTOR ELECTIONSISSUER4166762.0000000FOR4166762.000000FORS000002106Paylocity Holding Corporation70438V106US70438V106111/30/2023Election of Directors: Linda M. BreardDIRECTOR ELECTIONSISSUER4166762.0000000FOR4166762.000000FORS000002106Paylocity Holding Corporation70438V106US70438V106111/30/2023Election of Directors: Virginia G. BreenDIRECTOR ELECTIONSISSUER4166762.0000000FOR4166762.000000FORS000002106Paylocity Holding Corporation70438V106US70438V106111/30/2023Election of Directors: Jeffrey T. DiehlDIRECTOR ELECTIONSISSUER4166762.0000000FOR4166762.000000FORS000002106Paylocity Holding Corporation70438V106US70438V106111/30/2023Election of Directors: Robin L. PedersonDIRECTOR ELECTIONSISSUER4166762.0000000FOR4166762.000000FORS000002106Paylocity Holding Corporation70438V106US70438V106111/30/2023Election of Directors: Andres D. ReinerDIRECTOR ELECTIONSISSUER4166762.0000000FOR4166762.000000FORS000002106Paylocity Holding Corporation70438V106US70438V106111/30/2023Election of Directors: Kenneth B. RobinsonDIRECTOR ELECTIONSISSUER4166762.0000000FOR4166762.000000FORS000002106Paylocity Holding Corporation70438V106US70438V106111/30/2023Election of Directors: Steven I. SarowitzDIRECTOR ELECTIONSISSUER4166762.0000000FOR4166762.000000FORS000002106Paylocity Holding Corporation70438V106US70438V106111/30/2023Election of Directors: Ronald V. Waters IIIDIRECTOR ELECTIONSISSUER4166762.0000000FOR4166762.000000FORS000002106Paylocity Holding Corporation70438V106US70438V106111/30/2023Election of Directors: Toby J. WilliamsDIRECTOR ELECTIONSISSUER4166762.0000000FOR4166762.000000FORS000002106Paylocity Holding Corporation70438V106US70438V106111/30/2023Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending June 30, 2024.AUDIT-RELATEDISSUER4166762.0000000FOR4166762.000000FORS000002106Paylocity Holding Corporation70438V106US70438V106111/30/2023Advisory vote to approve the compensation of named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER4166762.0000000FOR4166762.000000FORS000002106Paylocity Holding Corporation70438V106US70438V106111/30/2023Approval of the 2023 Equity Incentive Plan.COMPENSATIONISSUER4166762.0000000FOR4166762.000000FORS000002106Paylocity Holding Corporation70438V106US70438V106111/30/2023Approval of an amendment to Article VI of the Second Amended and Restated Certificate of Incorporation to allow for the removal of directors with or without cause.CORPORATE GOVERNANCEISSUER4166762.0000000FOR4166762.000000FORS000002106Atlassian Corporation049468101US049468101012/06/2023Election of Directors: Shona L. BrownDIRECTOR ELECTIONSISSUER2428630.0000000FOR2428630.000000FORS000002106Atlassian Corporation049468101US049468101012/06/2023Election of Directors: Michael Cannon-BrookesDIRECTOR ELECTIONSISSUER2428630.0000000FOR2428630.000000FORS000002106Atlassian Corporation049468101US049468101012/06/2023Election of Directors: Scott FarquharDIRECTOR ELECTIONSISSUER2428630.0000000FOR2428630.000000FORS000002106Atlassian Corporation049468101US049468101012/06/2023Election of Directors: Heather M. FernandezDIRECTOR ELECTIONSISSUER2428630.0000000FOR2428630.000000FORS000002106Atlassian Corporation049468101US049468101012/06/2023Election of Directors: Sasan GoodarziDIRECTOR ELECTIONSISSUER2428630.0000000FOR2428630.000000FORS000002106Atlassian Corporation049468101US049468101012/06/2023Election of Directors: Jay ParikhDIRECTOR ELECTIONSISSUER2428630.0000000FOR2428630.000000FORS000002106Atlassian Corporation049468101US049468101012/06/2023Election of Directors: Enrique SalemDIRECTOR ELECTIONSISSUER2428630.0000000FOR2428630.000000FORS000002106Atlassian Corporation049468101US049468101012/06/2023Election of Directors: Steven SordelloDIRECTOR ELECTIONSISSUER2428630.0000000FOR2428630.000000FORS000002106Atlassian Corporation049468101US049468101012/06/2023Election of Directors: Richard P. WongDIRECTOR ELECTIONSISSUER2428630.0000000FOR2428630.000000FORS000002106Atlassian Corporation049468101US049468101012/06/2023Election of Directors: Michelle ZatlynDIRECTOR ELECTIONSISSUER2428630.0000000FOR2428630.000000FORS000002106Atlassian Corporation049468101US049468101012/06/2023Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2024.AUDIT-RELATEDISSUER2428630.0000000FOR2428630.000000FORS000002106Atlassian Corporation049468101US049468101012/06/2023An advisory vote to approve the fiscal year 2023 compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER2428630.0000000FOR2428630.000000FORS000002106Atlassian Corporation049468101US049468101012/06/2023An advisory vote on the frequency of holding future advisory votes to approve compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER2428630.0000000ONE YEAR2428630.000000FORS000002106Bill Holdings, Inc.090043100US090043100012/07/2023To elect the directors listed below: Rene LacerteDIRECTOR ELECTIONSISSUER6511990.0000000WITHHOLD11070.383000AGAINSTFOR6500919.617000FORS000002106Bill Holdings, Inc.090043100US090043100012/07/2023To elect the directors listed below: Peter KightDIRECTOR ELECTIONSISSUER6511990.0000000WITHHOLD308017.127000AGAINSTFOR6203972.873000FORS000002106Bill Holdings, Inc.090043100US090043100012/07/2023To elect the directors listed below: Tina ReichDIRECTOR ELECTIONSISSUER6511990.0000000WITHHOLD3907.194000AGAINSTFOR6508082.806000FORS000002106Bill Holdings, Inc.090043100US090043100012/07/2023To elect the directors listed below: Scott WagnerDIRECTOR ELECTIONSISSUER6511990.0000000WITHHOLD84655.870000AGAINSTFOR6427334.130000FORS000002106Bill Holdings, Inc.090043100US090043100012/07/2023To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent Registered Public Accounting Firm for the Fiscal Year Ending June 30, 2024.AUDIT-RELATEDISSUER6511990.0000000ABSTAIN651.199000AGAINSTAGAINST651.199000AGAINSTFOR6510687.602000FORS000002106Bill Holdings, Inc.090043100US090043100012/07/2023To approve, on an advisory basis, the compensation of our Named Executive Officers (Say-on-Pay).SECTION 14A SAY-ON-PAY VOTESISSUER6511990.0000000ABSTAIN9116.786000AGAINSTAGAINST122425.412000AGAINSTFOR6380447.802000FORS000002106Endava Plc29260V105US29260V105212/13/2023Accept Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER5248401.0000000FOR5248401.000000FORS000002106Endava Plc29260V105US29260V105212/13/2023Approve Remuneration ReportCOMPENSATIONISSUER5248401.0000000AGAINST5248401.000000AGAINSTS000002106Endava Plc29260V105US29260V105212/13/2023Appoint PricewaterhouseCoopers LLP as AuditorsAUDIT-RELATEDISSUER5248401.0000000FOR5248401.000000FORS000002106Endava Plc29260V105US29260V105212/13/2023Authorise Board to Fix Remuneration of AuditorsAUDIT-RELATEDISSUER5248401.0000000FOR5248401.000000FORS000002106Endava Plc29260V105US29260V105212/13/2023Elect John Cotterell as DirectorDIRECTOR ELECTIONSISSUER5248401.0000000FOR5248401.000000FORS000002106Endava Plc29260V105US29260V105212/13/2023Elect Mark Thurston as DirectorDIRECTOR ELECTIONSISSUER5248401.0000000FOR5248401.000000FORS000002106Endava Plc29260V105US29260V105212/13/2023Elect Patrick Butcher as DirectorDIRECTOR ELECTIONSISSUER5248401.0000000FOR5248401.000000FORS000002106Endava Plc29260V105US29260V105212/13/2023Elect Sulina Connal as DirectorDIRECTOR ELECTIONSISSUER5248401.0000000FOR5248401.000000FORS000002106Endava Plc29260V105US29260V105212/13/2023Elect Ben Druskin as DirectorDIRECTOR ELECTIONSISSUER5248401.0000000FOR5248401.000000FORS000002106Endava Plc29260V105US29260V105212/13/2023Elect Kathryn Hollister as DirectorDIRECTOR ELECTIONSISSUER5248401.0000000FOR5248401.000000FORS000002106Endava Plc29260V105US29260V105212/13/2023Elect David Pattillo as DirectorDIRECTOR ELECTIONSISSUER5248401.0000000FOR5248401.000000FORS000002106Endava Plc29260V105US29260V105212/13/2023Elect Trevor Smith as DirectorDIRECTOR ELECTIONSISSUER5248401.0000000FOR5248401.000000FORS000002106MACOM Technology Solutions Holdings, Inc.55405Y100US55405Y100103/07/2024Approve an amendment to the Company's Fifth Amended and Restated Certificate of incorporation to declassify our board of directors and phase-in annual director elections.SHAREHOLDER RIGHTS AND DEFENSESISSUER884905.0000000FOR884905.000000FORS000002106MACOM Technology Solutions Holdings, Inc.55405Y100US55405Y100103/07/2024The election of three directors nominated by our board of directors and named in the accompanying proxy materials to serve until either the 2025 annual meeting of stockholders (if Proposal 1 e adopted) or the 2027 annual meeting of stockholders (if Proposal 1 is not adopted): John RitchieDIRECTOR ELECTIONSISSUER884905.0000000FOR884905.000000FORS000002106MACOM Technology Solutions Holdings, Inc.55405Y100US55405Y100103/07/2024The election of three directors nominated by our board of directors and named in the accompanying proxy materials to serve until either the 2025 annual meeting of stockholders (if Proposal 1 e adopted) or the 2027 annual meeting of stockholders (if Proposal 1 is not adopted): Jihye Whang RosenbandDIRECTOR ELECTIONSISSUER884905.0000000FOR884905.000000FORS000002106MACOM Technology Solutions Holdings, Inc.55405Y100US55405Y100103/07/2024The election of three directors nominated by our board of directors and named in the accompanying proxy materials to serve until either the 2025 annual meeting of stockholders (if Proposal 1 e adopted) or the 2027 annual meeting of stockholders (if Proposal 1 is not adopted): Murugesan "Raj" ShanmugarajDIRECTOR ELECTIONSISSUER884905.0000000FOR884905.000000FORS000002106MACOM Technology Solutions Holdings, Inc.55405Y100US55405Y100103/07/2024Advisory vote to approve the compensation paid to the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER884905.0000000FOR884905.000000FORS000002106MACOM Technology Solutions Holdings, Inc.55405Y100US55405Y100103/07/2024Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending September 27, 2024.AUDIT-RELATEDISSUER884905.0000000FOR884905.000000FORS000002106The Toro Company891092108US891092108403/19/2024Election of Directors: Gary L. EllisDIRECTOR ELECTIONSISSUER3717765.0000000WITHHOLD3717765.000000AGAINSTS000002106The Toro Company891092108US891092108403/19/2024Election of Directors: Jill M. PembertonDIRECTOR ELECTIONSISSUER3717765.0000000WITHHOLD3717765.000000AGAINSTS000002106The Toro Company891092108US891092108403/19/2024Ratification of the selection of KPMG LLP as our independent registered public accounting firm for our fiscal year ending October 31, 2024.AUDIT-RELATEDISSUER3717765.0000000FOR3717765.000000FORS000002106The Toro Company891092108US891092108403/19/2024Approval of, on an advisory basis, our executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER3717765.0000000FOR3717765.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/26/2024Approve Financial Statements and Discharge DirectorsCAPITAL STRUCTURECORPORATE GOVERNANCEISSUER260528.0000000FOR260528.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/26/2024Approve Consolidated Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER260528.0000000FOR260528.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/26/2024Approve Allocation of Income and Dividends of EUR 0.69 per ShareCAPITAL STRUCTUREISSUER260528.0000000FOR260528.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/26/2024Approve Remuneration Policy of Directors; Approve Remuneration of Directors in the Aggregate Amount of EUR 600,000COMPENSATIONISSUER260528.0000000FOR260528.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/26/2024Approve Compensation Report of Corporate OfficersCOMPENSATIONISSUER260528.0000000FOR260528.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/26/2024Approve Compensation of Joachim Kreuzburg, Chairman and CEO from January 1, 2023 to March 27, 2023COMPENSATIONISSUER260528.0000000FOR260528.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/26/2024Approve Compensation of Rene Faber, Vice-CEO from January 1, 2023 to March 27, 2023COMPENSATIONISSUER260528.0000000FOR260528.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/26/2024Approve Compensation of Joachim Kreuzburg, Chairman of the Board from March 28, 2023 to December 31, 2023COMPENSATIONISSUER260528.0000000FOR260528.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/26/2024Approve Compensation of Rene Faber, CEO from March 28, 2023 to December 31, 2023COMPENSATIONISSUER260528.0000000FOR260528.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/26/2024Approve Remuneration Policy of Chairman of the BoardCOMPENSATIONISSUER260528.0000000FOR260528.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/26/2024Approve Remuneration Policy of CEOCOMPENSATIONISSUER260528.0000000FOR260528.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/26/2024Reelect Susan Dexter as DirectorDIRECTOR ELECTIONSISSUER260528.0000000FOR260528.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/26/2024Reelect Anne-Marie Graffin as DirectorDIRECTOR ELECTIONSISSUER260528.0000000FOR260528.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/26/2024Appoint PricewaterhouseCoopers Audit as AuditorAUDIT-RELATEDISSUER260528.0000000FOR260528.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/26/2024Appoint PricewaterhouseCoopers Audit as Sustainability AuditorAUDIT-RELATEDISSUER260528.0000000FOR260528.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/26/2024Authorize Repurchase of Up to 10 Percent of Issued Share CapitalCAPITAL STRUCTUREISSUER260528.0000000FOR260528.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/26/2024Amend Articles 17 and 22 of Bylaws Re: General MeetingsCORPORATE GOVERNANCEISSUER260528.0000000FOR260528.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/26/2024Authorize Issuance of Equity or Equity-Linked Securities with Preemptive Rights up to Aggregate Nominal Amount of EUR 6 MillionCAPITAL STRUCTUREISSUER260528.0000000FOR260528.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/26/2024Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 6 MillionCAPITAL STRUCTUREISSUER260528.0000000AGAINST260528.000000AGAINSTS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/26/2024Approve Issuance of Equity or Equity-Linked Securities Reserved for Qualified Investors, up to Aggregate Nominal Amount of EUR 6 MillionCAPITAL STRUCTUREISSUER260528.0000000AGAINST260528.000000AGAINSTS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/26/2024Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Under Items 18 to 19CAPITAL STRUCTUREISSUER260528.0000000AGAINST260528.000000AGAINSTS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/26/2024Authorize Capital Increase of up to 10 Percent of Issued Capital for Contributions in KindCAPITAL STRUCTUREISSUER260528.0000000FOR260528.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/26/2024Authorize Capitalization of Reserves of Up to EUR 6 Million for Bonus Issue or Increase in Par ValueCAPITAL STRUCTUREISSUER260528.0000000FOR260528.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/26/2024Authorize Capital Issuances for Use in Employee Stock Purchase PlansCOMPENSATIONISSUER260528.0000000AGAINST260528.000000AGAINSTS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/26/2024Authorize up to 2 Percent of Issued Capital for Use in Restricted Stock PlansCOMPENSATIONISSUER260528.0000000FOR260528.000000FORS000002106Sartorius Stedim Biotech SAF8005V210FR001315400203/26/2024Authorize Decrease in Share Capital via Cancellation of Repurchased SharesCAPITAL STRUCTUREISSUER260528.0000000FOR260528.000000FORS000002106West Pharmaceutical Services, Inc.955306105US955306105504/23/2024Election of Directors: Mark A. ButhmanDIRECTOR ELECTIONSISSUER1036787.0000000FOR1036787.000000FORS000002106West Pharmaceutical Services, Inc.955306105US955306105504/23/2024Election of Directors: William F. FeeheryDIRECTOR ELECTIONSISSUER1036787.0000000FOR1036787.000000FORS000002106West Pharmaceutical Services, Inc.955306105US955306105504/23/2024Election of Directors: Robert F. FrielDIRECTOR ELECTIONSISSUER1036787.0000000FOR1036787.000000FORS000002106West Pharmaceutical Services, Inc.955306105US955306105504/23/2024Election of Directors: Eric M. GreenDIRECTOR ELECTIONSISSUER1036787.0000000FOR1036787.000000FORS000002106West Pharmaceutical Services, Inc.955306105US955306105504/23/2024Election of Directors: Thomas W. HofmannDIRECTOR ELECTIONSISSUER1036787.0000000FOR1036787.000000FORS000002106West Pharmaceutical Services, Inc.955306105US955306105504/23/2024Election of Directors: Molly E. JosephDIRECTOR ELECTIONSISSUER1036787.0000000FOR1036787.000000FORS000002106West Pharmaceutical Services, Inc.955306105US955306105504/23/2024Election of Directors: Deborah L. V. KellerDIRECTOR ELECTIONSISSUER1036787.0000000FOR1036787.000000FORS000002106West Pharmaceutical Services, Inc.955306105US955306105504/23/2024Election of Directors: Myla P. Lai-GoldmanDIRECTOR ELECTIONSISSUER1036787.0000000FOR1036787.000000FORS000002106West Pharmaceutical Services, Inc.955306105US955306105504/23/2024Election of Directors: Stephen H. LockhartDIRECTOR ELECTIONSISSUER1036787.0000000FOR1036787.000000FORS000002106West Pharmaceutical Services, Inc.955306105US955306105504/23/2024Election of Directors: Douglas A. MichelsDIRECTOR ELECTIONSISSUER1036787.0000000FOR1036787.000000FORS000002106West Pharmaceutical Services, Inc.955306105US955306105504/23/2024Election of Directors: Paolo PucciDIRECTOR ELECTIONSISSUER1036787.0000000FOR1036787.000000FORS000002106West Pharmaceutical Services, Inc.955306105US955306105504/23/2024Advisory vote to approve named executive officer compensation;SECTION 14A SAY-ON-PAY VOTESISSUER1036787.0000000FOR1036787.000000FORS000002106West Pharmaceutical Services, Inc.955306105US955306105504/23/2024Amend and Restate Our Amended and Restated Articles of Incorporation to Eliminate Supermajority Transaction Requirement;CORPORATE GOVERNANCEISSUER1036787.0000000FOR1036787.000000FORS000002106West Pharmaceutical Services, Inc.955306105US955306105504/23/2024Amend and Restate Our Amended and Restated Articles of Incorporation to Eliminate Supermajority Amendment Requirement;CORPORATE GOVERNANCEISSUER1036787.0000000FOR1036787.000000FORS000002106West Pharmaceutical Services, Inc.955306105US955306105504/23/2024Ratification of the appointment of PricewaterhouseCoopers LLP ("PwC") as our independent registered public accounting firm for 2024; andAUDIT-RELATEDISSUER1036787.0000000FOR1036787.000000FORS000002106West Pharmaceutical Services, Inc.955306105US955306105504/23/2024Shareholder Proposal Entitled "Simple Majority Vote"CORPORATE GOVERNANCESECURITY HOLDER1036787.0000000AGAINST1036787.000000FORS000002106Entegris, Inc.29362U104US29362U104304/24/2024Election of Directors: James R. AndersonDIRECTOR ELECTIONSISSUER6125329.0000000FOR6125329.000000FORS000002106Entegris, Inc.29362U104US29362U104304/24/2024Election of Directors: Rodney ClarkDIRECTOR ELECTIONSISSUER6125329.0000000FOR6125329.000000FORS000002106Entegris, Inc.29362U104US29362U104304/24/2024Election of Directors: James F. GentilcoreDIRECTOR ELECTIONSISSUER6125329.0000000FOR6125329.000000FORS000002106Entegris, Inc.29362U104US29362U104304/24/2024Election of Directors: Yvette KanouffDIRECTOR ELECTIONSISSUER6125329.0000000FOR6125329.000000FORS000002106Entegris, Inc.29362U104US29362U104304/24/2024Election of Directors: James P. LedererDIRECTOR ELECTIONSISSUER6125329.0000000FOR6125329.000000FORS000002106Entegris, Inc.29362U104US29362U104304/24/2024Election of Directors: Bertrand LoyDIRECTOR ELECTIONSISSUER6125329.0000000FOR6125329.000000FORS000002106Entegris, Inc.29362U104US29362U104304/24/2024Election of Directors: David ReederDIRECTOR ELECTIONSISSUER6125329.0000000FOR6125329.000000FORS000002106Entegris, Inc.29362U104US29362U104304/24/2024Election of Directors: Azita Saleki-GerhardtDIRECTOR ELECTIONSISSUER6125329.0000000FOR6125329.000000FORS000002106Entegris, Inc.29362U104US29362U104304/24/2024Approval, by non-binding vote, of the compensation paid to Entegris, Inc.'s named executive officers (advisory vote).SECTION 14A SAY-ON-PAY VOTESISSUER6125329.0000000FOR6125329.000000FORS000002106Entegris, Inc.29362U104US29362U104304/24/2024Approval of the 2024 Employee Stock Purchase Plan (ESPP).COMPENSATIONISSUER6125329.0000000FOR6125329.000000FORS000002106Entegris, Inc.29362U104US29362U104304/24/2024Ratify the appointment of KPMG LLP as Entegris, Inc.'s Independent Registered Public Accounting Firm for 2024.AUDIT-RELATEDISSUER6125329.0000000FOR6125329.000000FORS000002106Moncler SpAT6730E110IT000496514804/24/2024Accept Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER0.0000000S000002106Moncler SpAT6730E110IT000496514804/24/2024Approve Allocation of IncomeCAPITAL STRUCTUREISSUER0.0000000S000002106Moncler SpAT6730E110IT000496514804/24/2024Approve Second Section of the Remuneration ReportCOMPENSATIONISSUER0.0000000S000002106Moncler SpAT6730E110IT000496514804/24/2024Authorize Share Repurchase Program and Reissuance of Repurchased SharesCAPITAL STRUCTUREISSUER0.0000000S000002106Moncler SpAT6730E110IT000496514804/24/2024Approve 2024 Performance Shares PlanCOMPENSATIONISSUER0.0000000S000002106Teledyne Technologies Incorporated879360105US879360105004/24/2024Election of directors: Denise R. SingletonDIRECTOR ELECTIONSISSUER1531771.0000000FOR1531771.000000FORS000002106Teledyne Technologies Incorporated879360105US879360105004/24/2024Election of directors: Simon M. LorneDIRECTOR ELECTIONSISSUER1531771.0000000FOR1531771.000000FORS000002106Teledyne Technologies Incorporated879360105US879360105004/24/2024Election of directors: Vincent J. MoralesDIRECTOR ELECTIONSISSUER1531771.0000000FOR1531771.000000FORS000002106Teledyne Technologies Incorporated879360105US879360105004/24/2024Election of directors: Wesley W. von SchackDIRECTOR ELECTIONSISSUER1531771.0000000FOR1531771.000000FORS000002106Teledyne Technologies Incorporated879360105US879360105004/24/2024Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for fiscal year 2024AUDIT-RELATEDISSUER1531771.0000000FOR1531771.000000FORS000002106Teledyne Technologies Incorporated879360105US879360105004/24/2024Approval of a non-binding advisory resolution on the Company's 2023 executive compensationSECTION 14A SAY-ON-PAY VOTESISSUER1531771.0000000FOR1531771.000000FORS000002106Teledyne Technologies Incorporated879360105US879360105004/24/2024Approval of a proposal to amend the Company's Restated Certificate of Incorporation to declassify the Board of Directors and provide for the annual election of directorsSHAREHOLDER RIGHTS AND DEFENSESISSUER1531771.0000000FOR1531771.000000FORS000002106Teledyne Technologies Incorporated879360105US879360105004/24/2024Approval of a proposal to amend the Company's Restated Certificate of Incorporation to provide for executive officer exculpationCORPORATE GOVERNANCEISSUER1531771.0000000FOR1531771.000000FORS000002106Teledyne Technologies Incorporated879360105US879360105004/24/2024Approval of a stockholder proposal to adopt simple majority votingCORPORATE GOVERNANCESECURITY HOLDER1531771.0000000AGAINST1531771.000000FORS000002106Eurofins Scientific SEL31839134FR0014000MR304/25/2024Receive and Approve Board's ReportsCORPORATE GOVERNANCEISSUER2964897.0000000FOR2964897.000000FORS000002106Eurofins Scientific SEL31839134FR0014000MR304/25/2024Receive and Approve Director's Special Report Re: Operations Carried Out Under the Authorized Capital EstablishedCORPORATE GOVERNANCEISSUER2964897.0000000FOR2964897.000000FORS000002106Eurofins Scientific SEL31839134FR0014000MR304/25/2024Receive and Approve Auditor's ReportsCORPORATE GOVERNANCEISSUER2964897.0000000FOR2964897.000000FORS000002106Eurofins Scientific SEL31839134FR0014000MR304/25/2024Approve Consolidated Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER2964897.0000000FOR2964897.000000FORS000002106Eurofins Scientific SEL31839134FR0014000MR304/25/2024Approve Financial StatementsCORPORATE GOVERNANCEISSUER2964897.0000000FOR2964897.000000FORS000002106Eurofins Scientific SEL31839134FR0014000MR304/25/2024Approve Allocation of IncomeCAPITAL STRUCTUREISSUER2964897.0000000FOR2964897.000000FORS000002106Eurofins Scientific SEL31839134FR0014000MR304/25/2024Approve Discharge of DirectorsCORPORATE GOVERNANCEISSUER2964897.0000000FOR2964897.000000FORS000002106Eurofins Scientific SEL31839134FR0014000MR304/25/2024Approve Discharge of AuditorsAUDIT-RELATEDCORPORATE GOVERNANCEISSUER2964897.0000000FOR2964897.000000FORS000002106Eurofins Scientific SEL31839134FR0014000MR304/25/2024Approve Remuneration PolicyCOMPENSATIONISSUER2964897.0000000AGAINST2964897.000000AGAINSTS000002106Eurofins Scientific SEL31839134FR0014000MR304/25/2024Approve Remuneration ReportCOMPENSATIONISSUER2964897.0000000AGAINST2964897.000000AGAINSTS000002106Eurofins Scientific SEL31839134FR0014000MR304/25/2024Reelect Gilles Martin as Executive DirectorDIRECTOR ELECTIONSISSUER2964897.0000000FOR2964897.000000FORS000002106Eurofins Scientific SEL31839134FR0014000MR304/25/2024Reelect Yves-Loic Martin as Non-Executive DirectorDIRECTOR ELECTIONSISSUER2964897.0000000FOR2964897.000000FORS000002106Eurofins Scientific SEL31839134FR0014000MR304/25/2024Reelect Valerie Hanote as Executive DirectorDIRECTOR ELECTIONSISSUER2964897.0000000FOR2964897.000000FORS000002106Eurofins Scientific SEL31839134FR0014000MR304/25/2024Reelect Pascal Rakovsky as Non-Executive DirectorDIRECTOR ELECTIONSISSUER2964897.0000000FOR2964897.000000FORS000002106Eurofins Scientific SEL31839134FR0014000MR304/25/2024Reelect Patrizia Luchetta as Non-Executive DirectorDIRECTOR ELECTIONSISSUER2964897.0000000FOR2964897.000000FORS000002106Eurofins Scientific SEL31839134FR0014000MR304/25/2024Reelect Evie Roos as Non-Executive DirectorDIRECTOR ELECTIONSISSUER2964897.0000000FOR2964897.000000FORS000002106Eurofins Scientific SEL31839134FR0014000MR304/25/2024Elect Erica Monfardini as Non-Executive DirectorDIRECTOR ELECTIONSISSUER2964897.0000000FOR2964897.000000FORS000002106Eurofins Scientific SEL31839134FR0014000MR304/25/2024Renewal Appointment of Deloitte Audit or Appointment of a New Approved Statutory AuditorAUDIT-RELATEDISSUER2964897.0000000FOR2964897.000000FORS000002106Eurofins Scientific SEL31839134FR0014000MR304/25/2024Approve Attendance Fees of DirectorsCOMPENSATIONISSUER2964897.0000000FOR2964897.000000FORS000002106Eurofins Scientific SEL31839134FR0014000MR304/25/2024Approve Transactions of the Share Capital Carried out by the Board of Directors in Accordance with the Buy-Back PrgoramCAPITAL STRUCTUREISSUER2964897.0000000FOR2964897.000000FORS000002106Eurofins Scientific SEL31839134FR0014000MR304/25/2024Approve Share Repurchase ProgramCAPITAL STRUCTUREISSUER2964897.0000000FOR2964897.000000FORS000002106Eurofins Scientific SEL31839134FR0014000MR304/25/2024Authorize Board to Ratify and Execute Approved ResolutionsCORPORATE GOVERNANCEISSUER2964897.0000000FOR2964897.000000FORS000002106Eurofins Scientific SEL31839134FR0014000MR304/25/2024Approve Reduction in Share Capital through Cancellation of SharesCAPITAL STRUCTUREISSUER2964897.0000000FOR2964897.000000FORS000002106Eurofins Scientific SEL31839134FR0014000MR304/25/2024Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights and Amend Article 8 of the Articles of AssociationCAPITAL STRUCTUREISSUER2964897.0000000AGAINST2964897.000000AGAINSTS000002106Eurofins Scientific SEL31839134FR0014000MR304/25/2024Authorize Board to Ratify and Execute Approved ResolutionsCORPORATE GOVERNANCEISSUER2964897.0000000FOR2964897.000000FORS000002106Saia, Inc.78709Y105US78709Y105504/25/2024Election of Directors: Di-Ann EisnorDIRECTOR ELECTIONSISSUER1064983.0000000FOR1064983.000000FORS000002106Saia, Inc.78709Y105US78709Y105504/25/2024Election of Directors: Donna E. EppsDIRECTOR ELECTIONSISSUER1064983.0000000FOR1064983.000000FORS000002106Saia, Inc.78709Y105US78709Y105504/25/2024Election of Directors: John P. Gainor, Jr.DIRECTOR ELECTIONSISSUER1064983.0000000FOR1064983.000000FORS000002106Saia, Inc.78709Y105US78709Y105504/25/2024Election of Directors: Kevin A. HenryDIRECTOR ELECTIONSISSUER1064983.0000000FOR1064983.000000FORS000002106Saia, Inc.78709Y105US78709Y105504/25/2024Election of Directors: Frederick J. Holzgrefe, IIIDIRECTOR ELECTIONSISSUER1064983.0000000FOR1064983.000000FORS000002106Saia, Inc.78709Y105US78709Y105504/25/2024Election of Directors: Donald R. JamesDIRECTOR ELECTIONSISSUER1064983.0000000FOR1064983.000000FORS000002106Saia, Inc.78709Y105US78709Y105504/25/2024Election of Directors: Randolph W. MehvilleDIRECTOR ELECTIONSISSUER1064983.0000000FOR1064983.000000FORS000002106Saia, Inc.78709Y105US78709Y105504/25/2024Election of Directors: Richard D. O'DellDIRECTOR ELECTIONSISSUER1064983.0000000FOR1064983.000000FORS000002106Saia, Inc.78709Y105US78709Y105504/25/2024Election of Directors: Jeffrey C. WardDIRECTOR ELECTIONSISSUER1064983.0000000FOR1064983.000000FORS000002106Saia, Inc.78709Y105US78709Y105504/25/2024Election of Directors: Susan F. WardDIRECTOR ELECTIONSISSUER1064983.0000000FOR1064983.000000FORS000002106Saia, Inc.78709Y105US78709Y105504/25/2024Approve on an advisory basis the compensation of Saia's Named Executive OfficersSECTION 14A SAY-ON-PAY VOTESISSUER1064983.0000000FOR1064983.000000FORS000002106Saia, Inc.78709Y105US78709Y105504/25/2024Approve and adopt an amendment and restatement of Saia's certificate of incorporation to limit the liability of certain officers and make various conforming and technical revisionsCORPORATE GOVERNANCEISSUER1064983.0000000FOR1064983.000000FORS000002106Saia, Inc.78709Y105US78709Y105504/25/2024Ratify the appointment of KPMG LLP as Saia's Independent Registered Public Accounting Firm for fiscal year 2024AUDIT-RELATEDISSUER1064983.0000000FOR1064983.000000FORS000002106Dayforce, Inc.15677J108US15677J108804/26/2024To elect nine directors to hold office until the 2025 Annual Meeting of Stockholders or until their successors are duly elected and qualified, subject to their earlier death, resignation or removal: Brent B. BickettDIRECTOR ELECTIONSISSUER10678154.0000000FOR10678154.000000FORS000002106Dayforce, Inc.15677J108US15677J108804/26/2024To elect nine directors to hold office until the 2025 Annual Meeting of Stockholders or until their successors are duly elected and qualified, subject to their earlier death, resignation or removal: Ronald F. ClarkeDIRECTOR ELECTIONSISSUER10678154.0000000FOR10678154.000000FORS000002106Dayforce, Inc.15677J108US15677J108804/26/2024To elect nine directors to hold office until the 2025 Annual Meeting of Stockholders or until their successors are duly elected and qualified, subject to their earlier death, resignation or removal: Deborah A. FarringtonDIRECTOR ELECTIONSISSUER10678154.0000000FOR10678154.000000FORS000002106Dayforce, Inc.15677J108US15677J108804/26/2024To elect nine directors to hold office until the 2025 Annual Meeting of Stockholders or until their successors are duly elected and qualified, subject to their earlier death, resignation or removal: Thomas M. HagertyDIRECTOR ELECTIONSISSUER10678154.0000000FOR10678154.000000FORS000002106Dayforce, Inc.15677J108US15677J108804/26/2024To elect nine directors to hold office until the 2025 Annual Meeting of Stockholders or until their successors are duly elected and qualified, subject to their earlier death, resignation or removal: Linda P. MantiaDIRECTOR ELECTIONSISSUER10678154.0000000FOR10678154.000000FORS000002106Dayforce, Inc.15677J108US15677J108804/26/2024To elect nine directors to hold office until the 2025 Annual Meeting of Stockholders or until their successors are duly elected and qualified, subject to their earlier death, resignation or removal: David D. OssipDIRECTOR ELECTIONSISSUER10678154.0000000FOR10678154.000000FORS000002106Dayforce, Inc.15677J108US15677J108804/26/2024To elect nine directors to hold office until the 2025 Annual Meeting of Stockholders or until their successors are duly elected and qualified, subject to their earlier death, resignation or removal: Ganesh B. RaoDIRECTOR ELECTIONSISSUER10678154.0000000FOR10678154.000000FORS000002106Dayforce, Inc.15677J108US15677J108804/26/2024To elect nine directors to hold office until the 2025 Annual Meeting of Stockholders or until their successors are duly elected and qualified, subject to their earlier death, resignation or removal: Andrea S. RosenDIRECTOR ELECTIONSISSUER10678154.0000000FOR10678154.000000FORS000002106Dayforce, Inc.15677J108US15677J108804/26/2024To elect nine directors to hold office until the 2025 Annual Meeting of Stockholders or until their successors are duly elected and qualified, subject to their earlier death, resignation or removal: Gerald C. ThroopDIRECTOR ELECTIONSISSUER10678154.0000000FOR10678154.000000FORS000002106Dayforce, Inc.15677J108US15677J108804/26/2024To approve, on a non-binding, advisory basis, the compensation of Dayforce's named executive officers (commonly known as a "Say on Pay" vote)SECTION 14A SAY-ON-PAY VOTESISSUER10678154.0000000FOR10678154.000000FORS000002106Dayforce, Inc.15677J108US15677J108804/26/2024To ratify the appointment of KPMG LLP as Dayforce's independent registered public accounting firm for the fiscal year ending December 31, 2024AUDIT-RELATEDISSUER10678154.0000000FOR10678154.000000FORS000002106Leidos Holdings, Inc.525327102US525327102804/26/2024Nominees: Thomas A. BellDIRECTOR ELECTIONSISSUER200500.0000000FOR200500.000000FORS000002106Leidos Holdings, Inc.525327102US525327102804/26/2024Nominees: Gregory R. DahlbergDIRECTOR ELECTIONSISSUER200500.0000000FOR200500.000000FORS000002106Leidos Holdings, Inc.525327102US525327102804/26/2024Nominees: David G. FubiniDIRECTOR ELECTIONSISSUER200500.0000000FOR200500.000000FORS000002106Leidos Holdings, Inc.525327102US525327102804/26/2024Nominees: Noel B. GeerDIRECTOR ELECTIONSISSUER200500.0000000FOR200500.000000FORS000002106Leidos Holdings, Inc.525327102US525327102804/26/2024Nominees: Robert C. Kovarik, Jr.DIRECTOR ELECTIONSISSUER200500.0000000FOR200500.000000FORS000002106Leidos Holdings, Inc.525327102US525327102804/26/2024Nominees: Harry M. J. Kraemer, Jr.DIRECTOR ELECTIONSISSUER200500.0000000FOR200500.000000FORS000002106Leidos Holdings, Inc.525327102US525327102804/26/2024Nominees: Gary S. MayDIRECTOR ELECTIONSISSUER200500.0000000FOR200500.000000FORS000002106Leidos Holdings, Inc.525327102US525327102804/26/2024Nominees: Surya N. MohapatraDIRECTOR ELECTIONSISSUER200500.0000000FOR200500.000000FORS000002106Leidos Holdings, Inc.525327102US525327102804/26/2024Nominees: Nancy A. NortonDIRECTOR ELECTIONSISSUER200500.0000000FOR200500.000000FORS000002106Leidos Holdings, Inc.525327102US525327102804/26/2024Nominees: Patrick M. ShanahanDIRECTOR ELECTIONSISSUER200500.0000000FOR200500.000000FORS000002106Leidos Holdings, Inc.525327102US525327102804/26/2024Nominees: Robert S. ShapardDIRECTOR ELECTIONSISSUER200500.0000000FOR200500.000000FORS000002106Leidos Holdings, Inc.525327102US525327102804/26/2024Nominees: Susan M. StalneckerDIRECTOR ELECTIONSISSUER200500.0000000FOR200500.000000FORS000002106Leidos Holdings, Inc.525327102US525327102804/26/2024Approve, by an advisory vote, executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER200500.0000000FOR200500.000000FORS000002106Leidos Holdings, Inc.525327102US525327102804/26/2024The ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending January 3, 2025.AUDIT-RELATEDISSUER200500.0000000FOR200500.000000FORS000002106Leidos Holdings, Inc.525327102US525327102804/26/2024Consider stockholder proposal regarding special shareholder meeting improvement, if properly presented.CORPORATE GOVERNANCESECURITY HOLDER200500.0000000AGAINST200500.000000FORS000002106TechnipFMC plcG87110105GB00BDSFG98204/26/2024Election of Directors - To elect each of our nine director nominees for a term expiring at the Company's 2025 Annual General Meeting of Shareholders: Douglas J. PferdehirtDIRECTOR ELECTIONSISSUER10146674.0000000FOR10146674.000000FORS000002106TechnipFMC plcG87110105GB00BDSFG98204/26/2024Election of Directors - To elect each of our nine director nominees for a term expiring at the Company's 2025 Annual General Meeting of Shareholders: Claire S. FarleyDIRECTOR ELECTIONSISSUER10146674.0000000FOR10146674.000000FORS000002106TechnipFMC plcG87110105GB00BDSFG98204/26/2024Election of Directors - To elect each of our nine director nominees for a term expiring at the Company's 2025 Annual General Meeting of Shareholders: Eleazar de Carvalho FilhoDIRECTOR ELECTIONSISSUER10146674.0000000FOR10146674.000000FORS000002106TechnipFMC plcG87110105GB00BDSFG98204/26/2024Election of Directors - To elect each of our nine director nominees for a term expiring at the Company's 2025 Annual General Meeting of Shareholders: Robert G. GwinDIRECTOR ELECTIONSISSUER10146674.0000000FOR10146674.000000FORS000002106TechnipFMC plcG87110105GB00BDSFG98204/26/2024Election of Directors - To elect each of our nine director nominees for a term expiring at the Company's 2025 Annual General Meeting of Shareholders: John O'LearyDIRECTOR ELECTIONSISSUER10146674.0000000FOR10146674.000000FORS000002106TechnipFMC plcG87110105GB00BDSFG98204/26/2024Election of Directors - To elect each of our nine director nominees for a term expiring at the Company's 2025 Annual General Meeting of Shareholders: Margareth OvrumDIRECTOR ELECTIONSISSUER10146674.0000000FOR10146674.000000FORS000002106TechnipFMC plcG87110105GB00BDSFG98204/26/2024Election of Directors - To elect each of our nine director nominees for a term expiring at the Company's 2025 Annual General Meeting of Shareholders: Kay G. PriestlyDIRECTOR ELECTIONSISSUER10146674.0000000FOR10146674.000000FORS000002106TechnipFMC plcG87110105GB00BDSFG98204/26/2024Election of Directors - To elect each of our nine director nominees for a term expiring at the Company's 2025 Annual General Meeting of Shareholders: John YearwoodDIRECTOR ELECTIONSISSUER10146674.0000000FOR10146674.000000FORS000002106TechnipFMC plcG87110105GB00BDSFG98204/26/2024Election of Directors - To elect each of our nine director nominees for a term expiring at the Company's 2025 Annual General Meeting of Shareholders: Sophie ZurquiyahDIRECTOR ELECTIONSISSUER10146674.0000000FOR10146674.000000FORS000002106TechnipFMC plcG87110105GB00BDSFG98204/26/20242023 U.S. Say-on-Pay for Named Executive Officers: To approve, as a non-binding advisory resolution, the Company's named executive officer compensation for the year ended December 31, 2023, as reported in the Company's Proxy StatementSECTION 14A SAY-ON-PAY VOTESISSUER10146674.0000000FOR10146674.000000FORS000002106TechnipFMC plcG87110105GB00BDSFG98204/26/20242023 U.K. Directors' Remuneration Report: To approve, as a non-binding advisory resolution, the Company's directors' remuneration report for the year ended December 31, 2023, as reported in the Company's UK. Annual Report and AccountsCOMPENSATIONISSUER10146674.0000000FOR10146674.000000FORS000002106TechnipFMC plcG87110105GB00BDSFG98204/26/2024Prospective Directors' Remuneration Policy: To approve the Company's prospective directors' remuneration policy for the three years ending December 31, 2027, in the form presented in the Company's directors' remuneration report for the year ended December 31, 2023 of the Company's U.K. Annual Report and Accounts, such policy to take effect immediately after the conclusion of the 2024 Annual General Meeting of ShareholdersCOMPENSATIONISSUER10146674.0000000FOR10146674.000000FORS000002106TechnipFMC plcG87110105GB00BDSFG98204/26/2024Receipt of U.K. Annual Report and Accounts: To receive the Company's audited U.K. accounts for the year ended December 31, 2023, including the reports of the directors and the auditor thereonCORPORATE GOVERNANCEISSUER10146674.0000000FOR10146674.000000FORS000002106TechnipFMC plcG87110105GB00BDSFG98204/26/2024Ratification of PwC as U.S. Auditor: To ratify the appointment of PricewaterhouseCoopers LLP ("PwC") as the Company's U.S. independent registered public accounting firm for the year ending December 31,2024AUDIT-RELATEDISSUER10146674.0000000FOR10146674.000000FORS000002106TechnipFMC plcG87110105GB00BDSFG98204/26/2024Reappointment of PwC as U.K. Statutory Auditor: To reappoint PwC as the Company's U.K. statutory auditor under the U.K. Companies Act 2006, to hold office from the conclusion of the 2024 Annual General Meeting of Shareholders until the next annual general meeting of shareholders at which accounts are laidAUDIT-RELATEDISSUER10146674.0000000FOR10146674.000000FORS000002106TechnipFMC plcG87110105GB00BDSFG98204/26/2024Approval of U.K. Statutory Auditor Fees: To authorize the Board and/or the Audit Committee to determine the remuneration of PwC, in its capacity as the Company's U.K. statutory auditor for the year ending December 31, 2024AUDIT-RELATEDISSUER10146674.0000000FOR10146674.000000FORS000002106TechnipFMC plcG87110105GB00BDSFG98204/26/2024Approval of Share Repurchase Contracts and Counterparties: To approve the forms of share repurchase contracts and repurchase broker-dealers in accordance with U.K. law and specific procedures for "off-market purchases" of ordinary shares through the NYSECAPITAL STRUCTUREISSUER10146674.0000000FOR10146674.000000FORS000002106TechnipFMC plcG87110105GB00BDSFG98204/26/2024Authority to Allot Equity Securities: To authorize the Board to allot equity securities in the CompanyCAPITAL STRUCTUREISSUER10146674.0000000FOR10146674.000000FORS000002106TechnipFMC plcG87110105GB00BDSFG98204/26/2024As a special resolution - Authority to Allot Equity Securities without Pre-emptive Rights: Pursuant to the authority contemplated by the resolution in Proposal 10, to authorize the Board to allot equity securities without pre-emptive rightsCAPITAL STRUCTUREISSUER10146674.0000000FOR10146674.000000FORS000002106Molina Healthcare, Inc.60855R100US60855R100505/01/2024To elect nine directors to hold office until the 2025 Annual Meeting: Barbara L. BrasierDIRECTOR ELECTIONSISSUER872861.0000000FOR872861.000000FORS000002106Molina Healthcare, Inc.60855R100US60855R100505/01/2024To elect nine directors to hold office until the 2025 Annual Meeting: Daniel CoopermanDIRECTOR ELECTIONSISSUER872861.0000000FOR872861.000000FORS000002106Molina Healthcare, Inc.60855R100US60855R100505/01/2024To elect nine directors to hold office until the 2025 Annual Meeting: Stephen H. LockhartDIRECTOR ELECTIONSISSUER872861.0000000FOR872861.000000FORS000002106Molina Healthcare, Inc.60855R100US60855R100505/01/2024To elect nine directors to hold office until the 2025 Annual Meeting: Steven J. OrlandoDIRECTOR ELECTIONSISSUER872861.0000000FOR872861.000000FORS000002106Molina Healthcare, Inc.60855R100US60855R100505/01/2024To elect nine directors to hold office until the 2025 Annual Meeting: Ronna E. RomneyDIRECTOR ELECTIONSISSUER872861.0000000FOR872861.000000FORS000002106Molina Healthcare, Inc.60855R100US60855R100505/01/2024To elect nine directors to hold office until the 2025 Annual Meeting: Richard M. SchapiroDIRECTOR ELECTIONSISSUER872861.0000000FOR872861.000000FORS000002106Molina Healthcare, Inc.60855R100US60855R100505/01/2024To elect nine directors to hold office until the 2025 Annual Meeting: Dale B. WolfDIRECTOR ELECTIONSISSUER872861.0000000FOR872861.000000FORS000002106Molina Healthcare, Inc.60855R100US60855R100505/01/2024To elect nine directors to hold office until the 2025 Annual Meeting: Richard C. ZoreticDIRECTOR ELECTIONSISSUER872861.0000000FOR872861.000000FORS000002106Molina Healthcare, Inc.60855R100US60855R100505/01/2024To elect nine directors to hold office until the 2025 Annual Meeting: Joseph M. ZubretskyDIRECTOR ELECTIONSISSUER872861.0000000FOR872861.000000FORS000002106Molina Healthcare, Inc.60855R100US60855R100505/01/2024To consider and approve, on a non-binding, advisory basis the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER872861.0000000FOR872861.000000FORS000002106Molina Healthcare, Inc.60855R100US60855R100505/01/2024To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for 2024.AUDIT-RELATEDISSUER872861.0000000FOR872861.000000FORS000002106Molina Healthcare, Inc.60855R100US60855R100505/01/2024Shareholder proposal regarding simple majority voting, if properly presented.CORPORATE GOVERNANCESECURITY HOLDER872861.0000000AGAINST872861.000000FORS000002106Hexcel Corporation428291108US428291108405/02/2024Election of Directors: Nick L. StanageDIRECTOR ELECTIONSISSUER218028.0000000FOR218028.000000FORS000002106Hexcel Corporation428291108US428291108405/02/2024Election of Directors: Jeffrey C. CampbellDIRECTOR ELECTIONSISSUER218028.0000000FOR218028.000000FORS000002106Hexcel Corporation428291108US428291108405/02/2024Election of Directors: James J. CannonDIRECTOR ELECTIONSISSUER218028.0000000FOR218028.000000FORS000002106Hexcel Corporation428291108US428291108405/02/2024Election of Directors: Cynthia M. EgnotovichDIRECTOR ELECTIONSISSUER218028.0000000FOR218028.000000FORS000002106Hexcel Corporation428291108US428291108405/02/2024Election of Directors: Thomas A. GendronDIRECTOR ELECTIONSISSUER218028.0000000FOR218028.000000FORS000002106Hexcel Corporation428291108US428291108405/02/2024Election of Directors: Guy C. HacheyDIRECTOR ELECTIONSISSUER218028.0000000FOR218028.000000FORS000002106Hexcel Corporation428291108US428291108405/02/2024Election of Directors: Dr. Patricia A. HubbardDIRECTOR ELECTIONSISSUER218028.0000000FOR218028.000000FORS000002106Hexcel Corporation428291108US428291108405/02/2024Election of Directors: Catherine A. SueverDIRECTOR ELECTIONSISSUER218028.0000000FOR218028.000000FORS000002106Hexcel Corporation428291108US428291108405/02/2024Advisory non-binding vote to approve 2023 executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER218028.0000000FOR218028.000000FORS000002106Hexcel Corporation428291108US428291108405/02/2024Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2024.AUDIT-RELATEDISSUER218028.0000000FOR218028.000000FORS000002106argenx SE04016X101US04016X101905/07/2024Approve Remuneration ReportCOMPENSATIONISSUER1068626.0000000FOR1068626.000000FORS000002106argenx SE04016X101US04016X101905/07/2024Adopt Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER1068626.0000000FOR1068626.000000FORS000002106argenx SE04016X101US04016X101905/07/2024Approve Allocation of Losses to the Retained Earnings of the CompanyCAPITAL STRUCTUREISSUER1068626.0000000FOR1068626.000000FORS000002106argenx SE04016X101US04016X101905/07/2024Approve Discharge of DirectorsCORPORATE GOVERNANCEISSUER1068626.0000000FOR1068626.000000FORS000002106argenx SE04016X101US04016X101905/07/2024Approve Remuneration PolicyCOMPENSATIONISSUER1068626.0000000FOR1068626.000000FORS000002106argenx SE04016X101US04016X101905/07/2024Elect Brian L. Kotzin as Non-Executive DirectorDIRECTOR ELECTIONSISSUER1068626.0000000FOR1068626.000000FORS000002106argenx SE04016X101US04016X101905/07/2024Reelect Peter Verhaeghe as Non-Executive DirectorDIRECTOR ELECTIONSISSUER1068626.0000000FOR1068626.000000FORS000002106argenx SE04016X101US04016X101905/07/2024Reelect Pamela Klein as Non-Executive DirectorDIRECTOR ELECTIONSISSUER1068626.0000000FOR1068626.000000FORS000002106argenx SE04016X101US04016X101905/07/2024Grant Board Authority to Issue Shares Up To 10 Percent of Issued Capital and Exclude Pre-emptive RightsCAPITAL STRUCTUREISSUER1068626.0000000FOR1068626.000000FORS000002106argenx SE04016X101US04016X101905/07/2024Amend Articles of Association and Authorization to Execute the Deed of AmendmentCORPORATE GOVERNANCEISSUER1068626.0000000FOR1068626.000000FORS000002106argenx SE04016X101US04016X101905/07/2024Ratify Deloitte Accountants B.V. as Auditors for the 2024 Financial YearAUDIT-RELATEDISSUER1068626.0000000FOR1068626.000000FORS000002106argenx SE04016X101US04016X101905/07/2024Ratify Ernst & Young Accountants LLP as Auditors for the 2025 Financial YearAUDIT-RELATEDISSUER1068626.0000000FOR1068626.000000FORS000002106Hubbell Incorporated443510607US443510607905/07/2024Election of Directors: Gerben W. BakkerDIRECTOR ELECTIONSISSUER964868.0000000FOR964868.000000FORS000002106Hubbell Incorporated443510607US443510607905/07/2024Election of Directors: Carlos M. CardosoDIRECTOR ELECTIONSISSUER964868.0000000FOR964868.000000FORS000002106Hubbell Incorporated443510607US443510607905/07/2024Election of Directors: Debra L. DialDIRECTOR ELECTIONSISSUER964868.0000000FOR964868.000000FORS000002106Hubbell Incorporated443510607US443510607905/07/2024Election of Directors: Anthony J. GuzziDIRECTOR ELECTIONSISSUER964868.0000000FOR964868.000000FORS000002106Hubbell Incorporated443510607US443510607905/07/2024Election of Directors: Rhett A. HernandezDIRECTOR ELECTIONSISSUER964868.0000000FOR964868.000000FORS000002106Hubbell Incorporated443510607US443510607905/07/2024Election of Directors: Neal J. KeatingDIRECTOR ELECTIONSISSUER964868.0000000FOR964868.000000FORS000002106Hubbell Incorporated443510607US443510607905/07/2024Election of Directors: Bonnie C. LindDIRECTOR ELECTIONSISSUER964868.0000000FOR964868.000000FORS000002106Hubbell Incorporated443510607US443510607905/07/2024Election of Directors: John F. MalloyDIRECTOR ELECTIONSISSUER964868.0000000FOR964868.000000FORS000002106Hubbell Incorporated443510607US443510607905/07/2024Election of Directors: Jennifer M. PollinoDIRECTOR ELECTIONSISSUER964868.0000000FOR964868.000000FORS000002106Hubbell Incorporated443510607US443510607905/07/2024To approve, by non-binding vote, the compensation of our named executive officers as presented in the 2024 Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER964868.0000000FOR964868.000000FORS000002106Hubbell Incorporated443510607US443510607905/07/2024To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year 2024.AUDIT-RELATEDISSUER964868.0000000FOR964868.000000FORS000002106IDEX Corporation45167R104US45167R104105/07/2024Election of three directors named in the proxy statement as follows: Mark A. ButhmanDIRECTOR ELECTIONSISSUER2785142.0000000FOR2785142.000000FORS000002106IDEX Corporation45167R104US45167R104105/07/2024Election of three directors named in the proxy statement as follows: Lakecia N. GunterDIRECTOR ELECTIONSISSUER2785142.0000000FOR2785142.000000FORS000002106IDEX Corporation45167R104US45167R104105/07/2024Election of three directors named in the proxy statement as follows: L. Paris Watts-StanfieldDIRECTOR ELECTIONSISSUER2785142.0000000FOR2785142.000000FORS000002106IDEX Corporation45167R104US45167R104105/07/2024Advisory vote to approve named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER2785142.0000000FOR2785142.000000FORS000002106IDEX Corporation45167R104US45167R104105/07/2024Approval of the IDEX Corporation 2024 Incentive Award Plan.COMPENSATIONISSUER2785142.0000000FOR2785142.000000FORS000002106IDEX Corporation45167R104US45167R104105/07/2024Ratification of the appointment of Deloitte & Touche LLP as our independent registered accounting firm for 2024.AUDIT-RELATEDISSUER2785142.0000000FOR2785142.000000FORS000002106IDEX Corporation45167R104US45167R104105/07/2024Vote on a stockholder proposal regarding a report on hiring practices related to people with arrest or incarceration records.HUMAN RIGHTS OR HUMAN CAPITAL/WORKFORCEDIVERSITY, EQUITY, AND INCLUSIONSECURITY HOLDER2785142.0000000AGAINST2785142.000000FORS000002106MKS Instruments, Inc.55306N104US55306N104605/07/2024The election of the three nominees listed below as Class I Directors, each to serve for a three-year term: Rajeev BatraDIRECTOR ELECTIONSISSUER1638421.0000000FOR1638421.000000FORS000002106MKS Instruments, Inc.55306N104US55306N104605/07/2024The election of the three nominees listed below as Class I Directors, each to serve for a three-year term: Gerald G. ColellaDIRECTOR ELECTIONSISSUER1638421.0000000FOR1638421.000000FORS000002106MKS Instruments, Inc.55306N104US55306N104605/07/2024The election of the three nominees listed below as Class I Directors, each to serve for a three-year term: Elizabeth A. MoraDIRECTOR ELECTIONSISSUER1638421.0000000FOR1638421.000000FORS000002106MKS Instruments, Inc.55306N104US55306N104605/07/2024The approval, on an advisory basis, of executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1638421.0000000FOR1638421.000000FORS000002106MKS Instruments, Inc.55306N104US55306N104605/07/2024The ratification of the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024.AUDIT-RELATEDISSUER1638421.0000000FOR1638421.000000FORS000002106MKS Instruments, Inc.55306N104US55306N104605/07/2024A shareholder proposal regarding simple majority voting, if properly presented at the meeting.CORPORATE GOVERNANCESECURITY HOLDER1638421.0000000FOR1638421.000000AGAINSTS000002106SiteOne Landscape Supply, Inc.82982L103US82982L103505/07/2024Election of Directors: Doug BlackDIRECTOR ELECTIONSISSUER2891590.0000000FOR2891590.000000FORS000002106SiteOne Landscape Supply, Inc.82982L103US82982L103505/07/2024Election of Directors: Judith (Judy) SansoneDIRECTOR ELECTIONSISSUER2891590.0000000FOR2891590.000000FORS000002106SiteOne Landscape Supply, Inc.82982L103US82982L103505/07/2024Election of Directors: Jack L. WyszomierskiDIRECTOR ELECTIONSISSUER2891590.0000000FOR2891590.000000FORS000002106SiteOne Landscape Supply, Inc.82982L103US82982L103505/07/2024Approval of an amendment to the company's Charter to limit the liability of certain officers.CORPORATE GOVERNANCEISSUER2891590.0000000FOR2891590.000000FORS000002106SiteOne Landscape Supply, Inc.82982L103US82982L103505/07/2024Ratification of the selection of Deloitte & Touche LLP as the company's independent registered public accounting firm for the fiscal year ending December 29, 2024.AUDIT-RELATEDISSUER2891590.0000000FOR2891590.000000FORS000002106SiteOne Landscape Supply, Inc.82982L103US82982L103505/07/2024Advisory vote to approve executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER2891590.0000000FOR2891590.000000FORS000002106Floor & Decor Holdings, Inc.339750101US339750101205/08/2024Election of Directors: Norman AxelrodDIRECTOR ELECTIONSISSUER3090813.0000000FOR3090813.000000FORS000002106Floor & Decor Holdings, Inc.339750101US339750101205/08/2024Election of Directors: William GilesDIRECTOR ELECTIONSISSUER3090813.0000000FOR3090813.000000FORS000002106Floor & Decor Holdings, Inc.339750101US339750101205/08/2024Election of Directors: Dwight JamesDIRECTOR ELECTIONSISSUER3090813.0000000FOR3090813.000000FORS000002106Floor & Decor Holdings, Inc.339750101US339750101205/08/2024Election of Directors: Melissa KerseyDIRECTOR ELECTIONSISSUER3090813.0000000FOR3090813.000000FORS000002106Floor & Decor Holdings, Inc.339750101US339750101205/08/2024Election of Directors: Ryan MarshallDIRECTOR ELECTIONSISSUER3090813.0000000FOR3090813.000000FORS000002106Floor & Decor Holdings, Inc.339750101US339750101205/08/2024Election of Directors: Peter StarrettDIRECTOR ELECTIONSISSUER3090813.0000000FOR3090813.000000FORS000002106Floor & Decor Holdings, Inc.339750101US339750101205/08/2024Election of Directors: Richard SullivanDIRECTOR ELECTIONSISSUER3090813.0000000FOR3090813.000000FORS000002106Floor & Decor Holdings, Inc.339750101US339750101205/08/2024Election of Directors: Thomas TaylorDIRECTOR ELECTIONSISSUER3090813.0000000FOR3090813.000000FORS000002106Floor & Decor Holdings, Inc.339750101US339750101205/08/2024Election of Directors: Felicia ThortonDIRECTOR ELECTIONSISSUER3090813.0000000FOR3090813.000000FORS000002106Floor & Decor Holdings, Inc.339750101US339750101205/08/2024Election of Directors: George Vincent WestDIRECTOR ELECTIONSISSUER3090813.0000000FOR3090813.000000FORS000002106Floor & Decor Holdings, Inc.339750101US339750101205/08/2024Election of Directors: Charles YoungDIRECTOR ELECTIONSISSUER3090813.0000000FOR3090813.000000FORS000002106Floor & Decor Holdings, Inc.339750101US339750101205/08/2024Ratify the appointment of Ernst & Young LLP as independent auditors for Floor & Decor Holdings, Inc.'s (the "Company") 2024 fiscal year.AUDIT-RELATEDISSUER3090813.0000000FOR3090813.000000FORS000002106Floor & Decor Holdings, Inc.339750101US339750101205/08/2024To approve, by non-binding vote, the compensation paid to the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER3090813.0000000FOR3090813.000000FORS000002106Floor & Decor Holdings, Inc.339750101US339750101205/08/2024To recommend, by non-binding vote, the frequency of future advisory votes on executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER3090813.0000000ONE YEAR3090813.000000FORS000002106Novanta Inc.67000B104CA67000B104005/08/2024ELECTION OF DIRECTORS: Election of Director: Lonny J. CarpenterDIRECTOR ELECTIONSISSUER1177494.0000000FOR1177494.000000FORS000002106Novanta Inc.67000B104CA67000B104005/08/2024ELECTION OF DIRECTORS: Election of Director: Matthijs GlastraDIRECTOR ELECTIONSISSUER1177494.0000000FOR1177494.000000FORS000002106Novanta Inc.67000B104CA67000B104005/08/2024ELECTION OF DIRECTORS: Election of Director: Barbara B. HulitDIRECTOR ELECTIONSISSUER1177494.0000000FOR1177494.000000FORS000002106Novanta Inc.67000B104CA67000B104005/08/2024ELECTION OF DIRECTORS: Election of Director: R. Matthew JohnsonDIRECTOR ELECTIONSISSUER1177494.0000000FOR1177494.000000FORS000002106Novanta Inc.67000B104CA67000B104005/08/2024ELECTION OF DIRECTORS: Election of Director: Maxine L. MauricioDIRECTOR ELECTIONSISSUER1177494.0000000FOR1177494.000000FORS000002106Novanta Inc.67000B104CA67000B104005/08/2024ELECTION OF DIRECTORS: Election of Director: Katherine A. OwenDIRECTOR ELECTIONSISSUER1177494.0000000FOR1177494.000000FORS000002106Novanta Inc.67000B104CA67000B104005/08/2024ELECTION OF DIRECTORS: Election of Director: Thomas N. SecorDIRECTOR ELECTIONSISSUER1177494.0000000FOR1177494.000000FORS000002106Novanta Inc.67000B104CA67000B104005/08/2024ELECTION OF DIRECTORS: Election of Director: Darlene J.S. SolomonDIRECTOR ELECTIONSISSUER1177494.0000000FOR1177494.000000FORS000002106Novanta Inc.67000B104CA67000B104005/08/2024ELECTION OF DIRECTORS: Election of Director: Frank A. WilsonDIRECTOR ELECTIONSISSUER1177494.0000000FOR1177494.000000FORS000002106Novanta Inc.67000B104CA67000B104005/08/2024Approval, on an advisory (non-binding) basis, of the Company's executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1177494.0000000FOR1177494.000000FORS000002106Novanta Inc.67000B104CA67000B104005/08/2024To appoint Deloitte & Touche LLP as the Company's independent registered public accounting firm to serve until the 2025 Annual Meeting of Shareholders.AUDIT-RELATEDISSUER1177494.0000000FOR1177494.000000FORS000002106Rentokil Initial PlcG7494G105GB00B082RF1105/08/2024Accept Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER9031347.0000000FOR9031347.000000FORS000002106Rentokil Initial PlcG7494G105GB00B082RF1105/08/2024Approve Remuneration ReportCOMPENSATIONISSUER9031347.0000000FOR9031347.000000FORS000002106Rentokil Initial PlcG7494G105GB00B082RF1105/08/2024Approve Remuneration PolicyCOMPENSATIONISSUER9031347.0000000AGAINST9031347.000000AGAINSTS000002106Rentokil Initial PlcG7494G105GB00B082RF1105/08/2024Approve Final DividendCAPITAL STRUCTUREISSUER9031347.0000000FOR9031347.000000FORS000002106Rentokil Initial PlcG7494G105GB00B082RF1105/08/2024Re-elect David Frear as DirectorDIRECTOR ELECTIONSISSUER9031347.0000000FOR9031347.000000FORS000002106Rentokil Initial PlcG7494G105GB00B082RF1105/08/2024Re-elect Stuart Ingall-Tombs as DirectorDIRECTOR ELECTIONSISSUER9031347.0000000FOR9031347.000000FORS000002106Rentokil Initial PlcG7494G105GB00B082RF1105/08/2024Re-elect Sally Johnson as DirectorDIRECTOR ELECTIONSISSUER9031347.0000000FOR9031347.000000FORS000002106Rentokil Initial PlcG7494G105GB00B082RF1105/08/2024Re-elect Sarosh Mistry as DirectorDIRECTOR ELECTIONSISSUER9031347.0000000FOR9031347.000000FORS000002106Rentokil Initial PlcG7494G105GB00B082RF1105/08/2024Re-elect John Pettigrew as DirectorDIRECTOR ELECTIONSISSUER9031347.0000000FOR9031347.000000FORS000002106Rentokil Initial PlcG7494G105GB00B082RF1105/08/2024Re-elect Andy Ransom as DirectorDIRECTOR ELECTIONSISSUER9031347.0000000FOR9031347.000000FORS000002106Rentokil Initial PlcG7494G105GB00B082RF1105/08/2024Re-elect Richard Solomons as DirectorDIRECTOR ELECTIONSISSUER9031347.0000000FOR9031347.000000FORS000002106Rentokil Initial PlcG7494G105GB00B082RF1105/08/2024Re-elect Cathy Turner as DirectorDIRECTOR ELECTIONSISSUER9031347.0000000ABSTAIN9031347.000000AGAINSTS000002106Rentokil Initial PlcG7494G105GB00B082RF1105/08/2024Re-elect Linda Yueh as DirectorDIRECTOR ELECTIONSISSUER9031347.0000000FOR9031347.000000FORS000002106Rentokil Initial PlcG7494G105GB00B082RF1105/08/2024Reappoint PricewaterhouseCoopers LLP as AuditorsAUDIT-RELATEDISSUER9031347.0000000FOR9031347.000000FORS000002106Rentokil Initial PlcG7494G105GB00B082RF1105/08/2024Authorise Board to Fix Remuneration of AuditorsAUDIT-RELATEDISSUER9031347.0000000FOR9031347.000000FORS000002106Rentokil Initial PlcG7494G105GB00B082RF1105/08/2024Authorise UK Political Donations and ExpenditureOTHER SOCIAL ISSUESISSUER9031347.0000000FOR9031347.000000FORS000002106Rentokil Initial PlcG7494G105GB00B082RF1105/08/2024Authorise Issue of EquityCAPITAL STRUCTUREISSUER9031347.0000000FOR9031347.000000FORS000002106Rentokil Initial PlcG7494G105GB00B082RF1105/08/2024Authorise Issue of Equity without Pre-emptive RightsCAPITAL STRUCTUREISSUER9031347.0000000FOR9031347.000000FORS000002106Rentokil Initial PlcG7494G105GB00B082RF1105/08/2024Authorise Issue of Equity without Pre-emptive Rights in Connection with an Acquisition or Other Capital InvestmentCAPITAL STRUCTUREISSUER9031347.0000000FOR9031347.000000FORS000002106Rentokil Initial PlcG7494G105GB00B082RF1105/08/2024Authorise Market Purchase of Ordinary SharesCAPITAL STRUCTUREISSUER9031347.0000000FOR9031347.000000FORS000002106Rentokil Initial PlcG7494G105GB00B082RF1105/08/2024Authorise the Company to Call General Meeting with Two Weeks' NoticeCORPORATE GOVERNANCEISSUER9031347.0000000FOR9031347.000000FORS000002106ESAB Corporation29605J106US29605J106005/09/2024Election of Directors: Class II Director Nominees: Patrick W. AllenderDIRECTOR ELECTIONSISSUER2875728.0000000FOR2875728.000000FORS000002106ESAB Corporation29605J106US29605J106005/09/2024Election of Directors: Class II Director Nominees: Rhonda L. JordanDIRECTOR ELECTIONSISSUER2875728.0000000FOR2875728.000000FORS000002106ESAB Corporation29605J106US29605J106005/09/2024To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER2875728.0000000FOR2875728.000000FORS000002106ESAB Corporation29605J106US29605J106005/09/2024To approve on an advisory basis the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER2875728.0000000FOR2875728.000000FORS000002106Osisko Gold Royalties Ltd68827L101CA68827L101305/09/2024Elect Director Jason AttewDIRECTOR ELECTIONSISSUER2501400.0000000FOR2501400.000000FORS000002106Osisko Gold Royalties Ltd68827L101CA68827L101305/09/2024Elect Director Joanne FerstmanDIRECTOR ELECTIONSISSUER2501400.0000000FOR2501400.000000FORS000002106Osisko Gold Royalties Ltd68827L101CA68827L101305/09/2024Elect Director Edie HofmeisterDIRECTOR ELECTIONSISSUER2501400.0000000FOR2501400.000000FORS000002106Osisko Gold Royalties Ltd68827L101CA68827L101305/09/2024Elect Director W. Murray JohnDIRECTOR ELECTIONSISSUER2501400.0000000FOR2501400.000000FORS000002106Osisko Gold Royalties Ltd68827L101CA68827L101305/09/2024Elect Director Robert KrcmarovDIRECTOR ELECTIONSISSUER2501400.0000000FOR2501400.000000FORS000002106Osisko Gold Royalties Ltd68827L101CA68827L101305/09/2024Elect Director Pierre LabbeDIRECTOR ELECTIONSISSUER2501400.0000000FOR2501400.000000FORS000002106Osisko Gold Royalties Ltd68827L101CA68827L101305/09/2024Elect Director Norman MacDonaldDIRECTOR ELECTIONSISSUER2501400.0000000FOR2501400.000000FORS000002106Osisko Gold Royalties Ltd68827L101CA68827L101305/09/2024Elect Director Candace MacGibbonDIRECTOR ELECTIONSISSUER2501400.0000000FOR2501400.000000FORS000002106Osisko Gold Royalties Ltd68827L101CA68827L101305/09/2024Elect Director David SmithDIRECTOR ELECTIONSISSUER2501400.0000000FOR2501400.000000FORS000002106Osisko Gold Royalties Ltd68827L101CA68827L101305/09/2024Approve PricewaterhouseCoopers LLP as Auditors and Authorize Board to Fix Their RemunerationAUDIT-RELATEDISSUER2501400.0000000FOR2501400.000000FORS000002106Osisko Gold Royalties Ltd68827L101CA68827L101305/09/2024Re-approve Employee Share Purchase PlanCOMPENSATIONISSUER2501400.0000000FOR2501400.000000FORS000002106Osisko Gold Royalties Ltd68827L101CA68827L101305/09/2024Re-approve Restricted Share Unit PlanCOMPENSATIONISSUER2501400.0000000FOR2501400.000000FORS000002106Osisko Gold Royalties Ltd68827L101CA68827L101305/09/2024Advisory Vote on Executive Compensation ApproachCOMPENSATIONISSUER2501400.0000000FOR2501400.000000FORS000002106Globant SAL44385109LU097429987605/10/2024Approve Consolidated Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER2394127.0000000FOR2394127.000000FORS000002106Globant SAL44385109LU097429987605/10/2024Approve Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER2394127.0000000FOR2394127.000000FORS000002106Globant SAL44385109LU097429987605/10/2024Approve Allocation of IncomeCAPITAL STRUCTUREISSUER2394127.0000000FOR2394127.000000FORS000002106Globant SAL44385109LU097429987605/10/2024Approve Discharge of DirectorsCORPORATE GOVERNANCEISSUER2394127.0000000FOR2394127.000000FORS000002106Globant SAL44385109LU097429987605/10/2024Approve Remuneration of Directors during the Financial Year Ending on December 31, 2023COMPENSATIONISSUER2394127.0000000FOR2394127.000000FORS000002106Globant SAL44385109LU097429987605/10/2024Approve Remuneration of Directors for the Financial Year Ending on December 31, 2024COMPENSATIONISSUER2394127.0000000FOR2394127.000000FORS000002106Globant SAL44385109LU097429987605/10/2024Appoint PricewaterhouseCoopers, Societe Cooperative as Auditor for Annual Accounts and EU IFRS Consolidated AccountsAUDIT-RELATEDISSUER2394127.0000000FOR2394127.000000FORS000002106Globant SAL44385109LU097429987605/10/2024Appoint Price Waterhouse & Co. S.R.L. as Auditor for IFRS Consolidated AccountsAUDIT-RELATEDISSUER2394127.0000000FOR2394127.000000FORS000002106Globant SAL44385109LU097429987605/10/2024Reelect Martin Migoya as DirectorDIRECTOR ELECTIONSISSUER2394127.0000000FOR2394127.000000FORS000002106Globant SAL44385109LU097429987605/10/2024Elect Andrew McLaughlin as DirectorDIRECTOR ELECTIONSISSUER2394127.0000000FOR2394127.000000FORS000002106Globant SAL44385109LU097429987605/10/2024Elect Alejandro Nicolas Aguzin as DirectorDIRECTOR ELECTIONSISSUER2394127.0000000FOR2394127.000000FORS000002106Globant SAL44385109LU097429987605/10/2024Approve Share RepurchaseCAPITAL STRUCTUREISSUER2394127.0000000FOR2394127.000000FORS000002106Globant SAL44385109LU097429987605/10/2024Increase Authorized Share Capital and Amend Articles of AssociationCAPITAL STRUCTUREISSUER2394127.0000000FOR2394127.000000FORS000002106Louisiana-Pacific Corporation546347105US546347105305/10/2024Election of Class III Directors: F. Nicholas Grasberger IIIDIRECTOR ELECTIONSISSUER67300.0000000FOR67300.000000FORS000002106Louisiana-Pacific Corporation546347105US546347105305/10/2024Election of Class III Directors: Ozey K. Horton, Jr.DIRECTOR ELECTIONSISSUER67300.0000000FOR67300.000000FORS000002106Louisiana-Pacific Corporation546347105US546347105305/10/2024Election of Class III Directors: W. Bradley SouthernDIRECTOR ELECTIONSISSUER67300.0000000FOR67300.000000FORS000002106Louisiana-Pacific Corporation546347105US546347105305/10/2024Ratification of the selection of Deloitte & Touche LLP as LP's independent registered public accounting firm for 2024AUDIT-RELATEDISSUER67300.0000000FOR67300.000000FORS000002106Louisiana-Pacific Corporation546347105US546347105305/10/2024Advisory vote to approve named executive officer compensationSECTION 14A SAY-ON-PAY VOTESISSUER67300.0000000FOR67300.000000FORS000002106MSA Safety, Inc.553498106US553498106405/10/2024Election of Directors for a term expiring in 2027: Steven C. BlancoDIRECTOR ELECTIONSISSUER304572.0000000FOR304572.000000FORS000002106MSA Safety, Inc.553498106US553498106405/10/2024Election of Directors for a term expiring in 2027: Sandra Phillips RogersDIRECTOR ELECTIONSISSUER304572.0000000FOR304572.000000FORS000002106MSA Safety, Inc.553498106US553498106405/10/2024Election of Directors for a term expiring in 2027: Luca SaviDIRECTOR ELECTIONSISSUER304572.0000000FOR304572.000000FORS000002106MSA Safety, Inc.553498106US553498106405/10/2024Approval of Adoption of the Company's 2024 Non-Employee Directors' Equity Incentive Plan.COMPENSATIONISSUER304572.0000000FOR304572.000000FORS000002106MSA Safety, Inc.553498106US553498106405/10/2024Selection of Ernst & Young LLP as the Company's independent registered public accounting firm.AUDIT-RELATEDISSUER304572.0000000FOR304572.000000FORS000002106MSA Safety, Inc.553498106US553498106405/10/2024To provide an advisory vote to approve the executive compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER304572.0000000FOR304572.000000FORS000002106Insmed Incorporated457669307US457669307505/13/2024Election of four Class III directors, David R. Brennan, Leo Lee, Carol A. Schafer, and Melvin Sharoky, M.D., to serve until the 2027 Annual Meeting of Shareholders: David R. BrennanDIRECTOR ELECTIONSISSUER4564030.0000000FOR4564030.000000FORS000002106Insmed Incorporated457669307US457669307505/13/2024Election of four Class III directors, David R. Brennan, Leo Lee, Carol A. Schafer, and Melvin Sharoky, M.D., to serve until the 2027 Annual Meeting of Shareholders: Leo LeeDIRECTOR ELECTIONSISSUER4564030.0000000FOR4564030.000000FORS000002106Insmed Incorporated457669307US457669307505/13/2024Election of four Class III directors, David R. Brennan, Leo Lee, Carol A. Schafer, and Melvin Sharoky, M.D., to serve until the 2027 Annual Meeting of Shareholders: Carol A. SchaferDIRECTOR ELECTIONSISSUER4564030.0000000FOR4564030.000000FORS000002106Insmed Incorporated457669307US457669307505/13/2024Election of four Class III directors, David R. Brennan, Leo Lee, Carol A. Schafer, and Melvin Sharoky, M.D., to serve until the 2027 Annual Meeting of Shareholders: Melvin Sharoky, M.D.DIRECTOR ELECTIONSISSUER4564030.0000000FOR4564030.000000FORS000002106Insmed Incorporated457669307US457669307505/13/2024An advisory vote on the 2023 compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER4564030.0000000FOR4564030.000000FORS000002106Insmed Incorporated457669307US457669307505/13/2024Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2024.AUDIT-RELATEDISSUER4564030.0000000FOR4564030.000000FORS000002106Insmed Incorporated457669307US457669307505/13/2024Approval of Amendment No. 1 to the Insmed Incorporated Amended and Restated 2019 Incentive Plan.COMPENSATIONISSUER4564030.0000000FOR4564030.000000FORS000002106Atmus Filtration Technologies, Inc.04956D107US04956D107205/14/2024Election of Directors: Gretchen R. HaggertyDIRECTOR ELECTIONSISSUER1376395.0000000FOR1376395.000000FORS000002106Atmus Filtration Technologies, Inc.04956D107US04956D107205/14/2024Election of Directors: Jane A. LeipoldDIRECTOR ELECTIONSISSUER1376395.0000000FOR1376395.000000FORS000002106Atmus Filtration Technologies, Inc.04956D107US04956D107205/14/2024Advisory vote to approve the executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1376395.0000000FOR1376395.000000FORS000002106Atmus Filtration Technologies, Inc.04956D107US04956D107205/14/2024Advisory vote to approve the frequency of an advisory vote on executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1376395.0000000ONE YEAR1376395.000000FORS000002106Atmus Filtration Technologies, Inc.04956D107US04956D107205/14/2024Ratification of the appointment of PricewaterhouseCoopers LLP.AUDIT-RELATEDISSUER1376395.0000000FOR1376395.000000FORS000002106Prothena Corporation plcG72800108IE00B91XRN2005/14/2024To elect, by separate resolutions, four directors to hold office until no later than the Annual General Meeting of the Company's Shareholders in 2027, unless they resign, are removed from office, or are otherwise disqualified from serving as directors of the Company: Richard T. CollierDIRECTOR ELECTIONSISSUER1814107.0000000FOR1814107.000000FORS000002106Prothena Corporation plcG72800108IE00B91XRN2005/14/2024To elect, by separate resolutions, four directors to hold office until no later than the Annual General Meeting of the Company's Shareholders in 2027, unless they resign, are removed from office, or are otherwise disqualified from serving as directors of the Company: Shane M. CookeDIRECTOR ELECTIONSISSUER1814107.0000000FOR1814107.000000FORS000002106Prothena Corporation plcG72800108IE00B91XRN2005/14/2024To elect, by separate resolutions, four directors to hold office until no later than the Annual General Meeting of the Company's Shareholders in 2027, unless they resign, are removed from office, or are otherwise disqualified from serving as directors of the Company: William H. Dunn, Jr.DIRECTOR ELECTIONSISSUER1814107.0000000FOR1814107.000000FORS000002106Prothena Corporation plcG72800108IE00B91XRN2005/14/2024To elect, by separate resolutions, four directors to hold office until no later than the Annual General Meeting of the Company's Shareholders in 2027, unless they resign, are removed from office, or are otherwise disqualified from serving as directors of the Company: Daniel G. WelchDIRECTOR ELECTIONSISSUER1814107.0000000FOR1814107.000000FORS000002106Prothena Corporation plcG72800108IE00B91XRN2005/14/2024To ratify, in a non-binding vote, the appointment of KPMG LLP as the Company's independent registered public accounting firm for its fiscal year 2024 and to authorize, in a binding vote, the Company's Board of Directors, acting through its Audit Committee, to approve the remuneration of that auditor.AUDIT-RELATEDISSUER1814107.0000000FOR1814107.000000FORS000002106Prothena Corporation plcG72800108IE00B91XRN2005/14/2024To approve, in a non-binding advisory vote, the compensation of the executive officers named in the Company's Proxy Statement for the Annual General Meeting.SECTION 14A SAY-ON-PAY VOTESISSUER1814107.0000000FOR1814107.000000FORS000002106Prothena Corporation plcG72800108IE00B91XRN2005/14/2024To approve an amendment to the Company's 2018 Long Term Incentive Plan to increase the number of ordinary shares available for issuance under that Plan by 2,000,000 ordinary shares.COMPENSATIONISSUER1814107.0000000FOR1814107.000000FORS000002106Cytokinetics, Incorporated23282W605US23282W605705/15/2024To elect two Class II Directors: Robert I. BlumDIRECTOR ELECTIONSISSUER1240227.0000000FOR1240227.000000FORS000002106Cytokinetics, Incorporated23282W605US23282W605705/15/2024To elect two Class II Directors: Robert A. Hammington, M.D.DIRECTOR ELECTIONSISSUER1240227.0000000WITHHOLD1240227.000000AGAINSTS000002106Cytokinetics, Incorporated23282W605US23282W605705/15/2024To approve the amendment and restatement of the Company's Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of authorized shares reserved for issuance under such plan by 300,000 shares of common stock.COMPENSATIONISSUER1240227.0000000FOR1240227.000000FORS000002106Cytokinetics, Incorporated23282W605US23282W605705/15/2024To ratify the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER1240227.0000000FOR1240227.000000FORS000002106Cytokinetics, Incorporated23282W605US23282W605705/15/2024To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER1240227.0000000FOR1240227.000000FORS000002106Old Dominion Freight Line, Inc.679580100US679580100905/15/2024Election of twelve directors named below to the Company's Board of Directors for one-year terms and until their respective successors have been elected and qualified, as set forth in the accompanying proxy statement: Sherry A. AaholmDIRECTOR ELECTIONSISSUER1066198.0000000FOR1066198.000000FORS000002106Old Dominion Freight Line, Inc.679580100US679580100905/15/2024Election of twelve directors named below to the Company's Board of Directors for one-year terms and until their respective successors have been elected and qualified, as set forth in the accompanying proxy statement: David S. CongdonDIRECTOR ELECTIONSISSUER1066198.0000000FOR1066198.000000FORS000002106Old Dominion Freight Line, Inc.679580100US679580100905/15/2024Election of twelve directors named below to the Company's Board of Directors for one-year terms and until their respective successors have been elected and qualified, as set forth in the accompanying proxy statement: John R. Congdon, Jr.DIRECTOR ELECTIONSISSUER1066198.0000000FOR1066198.000000FORS000002106Old Dominion Freight Line, Inc.679580100US679580100905/15/2024Election of twelve directors named below to the Company's Board of Directors for one-year terms and until their respective successors have been elected and qualified, as set forth in the accompanying proxy statement: Andrew S. DavisDIRECTOR ELECTIONSISSUER1066198.0000000FOR1066198.000000FORS000002106Old Dominion Freight Line, Inc.679580100US679580100905/15/2024Election of twelve directors named below to the Company's Board of Directors for one-year terms and until their respective successors have been elected and qualified, as set forth in the accompanying proxy statement: Kevin M. FreemanDIRECTOR ELECTIONSISSUER1066198.0000000FOR1066198.000000FORS000002106Old Dominion Freight Line, Inc.679580100US679580100905/15/2024Election of twelve directors named below to the Company's Board of Directors for one-year terms and until their respective successors have been elected and qualified, as set forth in the accompanying proxy statement: Bradley R. GaboschDIRECTOR ELECTIONSISSUER1066198.0000000FOR1066198.000000FORS000002106Old Dominion Freight Line, Inc.679580100US679580100905/15/2024Election of twelve directors named below to the Company's Board of Directors for one-year terms and until their respective successors have been elected and qualified, as set forth in the accompanying proxy statement: Greg C. GanttDIRECTOR ELECTIONSISSUER1066198.0000000FOR1066198.000000FORS000002106Old Dominion Freight Line, Inc.679580100US679580100905/15/2024Election of twelve directors named below to the Company's Board of Directors for one-year terms and until their respective successors have been elected and qualified, as set forth in the accompanying proxy statement: John D. KasardaDIRECTOR ELECTIONSISSUER1066198.0000000FOR1066198.000000FORS000002106Old Dominion Freight Line, Inc.679580100US679580100905/15/2024Election of twelve directors named below to the Company's Board of Directors for one-year terms and until their respective successors have been elected and qualified, as set forth in the accompanying proxy statement: Cheryl S. MillerDIRECTOR ELECTIONSISSUER1066198.0000000FOR1066198.000000FORS000002106Old Dominion Freight Line, Inc.679580100US679580100905/15/2024Election of twelve directors named below to the Company's Board of Directors for one-year terms and until their respective successors have been elected and qualified, as set forth in the accompanying proxy statement: Wendy T. StallingsDIRECTOR ELECTIONSISSUER1066198.0000000FOR1066198.000000FORS000002106Old Dominion Freight Line, Inc.679580100US679580100905/15/2024Election of twelve directors named below to the Company's Board of Directors for one-year terms and until their respective successors have been elected and qualified, as set forth in the accompanying proxy statement: Thomas A. Stith, IIIDIRECTOR ELECTIONSISSUER1066198.0000000FOR1066198.000000FORS000002106Old Dominion Freight Line, Inc.679580100US679580100905/15/2024Election of twelve directors named below to the Company's Board of Directors for one-year terms and until their respective successors have been elected and qualified, as set forth in the accompanying proxy statement: Leo H. SuggsDIRECTOR ELECTIONSISSUER1066198.0000000FOR1066198.000000FORS000002106Old Dominion Freight Line, Inc.679580100US679580100905/15/2024Approval, on an advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1066198.0000000FOR1066198.000000FORS000002106Old Dominion Freight Line, Inc.679580100US679580100905/15/2024Approval of an amendment to the Company's Amended and Restated Articles of Incorporation to Increase the number of authorized shares of our common stock.CAPITAL STRUCTUREISSUER1066198.0000000FOR1066198.000000FORS000002106Old Dominion Freight Line, Inc.679580100US679580100905/15/2024Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024.AUDIT-RELATEDISSUER1066198.0000000FOR1066198.000000FORS000002106Old Dominion Freight Line, Inc.679580100US679580100905/15/2024Shareholder proposal regarding greenhouse gas reduction.ENVIRONMENT OR CLIMATESECURITY HOLDER1066198.0000000AGAINST1066198.000000FORS000002106Reliance, Inc.759509102US759509102305/15/2024Election of Directors: Lisa L. BaldwinDIRECTOR ELECTIONSISSUER494729.0000000FOR494729.000000FORS000002106Reliance, Inc.759509102US759509102305/15/2024Election of Directors: Karen W. ColoniasDIRECTOR ELECTIONSISSUER494729.0000000FOR494729.000000FORS000002106Reliance, Inc.759509102US759509102305/15/2024Election of Directors: Frank J. DellaquilaDIRECTOR ELECTIONSISSUER494729.0000000FOR494729.000000FORS000002106Reliance, Inc.759509102US759509102305/15/2024Election of Directors: Mark V. KaminskiDIRECTOR ELECTIONSISSUER494729.0000000FOR494729.000000FORS000002106Reliance, Inc.759509102US759509102305/15/2024Election of Directors: Karla R. LewisDIRECTOR ELECTIONSISSUER494729.0000000FOR494729.000000FORS000002106Reliance, Inc.759509102US759509102305/15/2024Election of Directors: Robert A. McEvoyDIRECTOR ELECTIONSISSUER494729.0000000FOR494729.000000FORS000002106Reliance, Inc.759509102US759509102305/15/2024Election of Directors: David W. SeegerDIRECTOR ELECTIONSISSUER494729.0000000FOR494729.000000FORS000002106Reliance, Inc.759509102US759509102305/15/2024Election of Directors: Douglas W. StotlarDIRECTOR ELECTIONSISSUER494729.0000000FOR494729.000000FORS000002106Reliance, Inc.759509102US759509102305/15/2024To consider a non-binding, advisory vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER494729.0000000FOR494729.000000FORS000002106Reliance, Inc.759509102US759509102305/15/2024To ratify the appointment of KPMG LLP as our independent registered public accounting firm for 2024.AUDIT-RELATEDISSUER494729.0000000FOR494729.000000FORS000002106Reliance, Inc.759509102US759509102305/15/2024To approve an amendment to the Reliance, Inc. Second Amended and Restated 2015 Incentive Award Plan to extend its duration by 5 years.COMPENSATIONISSUER494729.0000000FOR494729.000000FORS000002106Vera Therapeutics, Inc.92337R101US92337R101405/15/2024To elect the two Class III directors named below to hold office until the Company's 2027 annual meeting of stockholders: Andrew Cheng, M.D., Ph.D.DIRECTOR ELECTIONSISSUER971887.0000000WITHHOLD971887.000000AGAINSTS000002106Vera Therapeutics, Inc.92337R101US92337R101405/15/2024To elect the two Class III directors named below to hold office until the Company's 2027 annual meeting of stockholders: Scott MorrisonDIRECTOR ELECTIONSISSUER971887.0000000FOR971887.000000FORS000002106Vera Therapeutics, Inc.92337R101US92337R101405/15/2024To ratify the selection by the Audit Committee of the Board of Directors of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER971887.0000000FOR971887.000000FORS000002106Alnylam Pharmaceuticals, Inc.02043Q107US02043Q107605/16/2024To elect the following nominees as Class II directors of Alnylam: Dennis A. Ausiello, M.D.DIRECTOR ELECTIONSISSUER1341345.0000000AGAINST1341345.000000AGAINSTS000002106Alnylam Pharmaceuticals, Inc.02043Q107US02043Q107605/16/2024To elect the following nominees as Class II directors of Alnylam: Olivier Brandicourt, M.D.DIRECTOR ELECTIONSISSUER1341345.0000000AGAINST1341345.000000AGAINSTS000002106Alnylam Pharmaceuticals, Inc.02043Q107US02043Q107605/16/2024To elect the following nominees as Class II directors of Alnylam: Peter N. KelloggDIRECTOR ELECTIONSISSUER1341345.0000000AGAINST1341345.000000AGAINSTS000002106Alnylam Pharmaceuticals, Inc.02043Q107US02043Q107605/16/2024To elect the following nominees as Class II directors of Alnylam: David E.I. PyottDIRECTOR ELECTIONSISSUER1341345.0000000AGAINST1341345.000000AGAINSTS000002106Alnylam Pharmaceuticals, Inc.02043Q107US02043Q107605/16/2024To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1341345.0000000FOR1341345.000000FORS000002106Alnylam Pharmaceuticals, Inc.02043Q107US02043Q107605/16/2024To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as Alnylam's independent auditors for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER1341345.0000000FOR1341345.000000FORS000002106Repligen Corporation759916109US759916109505/16/2024Election of Directors: Tony J. HuntDIRECTOR ELECTIONSISSUER2212883.0000000FOR2212883.000000FORS000002106Repligen Corporation759916109US759916109505/16/2024Election of Directors: Karen A. DawesDIRECTOR ELECTIONSISSUER2212883.0000000FOR2212883.000000FORS000002106Repligen Corporation759916109US759916109505/16/2024Election of Directors: Nicolas M. BarthelemyDIRECTOR ELECTIONSISSUER2212883.0000000FOR2212883.000000FORS000002106Repligen Corporation759916109US759916109505/16/2024Election of Directors: Carrie Eglinton MannerDIRECTOR ELECTIONSISSUER2212883.0000000FOR2212883.000000FORS000002106Repligen Corporation759916109US759916109505/16/2024Election of Directors: Konstantin Konstantinov, Ph.D.DIRECTOR ELECTIONSISSUER2212883.0000000FOR2212883.000000FORS000002106Repligen Corporation759916109US759916109505/16/2024Election of Directors: Martin D. Madaus, D.V.M., Ph.D.DIRECTOR ELECTIONSISSUER2212883.0000000FOR2212883.000000FORS000002106Repligen Corporation759916109US759916109505/16/2024Election of Directors: Rohin Mhatre, Ph.D.DIRECTOR ELECTIONSISSUER2212883.0000000FOR2212883.000000FORS000002106Repligen Corporation759916109US759916109505/16/2024Election of Directors: Glenn P. MuirDIRECTOR ELECTIONSISSUER2212883.0000000FOR2212883.000000FORS000002106Repligen Corporation759916109US759916109505/16/2024Election of Directors: Margaret A. PaxDIRECTOR ELECTIONSISSUER2212883.0000000FOR2212883.000000FORS000002106Repligen Corporation759916109US759916109505/16/2024Ratification of the selection of Ernst & Young LLP as Repligen Corporation's independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER2212883.0000000FOR2212883.000000FORS000002106Repligen Corporation759916109US759916109505/16/2024Advisory vote to approve the compensation paid to Repligen Corporation's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER2212883.0000000FOR2212883.000000FORS000002106SpringWorks Therapeutics, Inc.85205L107US85205L107005/16/2024Election of Class II Director: Freda Lewis-HallDIRECTOR ELECTIONSISSUER1375044.0000000FOR1375044.000000FORS000002106SpringWorks Therapeutics, Inc.85205L107US85205L107005/16/2024Ratification of the appointment of Ernst & Young LLP as SpringWorks Therapeutics' independent registered public accounting firm for the fiscal year ending December 31, 2024AUDIT-RELATEDISSUER1375044.0000000FOR1375044.000000FORS000002106SpringWorks Therapeutics, Inc.85205L107US85205L107005/16/2024Non-binding advisory vote on executive compensationSECTION 14A SAY-ON-PAY VOTESISSUER1375044.0000000AGAINST1375044.000000AGAINSTS000002106Nurix Therapeutics, Inc.67080M103US67080M103605/20/2024Election of Directors: Julia P. GregoryDIRECTOR ELECTIONSISSUER1140710.0000000FOR1140710.000000FORS000002106Nurix Therapeutics, Inc.67080M103US67080M103605/20/2024Election of Directors: David L. Lacey, M.D.DIRECTOR ELECTIONSISSUER1140710.0000000FOR1140710.000000FORS000002106Nurix Therapeutics, Inc.67080M103US67080M103605/20/2024Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending November 30, 2024.AUDIT-RELATEDISSUER1140710.0000000FOR1140710.000000FORS000002106Nurix Therapeutics, Inc.67080M103US67080M103605/20/2024To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER1140710.0000000FOR1140710.000000FORS000002106MacroGenics, Inc.556099109US556099109405/21/2024To elect three Class II directors listed in the proxy materials to hold office until the 2027 Annual Meeting of Stockholders or until their successors are elected and qualified, or until their earlier death, resignation or removal: Scott JacksonDIRECTOR ELECTIONSISSUER750706.0000000FOR750706.000000FORS000002106MacroGenics, Inc.556099109US556099109405/21/2024To elect three Class II directors listed in the proxy materials to hold office until the 2027 Annual Meeting of Stockholders or until their successors are elected and qualified, or until their earlier death, resignation or removal: Margaret Liu, M.D.DIRECTOR ELECTIONSISSUER750706.0000000FOR750706.000000FORS000002106MacroGenics, Inc.556099109US556099109405/21/2024To elect three Class II directors listed in the proxy materials to hold office until the 2027 Annual Meeting of Stockholders or until their successors are elected and qualified, or until their earlier death, resignation or removal: David Stump, M.D.DIRECTOR ELECTIONSISSUER750706.0000000FOR750706.000000FORS000002106MacroGenics, Inc.556099109US556099109405/21/2024To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER750706.0000000FOR750706.000000FORS000002106MacroGenics, Inc.556099109US556099109405/21/2024To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy materials.SECTION 14A SAY-ON-PAY VOTESISSUER750706.0000000FOR750706.000000FORS000002106MacroGenics, Inc.556099109US556099109405/21/2024To approve the amendment to the MacroGenics, Inc. 2023 Equity Incentive Plan, as disclosed in the proxy materials.COMPENSATIONISSUER750706.0000000FOR750706.000000FORS000002106Noble Corporation plcG65431127GB00BMXNWH0705/21/2024Re-elect or elect the following nominees as directors of the Company for a one-year term that will expire at the Annual General Meeting in 2025: Robert W. EiflerDIRECTOR ELECTIONSISSUER2248160.0000000FOR2248160.000000FORS000002106Noble Corporation plcG65431127GB00BMXNWH0705/21/2024Re-elect or elect the following nominees as directors of the Company for a one-year term that will expire at the Annual General Meeting in 2025: Claus V. HemmingsenDIRECTOR ELECTIONSISSUER2248160.0000000FOR2248160.000000FORS000002106Noble Corporation plcG65431127GB00BMXNWH0705/21/2024Re-elect or elect the following nominees as directors of the Company for a one-year term that will expire at the Annual General Meeting in 2025: Alan J. HirshbergDIRECTOR ELECTIONSISSUER2248160.0000000FOR2248160.000000FORS000002106Noble Corporation plcG65431127GB00BMXNWH0705/21/2024Re-elect or elect the following nominees as directors of the Company for a one-year term that will expire at the Annual General Meeting in 2025: Kristin H. HolthDIRECTOR ELECTIONSISSUER2248160.0000000FOR2248160.000000FORS000002106Noble Corporation plcG65431127GB00BMXNWH0705/21/2024Re-elect or elect the following nominees as directors of the Company for a one-year term that will expire at the Annual General Meeting in 2025: H. Keith JenningsDIRECTOR ELECTIONSISSUER2248160.0000000FOR2248160.000000FORS000002106Noble Corporation plcG65431127GB00BMXNWH0705/21/2024Re-elect or elect the following nominees as directors of the Company for a one-year term that will expire at the Annual General Meeting in 2025: Alastair MaxwellDIRECTOR ELECTIONSISSUER2248160.0000000FOR2248160.000000FORS000002106Noble Corporation plcG65431127GB00BMXNWH0705/21/2024Re-elect or elect the following nominees as directors of the Company for a one-year term that will expire at the Annual General Meeting in 2025: Ann PickardDIRECTOR ELECTIONSISSUER2248160.0000000FOR2248160.000000FORS000002106Noble Corporation plcG65431127GB00BMXNWH0705/21/2024Re-elect or elect the following nominees as directors of the Company for a one-year term that will expire at the Annual General Meeting in 2025: Charles M. SledgeDIRECTOR ELECTIONSISSUER2248160.0000000FOR2248160.000000FORS000002106Noble Corporation plcG65431127GB00BMXNWH0705/21/2024Ratification of Appointment of PricewaterhouseCoopers LLP (US) as Independent Registered Public Accounting Firm for Fiscal Year 2024AUDIT-RELATEDISSUER2248160.0000000FOR2248160.000000FORS000002106Noble Corporation plcG65431127GB00BMXNWH0705/21/2024Re-appointment of PricewaterhouseCoopers LLP (UK) as UK Statutory AuditorAUDIT-RELATEDISSUER2248160.0000000FOR2248160.000000FORS000002106Noble Corporation plcG65431127GB00BMXNWH0705/21/2024Authorization of Audit Committee to Determine UK Statutory Auditors' RemunerationAUDIT-RELATEDISSUER2248160.0000000FOR2248160.000000FORS000002106Noble Corporation plcG65431127GB00BMXNWH0705/21/2024Approval of the Company's Executive CompensationSECTION 14A SAY-ON-PAY VOTESISSUER2248160.0000000FOR2248160.000000FORS000002106Noble Corporation plcG65431127GB00BMXNWH0705/21/2024Approval of the Directors' Remuneration ReportCOMPENSATIONISSUER2248160.0000000FOR2248160.000000FORS000002106Noble Corporation plcG65431127GB00BMXNWH0705/21/2024Approval of an Amendment to the Noble Corporation plc 2022 Long-Term Incentive Plan to incorporate a new minimum vesting provision, increase the number of shares of common stock that may be issued under the plan and make other amendmentsCOMPENSATIONISSUER2248160.0000000FOR2248160.000000FORS000002106Dyne Therapeutics, Inc.26818M108US26818M108005/22/2024The election of three Class I directors, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders and until his or her respective successor has been duly elected and qualified: Carlo Incerti, M.D.DIRECTOR ELECTIONSISSUER495007.0000000FOR495007.000000FORS000002106Dyne Therapeutics, Inc.26818M108US26818M108005/22/2024The election of three Class I directors, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders and until his or her respective successor has been duly elected and qualified: Catherine Stehman-Breen, M.D.DIRECTOR ELECTIONSISSUER495007.0000000FOR495007.000000FORS000002106Dyne Therapeutics, Inc.26818M108US26818M108005/22/2024The election of three Class I directors, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders and until his or her respective successor has been duly elected and qualified: John G. CoxDIRECTOR ELECTIONSISSUER495007.0000000FOR495007.000000FORS000002106Dyne Therapeutics, Inc.26818M108US26818M108005/22/2024The ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER495007.0000000FOR495007.000000FORS000002106Neurocrine Biosciences, Inc.64125C109US64125C109905/22/2024Election of Directors: William H. Rastetter, Ph.D.DIRECTOR ELECTIONSISSUER236718.0000000WITHHOLD236718.000000AGAINSTS000002106Neurocrine Biosciences, Inc.64125C109US64125C109905/22/2024Election of Directors: George J. MorrowDIRECTOR ELECTIONSISSUER236718.0000000WITHHOLD236718.000000AGAINSTS000002106Neurocrine Biosciences, Inc.64125C109US64125C109905/22/2024Election of Directors: Leslie V. NorwalkDIRECTOR ELECTIONSISSUER236718.0000000WITHHOLD236718.000000AGAINSTS000002106Neurocrine Biosciences, Inc.64125C109US64125C109905/22/2024Election of Directors: Christine A. PoonDIRECTOR ELECTIONSISSUER236718.0000000FOR236718.000000FORS000002106Neurocrine Biosciences, Inc.64125C109US64125C109905/22/2024Advisory vote on the compensation paid to the Company's named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER236718.0000000FOR236718.000000FORS000002106Neurocrine Biosciences, Inc.64125C109US64125C109905/22/2024To approve an amendment of the Company's 2020 Equity Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 3,635,000 shares; andCOMPENSATIONISSUER236718.0000000FOR236718.000000FORS000002106Neurocrine Biosciences, Inc.64125C109US64125C109905/22/2024To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER236718.0000000FOR236718.000000FORS000002106Rapt Therapeutics, Inc.75382E109US75382E109105/22/2024Election of Directors: William J. RieflinDIRECTOR ELECTIONSISSUER1377775.0000000FOR1377775.000000FORS000002106Rapt Therapeutics, Inc.75382E109US75382E109105/22/2024Election of Directors: Linda KozickDIRECTOR ELECTIONSISSUER1377775.0000000FOR1377775.000000FORS000002106Rapt Therapeutics, Inc.75382E109US75382E109105/22/2024Election of Directors: Lori Lyons-WilliamsDIRECTOR ELECTIONSISSUER1377775.0000000FOR1377775.000000FORS000002106Rapt Therapeutics, Inc.75382E109US75382E109105/22/2024Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm of RAPT Therapeutics, Inc. for its fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER1377775.0000000FOR1377775.000000FORS000002106Day One Biopharmaceuticals, Inc.23954D109US23954D109005/23/2024Election of Class III Directors: Jeremy BenderDIRECTOR ELECTIONSISSUER1430839.0000000FOR1430839.000000FORS000002106Day One Biopharmaceuticals, Inc.23954D109US23954D109005/23/2024Election of Class III Directors: Habib DableDIRECTOR ELECTIONSISSUER1430839.0000000FOR1430839.000000FORS000002106Day One Biopharmaceuticals, Inc.23954D109US23954D109005/23/2024Election of Class III Directors: Saira RamasastryDIRECTOR ELECTIONSISSUER1430839.0000000FOR1430839.000000FORS000002106Day One Biopharmaceuticals, Inc.23954D109US23954D109005/23/2024Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024.AUDIT-RELATEDISSUER1430839.0000000FOR1430839.000000FORS000002106Day One Biopharmaceuticals, Inc.23954D109US23954D109005/23/2024Approval, on a non-binding advisory basis, of the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1430839.0000000FOR1430839.000000FORS000002106Day One Biopharmaceuticals, Inc.23954D109US23954D109005/23/2024Selection, on a non-binding advisory basis, of whether future advisory votes on the compensation of our named executive officers should be every one, two or three years.SECTION 14A SAY-ON-PAY VOTESISSUER1430839.0000000ONE YEAR1430839.000000FORS000002106Immunocore Holdings Plc45258D105US45258D105405/23/2024To re-appoint as a director Bahija Jallal, Ph.D., who retires in accordance with the articles of association.DIRECTOR ELECTIONSISSUER409100.0000000FOR409100.000000FORS000002106Immunocore Holdings Plc45258D105US45258D105405/23/2024To re-appoint as a director Professor Sir John Bell, who retires in accordance with the articles of association.DIRECTOR ELECTIONSISSUER409100.0000000FOR409100.000000FORS000002106Immunocore Holdings Plc45258D105US45258D105405/23/2024To approve, on advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER409100.0000000FOR409100.000000FORS000002106Immunocore Holdings Plc45258D105US45258D105405/23/2024To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER409100.0000000ONE YEAR409100.000000FORS000002106Immunocore Holdings Plc45258D105US45258D105405/23/2024To ratify the appointment of Deloitte LLP, a limited liability partnership organized under the laws of England, as the Company's U.S. independent registered public accounting firm for the year ending December 31, 2024.AUDIT-RELATEDISSUER409100.0000000FOR409100.000000FORS000002106Immunocore Holdings Plc45258D105US45258D105405/23/2024To re-appoint Deloitte LLP, a limited liability partnership organized under the laws of England, as the Company's U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders.AUDIT-RELATEDISSUER409100.0000000FOR409100.000000FORS000002106Immunocore Holdings Plc45258D105US45258D105405/23/2024To authorize the directors to determine the U.K. statutory auditors' remuneration for the year ending December 31, 2024.AUDIT-RELATEDISSUER409100.0000000FOR409100.000000FORS000002106Immunocore Holdings Plc45258D105US45258D105405/23/2024To receive and adopt the U.K. statutory annual accounts and reports for the year ended December 31, 2023 (the "2023 U.K. Annual Report").CORPORATE GOVERNANCEISSUER409100.0000000FOR409100.000000FORS000002106Immunocore Holdings Plc45258D105US45258D105405/23/2024To approve the directors' remuneration report for the year ended December 31, 2023, which is set forth as Annex A to the proxy statement and on pages 20 to 47 (inclusive) of the 2023 U.K. Annual Report.COMPENSATIONISSUER409100.0000000FOR409100.000000FORS000002106Immunocore Holdings Plc45258D105US45258D105405/23/2024To authorise the Company to make political donations/ incur political expenditure.OTHER SOCIAL ISSUESISSUER409100.0000000FOR409100.000000FORS000002106Immunocore Holdings Plc45258D105US45258D105405/23/2024That, with effect from the conclusion of the AGM, the draft articles of association produced to the AGM and, for the purpose of identification, initialed by the Chairman, be adopted as the articles of association of the Company in substitution for, and to the exclusion of, the Company's existing articles of association.CORPORATE GOVERNANCEISSUER409100.0000000FOR409100.000000FORS000002106Longboard Pharmaceuticals, Inc.54300N103US54300N103705/23/2024To elect the two Class III directors named herein to hold office until the Company's 2027 annual meeting of stockholders: Paul J. SekhriDIRECTOR ELECTIONSISSUER872701.0000000WITHHOLD872701.000000AGAINSTS000002106Longboard Pharmaceuticals, Inc.54300N103US54300N103705/23/2024To elect the two Class III directors named herein to hold office until the Company's 2027 annual meeting of stockholders: Phillip M. SchneiderDIRECTOR ELECTIONSISSUER872701.0000000FOR872701.000000FORS000002106Longboard Pharmaceuticals, Inc.54300N103US54300N103705/23/2024To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to limit the liability of officers of the Company to the maximum extent permitted by law as permitted pursuant to Section 102(b)(7) of the Delaware General Corporation Law.CORPORATE GOVERNANCEISSUER872701.0000000FOR872701.000000FORS000002106Longboard Pharmaceuticals, Inc.54300N103US54300N103705/23/2024To ratify the selection by the Audit Committee of the Board of Directors of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER872701.0000000FOR872701.000000FORS000002106On Holding AGH5919C104CH113454047005/23/2024Accept Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER168600.0000000FOR168600.000000FORS000002106On Holding AGH5919C104CH113454047005/23/2024Approve Allocation of Income and Omission of DividendsCAPITAL STRUCTUREISSUER168600.0000000FOR168600.000000FORS000002106On Holding AGH5919C104CH113454047005/23/2024Approve Non-Financial ReportCORPORATE GOVERNANCEENVIRONMENT OR CLIMATEHUMAN RIGHTS OR HUMAN CAPITAL/WORKFORCEDIVERSITY, EQUITY, AND INCLUSIONOTHER SOCIAL ISSUESISSUER168600.0000000FOR168600.000000FORS000002106On Holding AGH5919C104CH113454047005/23/2024Approve Discharge of Board and Senior ManagementCORPORATE GOVERNANCEISSUER168600.0000000FOR168600.000000FORS000002106On Holding AGH5919C104CH113454047005/23/2024Reelect Alex Perez as Representative of Class A Shares HoldersDIRECTOR ELECTIONSISSUER168600.0000000FOR168600.000000FORS000002106On Holding AGH5919C104CH113454047005/23/2024Reelect David Allemann as DirectorDIRECTOR ELECTIONSISSUER168600.0000000FOR168600.000000FORS000002106On Holding AGH5919C104CH113454047005/23/2024Reelect Amy Banse as DirectorDIRECTOR ELECTIONSISSUER168600.0000000FOR168600.000000FORS000002106On Holding AGH5919C104CH113454047005/23/2024Reelect Olivier Bernhard as DirectorDIRECTOR ELECTIONSISSUER168600.0000000FOR168600.000000FORS000002106On Holding AGH5919C104CH113454047005/23/2024Reelect Caspar Coppetti as DirectorDIRECTOR ELECTIONSISSUER168600.0000000FOR168600.000000FORS000002106On Holding AGH5919C104CH113454047005/23/2024Reelect Dennis Durkin as DirectorDIRECTOR ELECTIONSISSUER168600.0000000FOR168600.000000FORS000002106On Holding AGH5919C104CH113454047005/23/2024Reelect Kenneth Fox as DirectorDIRECTOR ELECTIONSISSUER168600.0000000FOR168600.000000FORS000002106On Holding AGH5919C104CH113454047005/23/2024Reelect Alex Perez as DirectorDIRECTOR ELECTIONSISSUER168600.0000000FOR168600.000000FORS000002106On Holding AGH5919C104CH113454047005/23/2024Elect Laura Miele as DirectorDIRECTOR ELECTIONSISSUER168600.0000000FOR168600.000000FORS000002106On Holding AGH5919C104CH113454047005/23/2024Reelect David Allemann as Board Co-ChairDIRECTOR ELECTIONSISSUER168600.0000000FOR168600.000000FORS000002106On Holding AGH5919C104CH113454047005/23/2024Reelect Caspar Coppetti as Board Co-ChairDIRECTOR ELECTIONSISSUER168600.0000000FOR168600.000000FORS000002106On Holding AGH5919C104CH113454047005/23/2024Reappoint Kenneth Fox as Member of the Nomination and Compensation CommitteeDIRECTOR ELECTIONSCORPORATE GOVERNANCEISSUER168600.0000000FOR168600.000000FORS000002106On Holding AGH5919C104CH113454047005/23/2024Reappoint Alex Perez as Member of the Nomination and Compensation CommitteeDIRECTOR ELECTIONSCORPORATE GOVERNANCEISSUER168600.0000000FOR168600.000000FORS000002106On Holding AGH5919C104CH113454047005/23/2024Reappoint Amy Banse as Member of the Nomination and Compensation CommitteeDIRECTOR ELECTIONSCORPORATE GOVERNANCEISSUER168600.0000000FOR168600.000000FORS000002106On Holding AGH5919C104CH113454047005/23/2024Designate Keller AG as Independent ProxyCORPORATE GOVERNANCEISSUER168600.0000000FOR168600.000000FORS000002106On Holding AGH5919C104CH113454047005/23/2024Ratify PricewaterhouseCoopers AG as AuditorsAUDIT-RELATEDISSUER168600.0000000FOR168600.000000FORS000002106On Holding AGH5919C104CH113454047005/23/2024Approve Remuneration Report (Non-Binding)COMPENSATIONISSUER168600.0000000FOR168600.000000FORS000002106On Holding AGH5919C104CH113454047005/23/2024Approve Remuneration of Directors in the Amount of CHF 2 MillionCOMPENSATIONISSUER168600.0000000FOR168600.000000FORS000002106On Holding AGH5919C104CH113454047005/23/2024Approve Remuneration of Executive Committee in the Amount of CHF 26 MillionCOMPENSATIONISSUER168600.0000000FOR168600.000000FORS000002106On Holding AGH5919C104CH113454047005/23/2024Transact Other Business (Voting)CORPORATE GOVERNANCEISSUER168600.0000000AGAINST168600.000000AGAINSTS000002106Wingstop Inc.974155103US974155103305/23/2024Elect three Class III directors nominated by the Board of Directors for a term that expires at the 2027 Annual Meeting of Stockholders: Kate S. LavelleDIRECTOR ELECTIONSISSUER1359824.0000000FOR1359824.000000FORS000002106Wingstop Inc.974155103US974155103305/23/2024Elect three Class III directors nominated by the Board of Directors for a term that expires at the 2027 Annual Meeting of Stockholders: Kilandigalu (Kay) M. MadatiDIRECTOR ELECTIONSISSUER1359824.0000000FOR1359824.000000FORS000002106Wingstop Inc.974155103US974155103305/23/2024Elect three Class III directors nominated by the Board of Directors for a term that expires at the 2027 Annual Meeting of Stockholders: Michael J. SkipworthDIRECTOR ELECTIONSISSUER1359824.0000000FOR1359824.000000FORS000002106Wingstop Inc.974155103US974155103305/23/2024Ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for fiscal year 2024;AUDIT-RELATEDISSUER1359824.0000000FOR1359824.000000FORS000002106Wingstop Inc.974155103US974155103305/23/2024Approve, on an advisory basis, the compensation of the Company's named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER1359824.0000000FOR1359824.000000FORS000002106Wingstop Inc.974155103US974155103305/23/2024Approve, on an advisory basis, the frequency of future advisory votes to approve the compensation of the Company's named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER1359824.0000000ONE YEAR1359824.000000FORS000002106Wingstop Inc.974155103US974155103305/23/2024Approve the Wingstop Inc. 2024 Omnibus Incentive Plan;COMPENSATIONISSUER1359824.0000000FOR1359824.000000FORS000002106Wingstop Inc.974155103US974155103305/23/2024Vote on a stockholder proposal regarding greenhouse gas emissions reporting and goals, if properly presented at the Annual Meeting of Stockholders; andENVIRONMENT OR CLIMATESECURITY HOLDER1359824.0000000AGAINST1359824.000000FORS000002106Arcellx, Inc.03940C100US03940C100905/24/2024To elect three Class II directors to hold office until our 2027 annual meeting of stockholders and until their respective successors are elected and qualified: Jill CarrollDIRECTOR ELECTIONSISSUER468633.0000000FOR468633.000000FORS000002106Arcellx, Inc.03940C100US03940C100905/24/2024To elect three Class II directors to hold office until our 2027 annual meeting of stockholders and until their respective successors are elected and qualified: Kavita PatelDIRECTOR ELECTIONSISSUER468633.0000000FOR468633.000000FORS000002106Arcellx, Inc.03940C100US03940C100905/24/2024To elect three Class II directors to hold office until our 2027 annual meeting of stockholders and until their respective successors are elected and qualified: Olivia WareDIRECTOR ELECTIONSISSUER468633.0000000FOR468633.000000FORS000002106Arcellx, Inc.03940C100US03940C100905/24/2024To approve, on an advisory basis, the compensation of the named executive officers identified in the 2023 Summary Compensation Table in the "Executive Compensation" section of the proxy statement (the "Say-on-Pay Vote").SECTION 14A SAY-ON-PAY VOTESISSUER468633.0000000AGAINST468633.000000AGAINSTS000002106Arcellx, Inc.03940C100US03940C100905/24/2024To approve, on an advisory basis, the frequency of future Say-on-Pay Votes.SECTION 14A SAY-ON-PAY VOTESISSUER468633.0000000ONE YEAR468633.000000FORS000002106Arcellx, Inc.03940C100US03940C100905/24/2024To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER468633.0000000FOR468633.000000FORS000002106Acadia Pharmaceuticals Inc.004225108US004225108405/29/2024To elect three Class II directors to hold office until the Company's 2027 Annual Meeting of Stockholders: Julian C. BakerDIRECTOR ELECTIONSISSUER1528364.0000000WITHHOLD1528364.000000AGAINSTS000002106Acadia Pharmaceuticals Inc.004225108US004225108405/29/2024To elect three Class II directors to hold office until the Company's 2027 Annual Meeting of Stockholders: Stephen R. Biggar, M.D., Ph.D.DIRECTOR ELECTIONSISSUER1528364.0000000WITHHOLD1528364.000000AGAINSTS000002106Acadia Pharmaceuticals Inc.004225108US004225108405/29/2024To elect three Class II directors to hold office until the Company's 2027 Annual Meeting of Stockholders: Daniel B. SolandDIRECTOR ELECTIONSISSUER1528364.0000000WITHHOLD1528364.000000AGAINSTS000002106Acadia Pharmaceuticals Inc.004225108US004225108405/29/2024To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in this proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER1528364.0000000FOR1528364.000000FORS000002106Acadia Pharmaceuticals Inc.004225108US004225108405/29/2024To approve the Company's 2024 Equity Incentive Plan.COMPENSATIONISSUER1528364.0000000FOR1528364.000000FORS000002106Acadia Pharmaceuticals Inc.004225108US004225108405/29/2024To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER1528364.0000000FOR1528364.000000FORS000002106Arvinas, Inc.04335A105US04335A105105/29/2024Election of Directors: Edward Kennedy, Jr.DIRECTOR ELECTIONSISSUER1760290.0000000FOR1760290.000000FORS000002106Arvinas, Inc.04335A105US04335A105105/29/2024Election of Directors: Everett CunninghamDIRECTOR ELECTIONSISSUER1760290.0000000FOR1760290.000000FORS000002106Arvinas, Inc.04335A105US04335A105105/29/2024Election of Directors: Briggs Morrison, M.D.DIRECTOR ELECTIONSISSUER1760290.0000000FOR1760290.000000FORS000002106Arvinas, Inc.04335A105US04335A105105/29/2024To approve, on an advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1760290.0000000FOR1760290.000000FORS000002106Arvinas, Inc.04335A105US04335A105105/29/2024Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER1760290.0000000FOR1760290.000000FORS000002106Ascendis Pharma A/S04351P101US04351P101205/30/2024Elect Chairman of MeetingCORPORATE GOVERNANCEISSUER734147.0000000FOR734147.000000FORS000002106Ascendis Pharma A/S04351P101US04351P101205/30/2024Approve Company Activity ReportCORPORATE GOVERNANCEISSUER734147.0000000FOR734147.000000FORS000002106Ascendis Pharma A/S04351P101US04351P101205/30/2024Accept Financial Statements and Statutory Reports; Approve Discharge of Management and BoardCAPITAL STRUCTURECORPORATE GOVERNANCEISSUER734147.0000000FOR734147.000000FORS000002106Ascendis Pharma A/S04351P101US04351P101205/30/2024Approve Treatment of Net LossCAPITAL STRUCTUREISSUER734147.0000000FOR734147.000000FORS000002106Ascendis Pharma A/S04351P101US04351P101205/30/2024Reelect Albert Cha as Director For Two Years TermDIRECTOR ELECTIONSISSUER734147.0000000FOR734147.000000FORS000002106Ascendis Pharma A/S04351P101US04351P101205/30/2024Reelect Lars Holtug as Director For Two Years TermDIRECTOR ELECTIONSISSUER734147.0000000FOR734147.000000FORS000002106Ascendis Pharma A/S04351P101US04351P101205/30/2024Ratify Deloitte as AuditorsAUDIT-RELATEDISSUER734147.0000000FOR734147.000000FORS000002106Ascendis Pharma A/S04351P101US04351P101205/30/2024Amend Articles Re: Board-RelatedCORPORATE GOVERNANCEISSUER734147.0000000FOR734147.000000FORS000002106Ascendis Pharma A/S04351P101US04351P101205/30/2024Approve Creation of DKK 9 Million Pool of Capital with Preemptive RightsCAPITAL STRUCTUREISSUER734147.0000000FOR734147.000000FORS000002106Ascendis Pharma A/S04351P101US04351P101205/30/2024Approve Warrant Plan for Key EmployeesCOMPENSATIONISSUER734147.0000000FOR734147.000000FORS000002106Keros Therapeutics, Inc.492327101US492327101305/30/2024To elect the three (3) nominees for director named below to hold office until the 2027 Annual Meeting of Stockholders: Jasbir SeehraDIRECTOR ELECTIONSISSUER926383.0000000FOR926383.000000FORS000002106Keros Therapeutics, Inc.492327101US492327101305/30/2024To elect the three (3) nominees for director named below to hold office until the 2027 Annual Meeting of Stockholders: Nima FarzanDIRECTOR ELECTIONSISSUER926383.0000000FOR926383.000000FORS000002106Keros Therapeutics, Inc.492327101US492327101305/30/2024To elect the three (3) nominees for director named below to hold office until the 2027 Annual Meeting of Stockholders: Julius KnowlesDIRECTOR ELECTIONSISSUER926383.0000000FOR926383.000000FORS000002106Keros Therapeutics, Inc.492327101US492327101305/30/2024To ratify the selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023.AUDIT-RELATEDISSUER926383.0000000FOR926383.000000FORS000002106Keros Therapeutics, Inc.492327101US492327101305/30/2024To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the accompanying Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER926383.0000000FOR926383.000000FORS000002106Keros Therapeutics, Inc.492327101US492327101305/30/2024To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER926383.0000000ONE YEAR926383.000000FORS000002106Tenaya Therapeutics, Inc.87990A106US87990A106005/30/2024To elect three Class III directors to hold office until our 2027 annual meeting of stockholders and until their respective successors are elected and qualified: Faraz Ali, M.B.A.DIRECTOR ELECTIONSISSUER2577095.0000000FOR2577095.000000FORS000002106Tenaya Therapeutics, Inc.87990A106US87990A106005/30/2024To elect three Class III directors to hold office until our 2027 annual meeting of stockholders and until their respective successors are elected and qualified: June Lee, M.D.DIRECTOR ELECTIONSISSUER2577095.0000000FOR2577095.000000FORS000002106Tenaya Therapeutics, Inc.87990A106US87990A106005/30/2024To elect three Class III directors to hold office until our 2027 annual meeting of stockholders and until their respective successors are elected and qualified: Deepak Srivastava, M.D.DIRECTOR ELECTIONSISSUER2577095.0000000WITHHOLD2577095.000000AGAINSTS000002106Tenaya Therapeutics, Inc.87990A106US87990A106005/30/2024To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER2577095.0000000FOR2577095.000000FORS000002106IDEAYA Biosciences, Inc.45166A102US45166A102505/31/2024To elect two Class II directors to hold office until the 2027 annual meeting of stockholders or until their successors are elected: Terry J. Rosen, Ph.D.DIRECTOR ELECTIONSISSUER1765435.0000000FOR1765435.000000FORS000002106IDEAYA Biosciences, Inc.45166A102US45166A102505/31/2024To elect two Class II directors to hold office until the 2027 annual meeting of stockholders or until their successors are elected: Wendy L. YarnoDIRECTOR ELECTIONSISSUER1765435.0000000FOR1765435.000000FORS000002106IDEAYA Biosciences, Inc.45166A102US45166A102505/31/2024To ratify the selection, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024; andAUDIT-RELATEDISSUER1765435.0000000FOR1765435.000000FORS000002106IDEAYA Biosciences, Inc.45166A102US45166A102505/31/2024To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement accompanying this Notice of Annual Meeting of Stockholders;SECTION 14A SAY-ON-PAY VOTESISSUER1765435.0000000FOR1765435.000000FORS000002106IDEAYA Biosciences, Inc.45166A102US45166A102505/31/2024To hold a non-binding advisory vote on the frequency of future advisory votes by stockholders on the compensation of the Company's named executive officers; andSECTION 14A SAY-ON-PAY VOTESISSUER1765435.0000000ONE YEAR1765435.000000FORS000002106Relay Therapeutics, Inc.75943R102US75943R102306/03/2024To elect two class I directors to our board of directors, to serve until the 2027 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Sanjiv K. Patel, M.D.DIRECTOR ELECTIONSISSUER2308191.0000000FOR2308191.000000FORS000002106Relay Therapeutics, Inc.75943R102US75943R102306/03/2024To elect two class I directors to our board of directors, to serve until the 2027 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Linda A. Hill, Ph.D.DIRECTOR ELECTIONSISSUER2308191.0000000FOR2308191.000000FORS000002106Relay Therapeutics, Inc.75943R102US75943R102306/03/2024To consider and act upon an advisory vote on the compensation of our named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER2308191.0000000AGAINST2308191.000000AGAINSTS000002106Relay Therapeutics, Inc.75943R102US75943R102306/03/2024To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024; andAUDIT-RELATEDISSUER2308191.0000000FOR2308191.000000FORS000002106CARGO Therapeutics, Inc.14179K101US14179K101606/04/2024To elect two Class I directors to hold office until the 2027 annual meeting of stockholders or until their successors are elected: Krishnan Viswanadhan, Pharm.D.DIRECTOR ELECTIONSISSUER572574.0000000FOR572574.000000FORS000002106CARGO Therapeutics, Inc.14179K101US14179K101606/04/2024To elect two Class I directors to hold office until the 2027 annual meeting of stockholders or until their successors are elected: Reid Huber, Ph.D.DIRECTOR ELECTIONSISSUER572574.0000000FOR572574.000000FORS000002106CARGO Therapeutics, Inc.14179K101US14179K101606/04/2024To ratify the appointment, by the Audit Committee of the Company's Board of Directors, of Deloitte & Touche LLP as the independent registered public accounting firm and independent auditor of the Company for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER572574.0000000FOR572574.000000FORS000002106Morphic Holding, Inc.61775R105US61775R105906/04/2024Election of three Class II directors to our Board of Directors to serve until the 2027 Annual Meeting of Stockholders: Gustav Christensen, MBADIRECTOR ELECTIONSISSUER980853.0000000FOR980853.000000FORS000002106Morphic Holding, Inc.61775R105US61775R105906/04/2024Election of three Class II directors to our Board of Directors to serve until the 2027 Annual Meeting of Stockholders: Susannah Gray, MBADIRECTOR ELECTIONSISSUER980853.0000000FOR980853.000000FORS000002106Morphic Holding, Inc.61775R105US61775R105906/04/2024Election of three Class II directors to our Board of Directors to serve until the 2027 Annual Meeting of Stockholders: Amir Nashat, Sc.D.DIRECTOR ELECTIONSISSUER980853.0000000FOR980853.000000FORS000002106Morphic Holding, Inc.61775R105US61775R105906/04/2024Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER980853.0000000FOR980853.000000FORS000002106Morphic Holding, Inc.61775R105US61775R105906/04/2024To approve, on a non-binding advisory basis, the compensation paid to the Company's Named Executive Officers.SECTION 14A SAY-ON-PAY VOTESISSUER980853.0000000FOR980853.000000FORS000002106Apellis Pharmaceuticals, Inc.03753U106US03753U106006/05/2024Election of two Class I directors to hold office until the 2027 annual meeting of stockholders: Paul FonteyneDIRECTOR ELECTIONSISSUER406018.0000000FOR406018.000000FORS000002106Apellis Pharmaceuticals, Inc.03753U106US03753U106006/05/2024Election of two Class I directors to hold office until the 2027 annual meeting of stockholders: Stephanie Monaghan O'BrienDIRECTOR ELECTIONSISSUER406018.0000000FOR406018.000000FORS000002106Apellis Pharmaceuticals, Inc.03753U106US03753U106006/05/2024Ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024;AUDIT-RELATEDISSUER406018.0000000FOR406018.000000FORS000002106Apellis Pharmaceuticals, Inc.03753U106US03753U106006/05/2024Approval of an advisory vote on executive compensation; andSECTION 14A SAY-ON-PAY VOTESISSUER406018.0000000FOR406018.000000FORS000002106BeiGene, Ltd.07725L102US07725L102606/05/2024Resolution 1 - Ordinary Resolution THAT Dr. Olivier Brandicourt be and is hereby re-elected to serve as a Class II director of the Company until the 2027 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal.DIRECTOR ELECTIONSISSUER144000.0000000FOR144000.000000FORS000002106BeiGene, Ltd.07725L102US07725L102606/05/2024Resolution 2 - Ordinary Resolution THAT Donald W. Glazer be and is hereby re-elected to serve as a Class II director of the Company until the 2027 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal.DIRECTOR ELECTIONSISSUER144000.0000000FOR144000.000000FORS000002106BeiGene, Ltd.07725L102US07725L102606/05/2024Resolution 3 - Ordinary Resolution THAT Michael Goller be and is hereby re-elected to serve as a Class II director of the Company until the 2027 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal.DIRECTOR ELECTIONSISSUER144000.0000000FOR144000.000000FORS000002106BeiGene, Ltd.07725L102US07725L102606/05/2024Resolution 4 - Ordinary Resolution THAT Dr. Corazon (Corsee) D. Sanders be and is hereby re-elected to serve as a Class II director of the Company until the 2027 annual general meeting of shareholders and until her successor is duly elected and qualified, subject to her earlier resignation or removal.DIRECTOR ELECTIONSISSUER144000.0000000FOR144000.000000FORS000002106BeiGene, Ltd.07725L102US07725L102606/05/2024Resolution 5 - Ordinary Resolution THAT the appointment of Ernst & Young LLP, Ernst & Young and Ernst & Young Hua Ming LLP as the Company's independent auditors for the fiscal year ending December 31, 2024 be and is hereby approved, ratified and confirmed.AUDIT-RELATEDISSUER144000.0000000FOR144000.000000FORS000002106BeiGene, Ltd.07725L102US07725L102606/05/2024Resolution 6 - Ordinary Resolution THAT the Board of Directors is hereby authorized to fix the auditors' compensation for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER144000.0000000FOR144000.000000FORS000002106BeiGene, Ltd.07725L102US07725L102606/05/2024Resolution 7 - Ordinary Resolution THAT the granting of a share issue mandate to the Board of Directors to issue, allot or deal with unissued ordinary shares and/or American Depositary Shares ("ADSs") (including any sale or transfer of treasury shares (which shall have the meaning ascribed to it under the HK Listing Rules coming into effect on June 11, 2024) out of treasury) not exceeding 20% of the total number of issued shares of the Company (excluding treasury shares) as of the date of passing of this ordinary resolution up to the next annual general meeting of shareholders of the Company be and is hereby approved.CAPITAL STRUCTUREISSUER144000.0000000AGAINST144000.000000AGAINSTS000002106BeiGene, Ltd.07725L102US07725L102606/05/2024Resolution 8 - Ordinary Resolution THAT the granting of a share repurchase mandate to the Board of Directors to repurchase an amount of ordinary shares (excluding RMB shares) and/or ADSs, not exceeding 10% of the total number of issued ordinary shares (excluding RMB shares and treasury shares) of the Company as of the date of passing of such ordinary resolution up to the next annual general meeting of shareholders of the Company be and is hereby approved.CAPITAL STRUCTUREISSUER144000.0000000FOR144000.000000FORS000002106BeiGene, Ltd.07725L102US07725L102606/05/2024Resolution 9 - Ordinary Resolution THAT the Company and its underwriters be and are hereby authorized, in their sole discretion, to allocate to each of Baker Bros. Advisors LP and Hillhouse Capital Management, Ltd. and parties affiliated with each of them (the "Existing Shareholders"), up to a maximum amount of shares in order to maintain the same shareholding percentage of each of the Existing Shareholders (based on the then-outstanding share capital of the Company) before and after the allocation of the corresponding securities issued pursuant to an offering conducted pursuant to the general mandate set forth in Resolution 7 for a period of five years, which period will be subject to an extension on a rolling basis each year.CAPITAL STRUCTUREISSUER144000.0000000AGAINST144000.000000AGAINSTS000002106BeiGene, Ltd.07725L102US07725L102606/05/2024Resolution 10 - Ordinary Resolution THAT the Company and its underwriters be and are hereby authorized, in their sole discretion, to allocate to Amgen Inc. ("Amgen"), up to a maximum amount of shares in order to maintain the same shareholding percentage of Amgen (based on the then-outstanding share capital of the Company) before and after the allocation of the corresponding securities issued pursuant to an offering conducted pursuant to the general mandate set forth in Resolution 7 for a period of five years, which period will be subject to an extension on a rolling basis each year.CAPITAL STRUCTUREISSUER144000.0000000AGAINST144000.000000AGAINSTS000002106BeiGene, Ltd.07725L102US07725L102606/05/2024Resolution 11 - Ordinary Resolution THAT the grant of restricted share units ("RSUs") with a grant date fair value of US$6,000,000 to Mr. John V. Oyler under the Second Amended and Restated 2016 Share Option and Incentive Plan (as amended, the "2016 Plan"), according to the terms and conditions described in the Proxy Statement, be and is hereby approved.COMPENSATIONISSUER144000.0000000AGAINST144000.000000AGAINSTS000002106BeiGene, Ltd.07725L102US07725L102606/05/2024Resolution 12 - Ordinary Resolution THAT the grant of performance share units ("PSUs") with a grant date fair value of US$6,000,000 to Mr. John V. Oyler under the 2016 Plan, according to the terms and conditions described in the Proxy Statement, be and is hereby approved.COMPENSATIONISSUER144000.0000000FOR144000.000000FORS000002106BeiGene, Ltd.07725L102US07725L102606/05/2024Resolution 13 - Ordinary Resolution THAT the grant of RSUs with a grant date fair value of US$1,333,333 to Dr. Xiaodong Wang under the 2016 Plan, according to the terms and conditions described in the Proxy Statement, be and is hereby approved.COMPENSATIONISSUER144000.0000000AGAINST144000.000000AGAINSTS000002106BeiGene, Ltd.07725L102US07725L102606/05/2024Resolution 14 - Ordinary Resolution THAT the grant of RSUs with a grant date fair value of US$200,000 to each of the independent non-executive directors, Dr. Olivier Brandicourt, Dr. Margaret Dugan, Mr. Donald W. Glazer, Mr. Michael Goller, Mr. Anthony C. Hooper, Mr. Ranjeev Krishana, Dr. Alessandro Riva, Dr. Corazon (Corsee) D. Sanders, and Mr. Qingqing Yi, under the 2016 Plan, according to the terms and conditions described in the Proxy Statement, be and is hereby approved.COMPENSATIONISSUER144000.0000000AGAINST144000.000000AGAINSTS000002106BeiGene, Ltd.07725L102US07725L102606/05/2024Resolution 15 - Ordinary Resolution THAT, on a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, be and is hereby approved.SECTION 14A SAY-ON-PAY VOTESISSUER144000.0000000AGAINST144000.000000AGAINSTS000002106BeiGene, Ltd.07725L102US07725L102606/05/2024Resolution 16 - Ordinary Resolution THAT, on a non-binding, advisory basis, the frequency of future advisory votes on the compensation of the Company's named executive officers will be held at the frequency hereby approved.SECTION 14A SAY-ON-PAY VOTESISSUER144000.0000000ONE YEAR144000.000000FORS000002106BeiGene, Ltd.07725L102US07725L102606/05/2024Resolution 17(a) - Ordinary Resolution THAT the Third Amended and Restated 2016 Share Option and Incentive Plan of the Company, as described in the Proxy Statement, be and is hereby approved.COMPENSATIONISSUER144000.0000000AGAINST144000.000000AGAINSTS000002106BeiGene, Ltd.07725L102US07725L102606/05/2024Resolution 17(b) - Ordinary Resolution THAT the consultant sublimit set out in the Third Amended and Restated 2016 Share Option and Incentive Plan of the Company, as described in the Proxy Statement, be and is hereby approved.COMPENSATIONISSUER144000.0000000FOR144000.000000FORS000002106BeiGene, Ltd.07725L102US07725L102606/05/2024Resolution 18 - Ordinary Resolution THAT the Fourth Amended and Restated 2018 Employee Share Purchase Plan of the Company, as described in the Proxy Statement, be and is hereby approved.COMPENSATIONISSUER144000.0000000FOR144000.000000FORS000002106BeiGene, Ltd.07725L102US07725L102606/05/2024Resolution 19 - Ordinary Resolution THAT the adjournment of the Annual Meeting by the chairman, if necessary, to solicit additional proxies if there are insufficient votes at the time of the Annual Meeting to approve any of the proposals described above, be and is hereby approved.CORPORATE GOVERNANCEISSUER144000.0000000AGAINST144000.000000AGAINSTS000002106Datadog, Inc.23804L103US23804L103506/05/2024To elect two Class II directors, each to hold office until our Annual Meeting of Stockholders in 2027: Alexis Le-QuocDIRECTOR ELECTIONSISSUER1954385.0000000FOR1954385.000000FORS000002106Datadog, Inc.23804L103US23804L103506/05/2024To elect two Class II directors, each to hold office until our Annual Meeting of Stockholders in 2027: Michael CallahanDIRECTOR ELECTIONSISSUER1954385.0000000FOR1954385.000000FORS000002106Datadog, Inc.23804L103US23804L103506/05/2024Advisory vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1954385.0000000FOR1954385.000000FORS000002106Datadog, Inc.23804L103US23804L103506/05/2024To ratify the selection by the Audit Committee of our Board of Directors of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER1954385.0000000FOR1954385.000000FORS000002106Mirum Pharmaceuticals, Inc.604749101US604749101306/05/2024Election of three Class II nominees for director to hold office until the Company's 2027 annual meeting of stockholders: Laurent Fischer, M.D.DIRECTOR ELECTIONSISSUER772989.0000000WITHHOLD772989.000000AGAINSTS000002106Mirum Pharmaceuticals, Inc.604749101US604749101306/05/2024Election of three Class II nominees for director to hold office until the Company's 2027 annual meeting of stockholders: Patrick J. HeronDIRECTOR ELECTIONSISSUER772989.0000000FOR772989.000000FORS000002106Mirum Pharmaceuticals, Inc.604749101US604749101306/05/2024Election of three Class II nominees for director to hold office until the Company's 2027 annual meeting of stockholders: Saira Ramasastry, M.S., M.Phil.DIRECTOR ELECTIONSISSUER772989.0000000FOR772989.000000FORS000002106Mirum Pharmaceuticals, Inc.604749101US604749101306/05/2024To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER772989.0000000FOR772989.000000FORS000002106Mirum Pharmaceuticals, Inc.604749101US604749101306/05/2024To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER772989.0000000FOR772989.000000FORS000002106Mirum Pharmaceuticals, Inc.604749101US604749101306/05/2024To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER772989.0000000ONE YEAR772989.000000FORS000002106MoonLake Immunotherapeutics61559X104KY61559X104506/05/2024Election of the two Class II director nominees to serve until the 2027 Annual General Meeting of Shareholders and until their successors are duly elected and qualified: Catherine MoukheibirDIRECTOR ELECTIONSISSUER522634.0000000FOR522634.000000FORS000002106MoonLake Immunotherapeutics61559X104KY61559X104506/05/2024Election of the two Class II director nominees to serve until the 2027 Annual General Meeting of Shareholders and until their successors are duly elected and qualified: Dr. Ramnik XavierDIRECTOR ELECTIONSISSUER522634.0000000FOR522634.000000FORS000002106MoonLake Immunotherapeutics61559X104KY61559X104506/05/2024Ratification, by ordinary resolution, of the selection of Baker Tilly US, LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024.AUDIT-RELATEDISSUER522634.0000000FOR522634.000000FORS000002106MoonLake Immunotherapeutics61559X104KY61559X104506/05/2024Approval of, on an advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER522634.0000000FOR522634.000000FORS000002106MoonLake Immunotherapeutics61559X104KY61559X104506/05/2024Non-binding advisory vote on the frequency of future advisory votes on executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER522634.0000000ONE YEAR522634.000000FORS000002106Penumbra, Inc.70975L107US70975L107006/05/2024To elect the nominees for Class III director to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Adam ElsesserDIRECTOR ELECTIONSISSUER809192.0000000FOR809192.000000FORS000002106Penumbra, Inc.70975L107US70975L107006/05/2024To elect the nominees for Class III director to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Harpreet GrewalDIRECTOR ELECTIONSISSUER809192.0000000FOR809192.000000FORS000002106Penumbra, Inc.70975L107US70975L107006/05/2024To ratify the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for Penumbra, Inc. for the fiscal year ending December 31, 2024; andAUDIT-RELATEDISSUER809192.0000000FOR809192.000000FORS000002106Penumbra, Inc.70975L107US70975L107006/05/2024To approve, on an advisory basis, the compensation of Penumbra, Inc.'s named executive officers as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER809192.0000000FOR809192.000000FORS000002106Praxis Precision Medicines, Inc.74006W207US74006W207006/05/2024Election of Class I Directors to serve until the 2027 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified: Dean MitchellDIRECTOR ELECTIONSISSUER133805.0000000WITHHOLD133805.000000AGAINSTS000002106Praxis Precision Medicines, Inc.74006W207US74006W207006/05/2024Election of Class I Directors to serve until the 2027 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified: Jill DeSimoneDIRECTOR ELECTIONSISSUER133805.0000000WITHHOLD133805.000000AGAINSTS000002106Praxis Precision Medicines, Inc.74006W207US74006W207006/05/2024To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER133805.0000000FOR133805.000000FORS000002106Praxis Precision Medicines, Inc.74006W207US74006W207006/05/2024To approve the amendment and restatement of the Company's 2020 Stock Option and Incentive Plan.COMPENSATIONISSUER133805.0000000AGAINST133805.000000AGAINSTS000002106Praxis Precision Medicines, Inc.74006W207US74006W207006/05/2024To approve, on an advisory (non-binding) basis, the compensation of the named executive officers as disclosed in the Company's proxy statement for the 2024 Annual Meeting of Stockholders pursuant to the applicable compensation disclosure rules of the SEC, including the compensation tables and narrative discussion.SECTION 14A SAY-ON-PAY VOTESISSUER133805.0000000AGAINST133805.000000AGAINSTS000002106Corpay, Inc.219948106US219948106806/06/2024Elect Directors nominated by the Board of Directors for a one-year term: Annabelle BexigaDIRECTOR ELECTIONSISSUER772787.0000000FOR772787.000000FORS000002106Corpay, Inc.219948106US219948106806/06/2024Elect Directors nominated by the Board of Directors for a one-year term: Ronald F. ClarkeDIRECTOR ELECTIONSISSUER772787.0000000FOR772787.000000FORS000002106Corpay, Inc.219948106US219948106806/06/2024Elect Directors nominated by the Board of Directors for a one-year term: Joseph W. FarrellyDIRECTOR ELECTIONSISSUER772787.0000000FOR772787.000000FORS000002106Corpay, Inc.219948106US219948106806/06/2024Elect Directors nominated by the Board of Directors for a one-year term: Rahul GuptaDIRECTOR ELECTIONSISSUER772787.0000000FOR772787.000000FORS000002106Corpay, Inc.219948106US219948106806/06/2024Elect Directors nominated by the Board of Directors for a one-year term: Thomas M. HagertyDIRECTOR ELECTIONSISSUER772787.0000000FOR772787.000000FORS000002106Corpay, Inc.219948106US219948106806/06/2024Elect Directors nominated by the Board of Directors for a one-year term: Archie L. Jones, Jr.DIRECTOR ELECTIONSISSUER772787.0000000FOR772787.000000FORS000002106Corpay, Inc.219948106US219948106806/06/2024Elect Directors nominated by the Board of Directors for a one-year term: Richard MacchiaDIRECTOR ELECTIONSISSUER772787.0000000FOR772787.000000FORS000002106Corpay, Inc.219948106US219948106806/06/2024Elect Directors nominated by the Board of Directors for a one-year term: Hala G. ModdelmogDIRECTOR ELECTIONSISSUER772787.0000000FOR772787.000000FORS000002106Corpay, Inc.219948106US219948106806/06/2024Elect Directors nominated by the Board of Directors for a one-year term: Jeffrey S. SloanDIRECTOR ELECTIONSISSUER772787.0000000FOR772787.000000FORS000002106Corpay, Inc.219948106US219948106806/06/2024Elect Directors nominated by the Board of Directors for a one-year term: Steven T. StullDIRECTOR ELECTIONSISSUER772787.0000000FOR772787.000000FORS000002106Corpay, Inc.219948106US219948106806/06/2024Elect Directors nominated by the Board of Directors for a one-year term: Gerald ThroopDIRECTOR ELECTIONSISSUER772787.0000000FOR772787.000000FORS000002106Corpay, Inc.219948106US219948106806/06/2024Ratify the re-appointment of Ernst & Young LLP as Corpay's independent public accounting firm for 2024.AUDIT-RELATEDISSUER772787.0000000FOR772787.000000FORS000002106Corpay, Inc.219948106US219948106806/06/2024Advisory vote to approve named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER772787.0000000FOR772787.000000FORS000002106Corpay, Inc.219948106US219948106806/06/2024Shareholder proposal regarding an independent Board chair requirement, if properly presented at the meeting.CORPORATE GOVERNANCESECURITY HOLDER772787.0000000FOR772787.000000AGAINSTS000002106Generation Bio Co.37148K100US37148K100706/06/2024Election of three Class I directors to our board of directors, each to serve until the 2027 Annual Meeting of Stockholders: Jeffrey JonasDIRECTOR ELECTIONSISSUER5373934.0000000FOR5373934.000000FORS000002106Generation Bio Co.37148K100US37148K100706/06/2024Election of three Class I directors to our board of directors, each to serve until the 2027 Annual Meeting of Stockholders: Geoff McDonoughDIRECTOR ELECTIONSISSUER5373934.0000000FOR5373934.000000FORS000002106Generation Bio Co.37148K100US37148K100706/06/2024Election of three Class I directors to our board of directors, each to serve until the 2027 Annual Meeting of Stockholders: Donald NicholsonDIRECTOR ELECTIONSISSUER5373934.0000000FOR5373934.000000FORS000002106Generation Bio Co.37148K100US37148K100706/06/2024Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER5373934.0000000FOR5373934.000000FORS000002106Generation Bio Co.37148K100US37148K100706/06/2024Approval, on an advisory (non-binding) basis, of the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER5373934.0000000FOR5373934.000000FORS000002106GoDaddy Inc.380237107US380237107606/06/2024Election of Directors: Herald ChenDIRECTOR ELECTIONSISSUER599918.0000000FOR599918.000000FORS000002106GoDaddy Inc.380237107US380237107606/06/2024Election of Directors: Mark GarrettDIRECTOR ELECTIONSISSUER599918.0000000FOR599918.000000FORS000002106GoDaddy Inc.380237107US380237107606/06/2024Election of Directors: Brian SharplesDIRECTOR ELECTIONSISSUER599918.0000000FOR599918.000000FORS000002106GoDaddy Inc.380237107US380237107606/06/2024Election of Directors: Leah SweetDIRECTOR ELECTIONSISSUER599918.0000000FOR599918.000000FORS000002106GoDaddy Inc.380237107US380237107606/06/2024Election of Directors: Srinivas TallapragadaDIRECTOR ELECTIONSISSUER599918.0000000FOR599918.000000FORS000002106GoDaddy Inc.380237107US380237107606/06/2024Election of Directors: Sigal ZarmiDIRECTOR ELECTIONSISSUER599918.0000000FOR599918.000000FORS000002106GoDaddy Inc.380237107US380237107606/06/2024Advisory, non-binding vote to approve named executive officer compensationSECTION 14A SAY-ON-PAY VOTESISSUER599918.0000000FOR599918.000000FORS000002106GoDaddy Inc.380237107US380237107606/06/2024Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2024AUDIT-RELATEDISSUER599918.0000000FOR599918.000000FORS000002106GoDaddy Inc.380237107US380237107606/06/2024Approval of the GoDaddy Inc. 2024 Omnibus Incentive PlanCOMPENSATIONISSUER599918.0000000FOR599918.000000FORS000002106GoDaddy Inc.380237107US380237107606/06/2024Approval of the GoDaddy Inc. 2024 Employee Stock Purchase PlanCOMPENSATIONISSUER599918.0000000FOR599918.000000FORS000002106Ionis Pharmaceuticals, Inc.462222100US462222100406/06/2024Election of Directors: Brett P. MoniaDIRECTOR ELECTIONSISSUER1146309.0000000FOR1146309.000000FORS000002106Ionis Pharmaceuticals, Inc.462222100US462222100406/06/2024Election of Directors: Michael YangDIRECTOR ELECTIONSISSUER1146309.0000000FOR1146309.000000FORS000002106Ionis Pharmaceuticals, Inc.462222100US462222100406/06/2024To make an advisory vote on executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1146309.0000000FOR1146309.000000FORS000002106Ionis Pharmaceuticals, Inc.462222100US462222100406/06/2024To approve an amendment of the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan by 3,300,000 shares to an aggregate of 38,500,000 shares and to prohibit certain share recycling on full value awards.COMPENSATIONISSUER1146309.0000000FOR1146309.000000FORS000002106Ionis Pharmaceuticals, Inc.462222100US462222100406/06/2024To ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2024 fiscal year.AUDIT-RELATEDISSUER1146309.0000000FOR1146309.000000FORS000002106Procore Technologies, Inc.74275K108US74275K108806/06/2024To elect three Class III directors to hold office until the Company's 2027 annual meeting of stockholders or until their respective successors are duly elected and qualified: William J.G. Griffith IVDIRECTOR ELECTIONSISSUER6545744.0000000FOR6545744.000000FORS000002106Procore Technologies, Inc.74275K108US74275K108806/06/2024To elect three Class III directors to hold office until the Company's 2027 annual meeting of stockholders or until their respective successors are duly elected and qualified: Graham V. SmithDIRECTOR ELECTIONSISSUER6545744.0000000FOR6545744.000000FORS000002106Procore Technologies, Inc.74275K108US74275K108806/06/2024To elect three Class III directors to hold office until the Company's 2027 annual meeting of stockholders or until their respective successors are duly elected and qualified: Elisa A. SteeleDIRECTOR ELECTIONSISSUER6545744.0000000FOR6545744.000000FORS000002106Procore Technologies, Inc.74275K108US74275K108806/06/2024To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER6545744.0000000FOR6545744.000000FORS000002106Procore Technologies, Inc.74275K108US74275K108806/06/2024To approve, on an advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER6545744.0000000FOR6545744.000000FORS000002106Toast, Inc.888787108US888787108006/06/2024Election of Directors: Stephen FredetteDIRECTOR ELECTIONSISSUER14242919.0000000FOR14242919.000000FORS000002106Toast, Inc.888787108US888787108006/06/2024Election of Directors: Aman NarangDIRECTOR ELECTIONSISSUER14242919.0000000FOR14242919.000000FORS000002106Toast, Inc.888787108US888787108006/06/2024Election of Directors: Deval L. PatrickDIRECTOR ELECTIONSISSUER14242919.0000000FOR14242919.000000FORS000002106Toast, Inc.888787108US888787108006/06/2024Ratification of Appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER14242919.0000000FOR14242919.000000FORS000002106Toast, Inc.888787108US888787108006/06/2024To approve, on an advisory (non-binding) basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER14242919.0000000FOR14242919.000000FORS000002106Toast, Inc.888787108US888787108006/06/2024To approve an amendment to our Amended and Restated Certificate of Incorporation to limit the liability of certain officers of the Company as permitted by Delaware law.CORPORATE GOVERNANCEISSUER14242919.0000000AGAINST14242919.000000AGAINSTS000002106Vaxcyte, Inc.92243G108US92243G108506/06/2024Election of Class I Directors Nominees would serve until the 2027 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director's death, resignation or removal: Annie DrapeauDIRECTOR ELECTIONSISSUER1230476.0000000FOR1230476.000000FORS000002106Vaxcyte, Inc.92243G108US92243G108506/06/2024Election of Class I Directors Nominees would serve until the 2027 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director's death, resignation or removal: Teri LoxamDIRECTOR ELECTIONSISSUER1230476.0000000FOR1230476.000000FORS000002106Vaxcyte, Inc.92243G108US92243G108506/06/2024Election of Class I Directors Nominees would serve until the 2027 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director's death, resignation or removal: Carlos Paya, M.D., Ph.D.DIRECTOR ELECTIONSISSUER1230476.0000000FOR1230476.000000FORS000002106Vaxcyte, Inc.92243G108US92243G108506/06/2024Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER1230476.0000000FOR1230476.000000FORS000002106Vaxcyte, Inc.92243G108US92243G108506/06/2024Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1230476.0000000FOR1230476.000000FORS000002106Akero Therapeutics, Inc.00973Y108US00973Y108206/07/2024Election of Class II Directors to serve until the 2027 annual meeting of stockholders and until his or her successor has been duly elected and qualified: Seth L. Harrison, M.D.DIRECTOR ELECTIONSISSUER2000526.0000000WITHHOLD2000526.000000AGAINSTS000002106Akero Therapeutics, Inc.00973Y108US00973Y108206/07/2024Election of Class II Directors to serve until the 2027 annual meeting of stockholders and until his or her successor has been duly elected and qualified: Graham Walmsley, M.D., Ph.DDIRECTOR ELECTIONSISSUER2000526.0000000WITHHOLD2000526.000000AGAINSTS000002106Akero Therapeutics, Inc.00973Y108US00973Y108206/07/2024Election of Class II Directors to serve until the 2027 annual meeting of stockholders and until his or her successor has been duly elected and qualified: Yuan Xu, Ph.DDIRECTOR ELECTIONSISSUER2000526.0000000WITHHOLD2000526.000000AGAINSTS000002106Akero Therapeutics, Inc.00973Y108US00973Y108206/07/2024To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER2000526.0000000FOR2000526.000000FORS000002106Akero Therapeutics, Inc.00973Y108US00973Y108206/07/2024To consider and act upon a non-binding, advisory vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER2000526.0000000FOR2000526.000000FORS000002106Akero Therapeutics, Inc.00973Y108US00973Y108206/07/2024To approve an Amendment to our Fourth Amended and Restated Certificate of Incorporation, to limit the liability of certain officers of Akero Therapeutics, Inc., as permitted by recent amendments to Delaware law.CORPORATE GOVERNANCEISSUER2000526.0000000FOR2000526.000000FORS000002106Crinetics Pharmaceuticals, Inc.22663K107US22663K107906/07/2024To elect two directors to serve as Class III directors for a three-year term to expire at the 2027 annual meeting of stockholders: Camille Bedrosian, M.D.DIRECTOR ELECTIONSISSUER1499632.0000000FOR1499632.000000FORS000002106Crinetics Pharmaceuticals, Inc.22663K107US22663K107906/07/2024To elect two directors to serve as Class III directors for a three-year term to expire at the 2027 annual meeting of stockholders: Wendell Wierenga, Ph.D.DIRECTOR ELECTIONSISSUER1499632.0000000FOR1499632.000000FORS000002106Crinetics Pharmaceuticals, Inc.22663K107US22663K107906/07/2024To consider and vote upon the ratification of the selection of BDO USA, P.C. as our independent registered public accounting firm for the fiscal year ending December 31, 2024;AUDIT-RELATEDISSUER1499632.0000000FOR1499632.000000FORS000002106Crinetics Pharmaceuticals, Inc.22663K107US22663K107906/07/2024To consider and vote upon, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission; andSECTION 14A SAY-ON-PAY VOTESISSUER1499632.0000000FOR1499632.000000FORS000002106WillScot Mobile Mini Holdings Corp.971378104US971378104806/07/2024If Proposal 1 is approved, the election as directors of all nominees listed to serve a one-year term: Mark S. BartlettDIRECTOR ELECTIONSISSUER7419008.0000000FOR7419008.000000FORS000002106WillScot Mobile Mini Holdings Corp.971378104US971378104806/07/2024If Proposal 1 is approved, the election as directors of all nominees listed to serve a one-year term: Erika T. DavisDIRECTOR ELECTIONSISSUER7419008.0000000FOR7419008.000000FORS000002106WillScot Mobile Mini Holdings Corp.971378104US971378104806/07/2024If Proposal 1 is approved, the election as directors of all nominees listed to serve a one-year term: Gerard E. HolthausDIRECTOR ELECTIONSISSUER7419008.0000000FOR7419008.000000FORS000002106WillScot Mobile Mini Holdings Corp.971378104US971378104806/07/2024If Proposal 1 is approved, the election as directors of all nominees listed to serve a one-year term: Natalia JohnsonDIRECTOR ELECTIONSISSUER7419008.0000000FOR7419008.000000FORS000002106WillScot Mobile Mini Holdings Corp.971378104US971378104806/07/2024If Proposal 1 is approved, the election as directors of all nominees listed to serve a one-year term: Erik OlssonDIRECTOR ELECTIONSISSUER7419008.0000000FOR7419008.000000FORS000002106WillScot Mobile Mini Holdings Corp.971378104US971378104806/07/2024If Proposal 1 is approved, the election as directors of all nominees listed to serve a one-year term: Rebecca L. OwenDIRECTOR ELECTIONSISSUER7419008.0000000FOR7419008.000000FORS000002106WillScot Mobile Mini Holdings Corp.971378104US971378104806/07/2024If Proposal 1 is approved, the election as directors of all nominees listed to serve a one-year term: Jeff SaganskyDIRECTOR ELECTIONSISSUER7419008.0000000FOR7419008.000000FORS000002106WillScot Mobile Mini Holdings Corp.971378104US971378104806/07/2024If Proposal 1 is approved, the election as directors of all nominees listed to serve a one-year term: Bradley L. SoultzDIRECTOR ELECTIONSISSUER7419008.0000000FOR7419008.000000FORS000002106WillScot Mobile Mini Holdings Corp.971378104US971378104806/07/2024If Proposal 1 is approved, the election as directors of all nominees listed to serve a one-year term: Michael W. UpchurchDIRECTOR ELECTIONSISSUER7419008.0000000FOR7419008.000000FORS000002106WillScot Mobile Mini Holdings Corp.971378104US971378104806/07/2024To ratify the appointment of Ernst & Young LLP as independent registered public accounting firm of WillScot Mobile Mini Holdings Corp. for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER7419008.0000000FOR7419008.000000FORS000002106WillScot Mobile Mini Holdings Corp.971378104US971378104806/07/2024To approve, on an advisory and non-binding basis, the compensation of the named executive officers of WillScot Mobile Holdings Corp.SECTION 14A SAY-ON-PAY VOTESISSUER7419008.0000000FOR7419008.000000FORS000002106WillScot Mobile Mini Holdings Corp.971378104US971378104806/07/2024To approve an amendment to the Amended and Restated Certificate of Incorporation to provide for the exculpation of officers.CORPORATE GOVERNANCEISSUER7419008.0000000FOR7419008.000000FORS000002106Five Below, Inc.33829M101US33829M101806/11/2024Election of Directors: Joel D. AndersonDIRECTOR ELECTIONSISSUER2705110.0000000FOR2705110.000000FORS000002106Five Below, Inc.33829M101US33829M101806/11/2024Election of Directors: Kathleen S. BarclayDIRECTOR ELECTIONSISSUER2705110.0000000FOR2705110.000000FORS000002106Five Below, Inc.33829M101US33829M101806/11/2024Election of Directors: Karen BowmanDIRECTOR ELECTIONSISSUER2705110.0000000FOR2705110.000000FORS000002106Five Below, Inc.33829M101US33829M101806/11/2024Election of Directors: Dinesh S. LathiDIRECTOR ELECTIONSISSUER2705110.0000000FOR2705110.000000FORS000002106Five Below, Inc.33829M101US33829M101806/11/2024Election of Directors: Richard L. MarkeeDIRECTOR ELECTIONSISSUER2705110.0000000FOR2705110.000000FORS000002106Five Below, Inc.33829M101US33829M101806/11/2024Election of Directors: Thomas M. RyanDIRECTOR ELECTIONSISSUER2705110.0000000FOR2705110.000000FORS000002106Five Below, Inc.33829M101US33829M101806/11/2024Election of Directors: Mimi E. VaughnDIRECTOR ELECTIONSISSUER2705110.0000000FOR2705110.000000FORS000002106Five Below, Inc.33829M101US33829M101806/11/2024Election of Directors: Thomas G. VelliosDIRECTOR ELECTIONSISSUER2705110.0000000FOR2705110.000000FORS000002106Five Below, Inc.33829M101US33829M101806/11/2024Election of Directors: Zuhairah S. WashingtonDIRECTOR ELECTIONSISSUER2705110.0000000FOR2705110.000000FORS000002106Five Below, Inc.33829M101US33829M101806/11/2024To ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for the current fiscal year ending February 1, 2025.AUDIT-RELATEDISSUER2705110.0000000FOR2705110.000000FORS000002106Five Below, Inc.33829M101US33829M101806/11/2024To approve, by non-binding advisory vote, the Company's Named Executive Officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER2705110.0000000FOR2705110.000000FORS000002106HubSpot, Inc.443573100US443573100906/11/2024Elect three Class I directors to hold office until the 2027 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier resignation or removal: Brian HalliganDIRECTOR ELECTIONSISSUER1028352.0000000FOR1028352.000000FORS000002106HubSpot, Inc.443573100US443573100906/11/2024Elect three Class I directors to hold office until the 2027 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier resignation or removal: Ron GillDIRECTOR ELECTIONSISSUER1028352.0000000FOR1028352.000000FORS000002106HubSpot, Inc.443573100US443573100906/11/2024Elect three Class I directors to hold office until the 2027 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier resignation or removal: Jill WardDIRECTOR ELECTIONSISSUER1028352.0000000FOR1028352.000000FORS000002106HubSpot, Inc.443573100US443573100906/11/2024Ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024;AUDIT-RELATEDISSUER1028352.0000000FOR1028352.000000FORS000002106HubSpot, Inc.443573100US443573100906/11/2024Non-binding advisory vote to approve the compensation of the Company's named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER1028352.0000000FOR1028352.000000FORS000002106HubSpot, Inc.443573100US443573100906/11/2024Approve the HubSpot, Inc. 2024 Stock Option and Incentive Plan; andCOMPENSATIONISSUER1028352.0000000FOR1028352.000000FORS000002106HubSpot, Inc.443573100US443573100906/11/2024Approve an amendment to the HubSpot, Inc. Seventh Amended and Restated Certificate of Incorporation to limit the liability of certain officers in certain circumstances as permitted pursuant to recent amendments to Delaware law.CORPORATE GOVERNANCEISSUER1028352.0000000FOR1028352.000000FORS000002106IGM Biosciences, Inc.449585108US449585108506/11/2024Election of Directors: M. Kathleen Behrens, Ph.D.DIRECTOR ELECTIONSISSUER1865951.0000000FOR1865951.000000FORS000002106IGM Biosciences, Inc.449585108US449585108506/11/2024Election of Directors: Elizabeth H.Z. Thompson, Ph.D.DIRECTOR ELECTIONSISSUER1865951.0000000FOR1865951.000000FORS000002106IGM Biosciences, Inc.449585108US449585108506/11/2024Election of Directors: Christina Teng TopsoeDIRECTOR ELECTIONSISSUER1865951.0000000FOR1865951.000000FORS000002106IGM Biosciences, Inc.449585108US449585108506/11/2024Ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER1865951.0000000FOR1865951.000000FORS000002106IGM Biosciences, Inc.449585108US449585108506/11/2024Approval of an amendment to our amended and restated certificate of incorporation to limit the liability of certain officers as permitted by Delaware law.CORPORATE GOVERNANCEISSUER1865951.0000000FOR1865951.000000FORS000002106IGM Biosciences, Inc.449585108US449585108506/11/2024Approval of a stock option exchange program for employees (excluding our chief executive officer and non-employee directors).COMPENSATIONISSUER1865951.0000000FOR1865951.000000FORS000002106Blueprint Medicines Corporation09627Y109US09627Y109106/12/2024Election of Directors: Daniella BeckmanDIRECTOR ELECTIONSISSUER2076664.0000000FOR2076664.000000FORS000002106Blueprint Medicines Corporation09627Y109US09627Y109106/12/2024Election of Directors: Habib DableDIRECTOR ELECTIONSISSUER2076664.0000000FOR2076664.000000FORS000002106Blueprint Medicines Corporation09627Y109US09627Y109106/12/2024Election of Directors: Lynn SeelyDIRECTOR ELECTIONSISSUER2076664.0000000FOR2076664.000000FORS000002106Blueprint Medicines Corporation09627Y109US09627Y109106/12/2024Approval of a non-binding advisory vote on the frequency of future advisory votes on the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER2076664.0000000ONE YEAR2076664.000000FORS000002106Blueprint Medicines Corporation09627Y109US09627Y109106/12/2024Approval of a non-binding advisory vote on the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER2076664.0000000FOR2076664.000000FORS000002106Blueprint Medicines Corporation09627Y109US09627Y109106/12/2024Approval of the Blueprint Medicines Corporation 2024 Stock Incentive Plan.COMPENSATIONISSUER2076664.0000000FOR2076664.000000FORS000002106Blueprint Medicines Corporation09627Y109US09627Y109106/12/2024Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER2076664.0000000FOR2076664.000000FORS000002106Confluent, Inc.20717M103US20717M103606/12/2024Election of three Class III directors of Confluent, Inc. named in the Proxy Statement, each to hold office until the 2027 Annual Meeting of Stockholders: Lara CaimiDIRECTOR ELECTIONSISSUER3900811.0000000FOR3900811.000000FORS000002106Confluent, Inc.20717M103US20717M103606/12/2024Election of three Class III directors of Confluent, Inc. named in the Proxy Statement, each to hold office until the 2027 Annual Meeting of Stockholders: Jonathan ChadwickDIRECTOR ELECTIONSISSUER3900811.0000000FOR3900811.000000FORS000002106Confluent, Inc.20717M103US20717M103606/12/2024Election of three Class III directors of Confluent, Inc. named in the Proxy Statement, each to hold office until the 2027 Annual Meeting of Stockholders: Neha NarkhedeDIRECTOR ELECTIONSISSUER3900811.0000000WITHHOLD3900811.000000AGAINSTS000002106Confluent, Inc.20717M103US20717M103606/12/2024Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2024.AUDIT-RELATEDISSUER3900811.0000000FOR3900811.000000FORS000002106Confluent, Inc.20717M103US20717M103606/12/2024Approval, on a non-binding advisory basis, of the compensation of our named executive officers, as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER3900811.0000000FOR3900811.000000FORS000002106Disc Medicine, Inc.254604101US254604101106/12/2024ELECTION OF DIRECTORS: Mona AshiyaDIRECTOR ELECTIONSISSUER453611.0000000FOR453611.000000FORS000002106Disc Medicine, Inc.254604101US254604101106/12/2024ELECTION OF DIRECTORS: Kevin BittermanDIRECTOR ELECTIONSISSUER453611.0000000FOR453611.000000FORS000002106Disc Medicine, Inc.254604101US254604101106/12/2024To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER453611.0000000FOR453611.000000FORS000002106Immunome, Inc.45257U108US45257U108806/12/2024Election of the two nominees for Class I director named herein to hold office until the 2027 annual meeting of stockholders and until his or her respective successor has been duly elected and qualified, or until his or her respective earlier death, resignation or removal: Clay B. Siegall, Ph.D.DIRECTOR ELECTIONSISSUER251199.0000000FOR251199.000000FORS000002106Immunome, Inc.45257U108US45257U108806/12/2024Election of the two nominees for Class I director named herein to hold office until the 2027 annual meeting of stockholders and until his or her respective successor has been duly elected and qualified, or until his or her respective earlier death, resignation or removal: Carol SchaferDIRECTOR ELECTIONSISSUER251199.0000000FOR251199.000000FORS000002106Immunome, Inc.45257U108US45257U108806/12/2024To ratify, in a non-binding vote, the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER251199.0000000FOR251199.000000FORS000002106Intellia Therapeutics, Inc.45826J105US45826J105106/12/2024Election of Directors. Election of the following individuals nominated to serve as Class II directors, for a three-year term ending at the annual meeting of stockholders to be held in 2027: Fred Cohen, M.D., D.Phil.DIRECTOR ELECTIONSISSUER727740.0000000FOR727740.000000FORS000002106Intellia Therapeutics, Inc.45826J105US45826J105106/12/2024Election of Directors. Election of the following individuals nominated to serve as Class II directors, for a three-year term ending at the annual meeting of stockholders to be held in 2027: Frank Verwiel, M.D.DIRECTOR ELECTIONSISSUER727740.0000000FOR727740.000000FORS000002106Intellia Therapeutics, Inc.45826J105US45826J105106/12/2024Ratification of the appointment of Deloitte & Touche LLP as Intellia's independent registered public accounting firm for the fiscal year ending December 31, 2024AUDIT-RELATEDISSUER727740.0000000FOR727740.000000FORS000002106Intellia Therapeutics, Inc.45826J105US45826J105106/12/2024Approve, on a non-binding advisory basis, the compensation of the named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER727740.0000000FOR727740.000000FORS000002106Intellia Therapeutics, Inc.45826J105US45826J105106/12/2024Approval of a second amendment to our Second Amended and Restated Certificate of Incorporation, as amended, to limit the liability of certain officers of the Company as permitted by recent amendments to the Delaware General Corporation Law.CORPORATE GOVERNANCEISSUER727740.0000000FOR727740.000000FORS000002106Monte Rosa Therapeutics, Inc.61225M102US61225M102706/12/2024To elect two Class III director nominees to our board of directors, to serve until the Company's 2027 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal: Markus WarmuthDIRECTOR ELECTIONSISSUER2941087.0000000FOR2941087.000000FORS000002106Monte Rosa Therapeutics, Inc.61225M102US61225M102706/12/2024To elect two Class III director nominees to our board of directors, to serve until the Company's 2027 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal: Ali BehbahaniDIRECTOR ELECTIONSISSUER2941087.0000000WITHHOLD2941087.000000AGAINSTS000002106Monte Rosa Therapeutics, Inc.61225M102US61225M102706/12/2024To ratify the appointment of Deloitte & Touche, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024 andAUDIT-RELATEDISSUER2941087.0000000FOR2941087.000000FORS000002106Nuvalent, Inc.670703107US670703107506/12/2024Election of the following nominees as Class III directors: Emily Drabant Conley, Ph.D.DIRECTOR ELECTIONSISSUER476171.0000000FOR476171.000000FORS000002106Nuvalent, Inc.670703107US670703107506/12/2024Election of the following nominees as Class III directors: Sapna Srivastava, Ph.D.DIRECTOR ELECTIONSISSUER476171.0000000FOR476171.000000FORS000002106Nuvalent, Inc.670703107US670703107506/12/2024Election of the following nominees as Class III directors: Cameron Wheeler, Ph.D.DIRECTOR ELECTIONSISSUER476171.0000000FOR476171.000000FORS000002106Nuvalent, Inc.670703107US670703107506/12/2024To approve, on an advisory basis, the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER476171.0000000FOR476171.000000FORS000002106Nuvalent, Inc.670703107US670703107506/12/2024To approve, on an advisory basis, the frequency of future advisory votes to approve the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER476171.0000000ONE YEAR476171.000000FORS000002106Nuvalent, Inc.670703107US670703107506/12/2024To ratify the appointment of KPMG LLP as Nuvalent, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER476171.0000000FOR476171.000000FORS000002106Prime Medicine, Inc.74168J101US74168J101606/12/2024To elect Wendy Chung, M.D., Ph.D., Kaye Foster, Keith Gottesdiener, M.D., and Jeffrey Marrazzo as Class II Directors: Wendy Chung, M.D., Ph.D.DIRECTOR ELECTIONSISSUER1631137.0000000FOR1631137.000000FORS000002106Prime Medicine, Inc.74168J101US74168J101606/12/2024To elect Wendy Chung, M.D., Ph.D., Kaye Foster, Keith Gottesdiener, M.D., and Jeffrey Marrazzo as Class II Directors: Kaye FosterDIRECTOR ELECTIONSISSUER1631137.0000000FOR1631137.000000FORS000002106Prime Medicine, Inc.74168J101US74168J101606/12/2024To elect Wendy Chung, M.D., Ph.D., Kaye Foster, Keith Gottesdiener, M.D., and Jeffrey Marrazzo as Class II Directors: Keith Gottesdiener, M.D.DIRECTOR ELECTIONSISSUER1631137.0000000FOR1631137.000000FORS000002106Prime Medicine, Inc.74168J101US74168J101606/12/2024To elect Wendy Chung, M.D., Ph.D., Kaye Foster, Keith Gottesdiener, M.D., and Jeffrey Marrazzo as Class II Directors: Jeffrey MarrazzoDIRECTOR ELECTIONSISSUER1631137.0000000FOR1631137.000000FORS000002106Prime Medicine, Inc.74168J101US74168J101606/12/2024To approve an amendment to our Third Amended and Restated Certificate of Incorporation to limit the liability of certain of our officers as permitted by Delaware law.CORPORATE GOVERNANCEISSUER1631137.0000000FOR1631137.000000FORS000002106Prime Medicine, Inc.74168J101US74168J101606/12/2024To ratify the appointment of PricewaterhouseCoopers LLP as our Independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER1631137.0000000FOR1631137.000000FORS000002106Roper Technologies, Inc.776696106US776696106106/12/2024Election of ten directors for a one-year term: Shellye L. ArchambeauDIRECTOR ELECTIONSISSUER867424.0000000FOR867424.000000FORS000002106Roper Technologies, Inc.776696106US776696106106/12/2024Election of ten directors for a one-year term: Amy Woods BrinkleyDIRECTOR ELECTIONSISSUER867424.0000000FOR867424.000000FORS000002106Roper Technologies, Inc.776696106US776696106106/12/2024Election of ten directors for a one-year term: Irene M. EstevesDIRECTOR ELECTIONSISSUER867424.0000000FOR867424.000000FORS000002106Roper Technologies, Inc.776696106US776696106106/12/2024Election of ten directors for a one-year term: L. Neil HunnDIRECTOR ELECTIONSISSUER867424.0000000FOR867424.000000FORS000002106Roper Technologies, Inc.776696106US776696106106/12/2024Election of ten directors for a one-year term: Robert D. JohnsonDIRECTOR ELECTIONSISSUER867424.0000000FOR867424.000000FORS000002106Roper Technologies, Inc.776696106US776696106106/12/2024Election of ten directors for a one-year term: Thomas P. Joyce, Jr.DIRECTOR ELECTIONSISSUER867424.0000000FOR867424.000000FORS000002106Roper Technologies, Inc.776696106US776696106106/12/2024Election of ten directors for a one-year term: John F. MurphyDIRECTOR ELECTIONSISSUER867424.0000000FOR867424.000000FORS000002106Roper Technologies, Inc.776696106US776696106106/12/2024Election of ten directors for a one-year term: Laura G. ThatcherDIRECTOR ELECTIONSISSUER867424.0000000FOR867424.000000FORS000002106Roper Technologies, Inc.776696106US776696106106/12/2024Election of ten directors for a one-year term: Richard F. WallmanDIRECTOR ELECTIONSISSUER867424.0000000FOR867424.000000FORS000002106Roper Technologies, Inc.776696106US776696106106/12/2024Election of ten directors for a one-year term: Christopher WrightDIRECTOR ELECTIONSISSUER867424.0000000FOR867424.000000FORS000002106Roper Technologies, Inc.776696106US776696106106/12/2024Advisory vote to approve the compensation of our named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER867424.0000000FOR867424.000000FORS000002106Roper Technologies, Inc.776696106US776696106106/12/2024Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2024;AUDIT-RELATEDISSUER867424.0000000FOR867424.000000FORS000002106Roper Technologies, Inc.776696106US776696106106/12/2024Shareholder proposal regarding majority voting requirements; andCORPORATE GOVERNANCESECURITY HOLDER867424.0000000FOR867424.000000NONES000002106Veeva Systems Inc.922475108US922475108406/12/2024To elect the following to serve as directors until the annual meeting to be held in 2025 or until their successors are duly elected and qualified: Tim CabralDIRECTOR ELECTIONSISSUER2308602.0000000FOR2308602.000000FORS000002106Veeva Systems Inc.922475108US922475108406/12/2024To elect the following to serve as directors until the annual meeting to be held in 2025 or until their successors are duly elected and qualified: Mark CargesDIRECTOR ELECTIONSISSUER2308602.0000000FOR2308602.000000FORS000002106Veeva Systems Inc.922475108US922475108406/12/2024To elect the following to serve as directors until the annual meeting to be held in 2025 or until their successors are duly elected and qualified: Peter P. GassnerDIRECTOR ELECTIONSISSUER2308602.0000000FOR2308602.000000FORS000002106Veeva Systems Inc.922475108US922475108406/12/2024To elect the following to serve as directors until the annual meeting to be held in 2025 or until their successors are duly elected and qualified: Mary Lynne HedleyDIRECTOR ELECTIONSISSUER2308602.0000000FOR2308602.000000FORS000002106Veeva Systems Inc.922475108US922475108406/12/2024To elect the following to serve as directors until the annual meeting to be held in 2025 or until their successors are duly elected and qualified: Priscilla HungDIRECTOR ELECTIONSISSUER2308602.0000000FOR2308602.000000FORS000002106Veeva Systems Inc.922475108US922475108406/12/2024To elect the following to serve as directors until the annual meeting to be held in 2025 or until their successors are duly elected and qualified: Tina HuntDIRECTOR ELECTIONSISSUER2308602.0000000FOR2308602.000000FORS000002106Veeva Systems Inc.922475108US922475108406/12/2024To elect the following to serve as directors until the annual meeting to be held in 2025 or until their successors are duly elected and qualified: Marshall MohrDIRECTOR ELECTIONSISSUER2308602.0000000FOR2308602.000000FORS000002106Veeva Systems Inc.922475108US922475108406/12/2024To elect the following to serve as directors until the annual meeting to be held in 2025 or until their successors are duly elected and qualified: Gordon RitterDIRECTOR ELECTIONSISSUER2308602.0000000FOR2308602.000000FORS000002106Veeva Systems Inc.922475108US922475108406/12/2024To elect the following to serve as directors until the annual meeting to be held in 2025 or until their successors are duly elected and qualified: Paul SekhriDIRECTOR ELECTIONSISSUER2308602.0000000AGAINST2308602.000000AGAINSTS000002106Veeva Systems Inc.922475108US922475108406/12/2024To elect the following to serve as directors until the annual meeting to be held in 2025 or until their successors are duly elected and qualified: Matthew J. WallachDIRECTOR ELECTIONSISSUER2308602.0000000AGAINST2308602.000000AGAINSTS000002106Veeva Systems Inc.922475108US922475108406/12/2024To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending January 31, 2025.AUDIT-RELATEDISSUER2308602.0000000FOR2308602.000000FORS000002106Veeva Systems Inc.922475108US922475108406/12/2024To approve an amendment and restatement of our Certificate of Incorporation to reflect the Delaware law provisions regarding officer exculpation.CORPORATE GOVERNANCEISSUER2308602.0000000FOR2308602.000000FORS000002106Veeva Systems Inc.922475108US922475108406/12/2024To hold an advisory (non-binding) vote to approve named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER2308602.0000000FOR2308602.000000FORS000002106Weatherford International plcG48833118IE00BLNN369106/12/2024Election of Directors: Benjamin C. Duster, IVDIRECTOR ELECTIONSISSUER4146288.0000000FOR4146288.000000FORS000002106Weatherford International plcG48833118IE00BLNN369106/12/2024Election of Directors: Neal P. GoldmanDIRECTOR ELECTIONSISSUER4146288.0000000FOR4146288.000000FORS000002106Weatherford International plcG48833118IE00BLNN369106/12/2024Election of Directors: Jacqueline C. MutschlerDIRECTOR ELECTIONSISSUER4146288.0000000FOR4146288.000000FORS000002106Weatherford International plcG48833118IE00BLNN369106/12/2024Election of Directors: Girishchandra K. SaligramDIRECTOR ELECTIONSISSUER4146288.0000000FOR4146288.000000FORS000002106Weatherford International plcG48833118IE00BLNN369106/12/2024Election of Directors: Charles M. SledgeDIRECTOR ELECTIONSISSUER4146288.0000000FOR4146288.000000FORS000002106Weatherford International plcG48833118IE00BLNN369106/12/2024To ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm and auditor for the financial year ending December 31, 2024 and KPMG Chartered Accountants, Dublin, as the Company's statutory auditor under Irish law to hold office until the close of the 2025 AGM, and to authorize the Board of Directors of the Company, acting through the Audit Committee, to determine the auditors' remuneration.AUDIT-RELATEDISSUER4146288.0000000FOR4146288.000000FORS000002106Weatherford International plcG48833118IE00BLNN369106/12/2024To approve, on a non-binding advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER4146288.0000000FOR4146288.000000FORS000002106Weatherford International plcG48833118IE00BLNN369106/12/2024To grant the Board authority to issue shares under Irish law.CAPITAL STRUCTUREISSUER4146288.0000000FOR4146288.000000FORS000002106Weatherford International plcG48833118IE00BLNN369106/12/2024To grant the Board the power to opt-out of statutory preemption rights under Irish law.CAPITAL STRUCTUREISSUER4146288.0000000FOR4146288.000000FORS000002106Avidity Biosciences, Inc.05370A108US05370A108806/13/2024To elect three directors to serve as Class I directors for a three-year term expiring at the 2027 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified: Carsten BoessDIRECTOR ELECTIONSISSUER3911225.0000000FOR3911225.000000FORS000002106Avidity Biosciences, Inc.05370A108US05370A108806/13/2024To elect three directors to serve as Class I directors for a three-year term expiring at the 2027 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified: Sarah BoyceDIRECTOR ELECTIONSISSUER3911225.0000000FOR3911225.000000FORS000002106Avidity Biosciences, Inc.05370A108US05370A108806/13/2024To elect three directors to serve as Class I directors for a three-year term expiring at the 2027 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified: Dr. Troy WilsonDIRECTOR ELECTIONSISSUER3911225.0000000WITHHOLD3911225.000000AGAINSTS000002106Avidity Biosciences, Inc.05370A108US05370A108806/13/2024To ratify the appointment of BDO USA, P.C. as our independent registered public accounting firm for the fiscal year ending December 31, 2024;AUDIT-RELATEDISSUER3911225.0000000FOR3911225.000000FORS000002106Avidity Biosciences, Inc.05370A108US05370A108806/13/2024To consider and vote upon, on an advisory basis, the compensation of our named executive officers as disclosed in the related proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission; andSECTION 14A SAY-ON-PAY VOTESISSUER3911225.0000000FOR3911225.000000FORS000002106Celldex Therapeutics, Inc.15117B202US15117B202506/13/2024Election of Directors: Karen L. ShoosDIRECTOR ELECTIONSISSUER761585.0000000FOR761585.000000FORS000002106Celldex Therapeutics, Inc.15117B202US15117B202506/13/2024Election of Directors: Anthony S. MarucciDIRECTOR ELECTIONSISSUER761585.0000000FOR761585.000000FORS000002106Celldex Therapeutics, Inc.15117B202US15117B202506/13/2024Election of Directors: Keith L. BrownlieDIRECTOR ELECTIONSISSUER761585.0000000FOR761585.000000FORS000002106Celldex Therapeutics, Inc.15117B202US15117B202506/13/2024Election of Directors: Cheryl L. CohenDIRECTOR ELECTIONSISSUER761585.0000000FOR761585.000000FORS000002106Celldex Therapeutics, Inc.15117B202US15117B202506/13/2024Election of Directors: Herbert J. ConradDIRECTOR ELECTIONSISSUER761585.0000000FOR761585.000000FORS000002106Celldex Therapeutics, Inc.15117B202US15117B202506/13/2024Election of Directors: Rita I. Jain, M.D.DIRECTOR ELECTIONSISSUER761585.0000000FOR761585.000000FORS000002106Celldex Therapeutics, Inc.15117B202US15117B202506/13/2024Election of Directors: James J. MarinoDIRECTOR ELECTIONSISSUER761585.0000000FOR761585.000000FORS000002106Celldex Therapeutics, Inc.15117B202US15117B202506/13/2024Election of Directors: Garry Neil, M.D.DIRECTOR ELECTIONSISSUER761585.0000000FOR761585.000000FORS000002106Celldex Therapeutics, Inc.15117B202US15117B202506/13/2024Election of Directors: Harry H. Penner, Jr.DIRECTOR ELECTIONSISSUER761585.0000000FOR761585.000000FORS000002106Celldex Therapeutics, Inc.15117B202US15117B202506/13/2024To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2024.AUDIT-RELATEDISSUER761585.0000000FOR761585.000000FORS000002106Celldex Therapeutics, Inc.15117B202US15117B202506/13/2024To approve an amendment to our 2021 Omnibus Equity Incentive Plan, including an increase in the number of shares reserved for issuance thereunder by 3,200,000 shares to 7,500,000 shares.COMPENSATIONISSUER761585.0000000FOR761585.000000FORS000002106Celldex Therapeutics, Inc.15117B202US15117B202506/13/2024To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in this Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER761585.0000000FOR761585.000000FORS000002106Entrada Therapeutics, Inc.29384C108US29384C108006/13/2024Election of Director: Gina ChapmanDIRECTOR ELECTIONSISSUER1763519.0000000FOR1763519.000000FORS000002106Entrada Therapeutics, Inc.29384C108US29384C108006/13/2024Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER1763519.0000000FOR1763519.000000FORS000002106Entrada Therapeutics, Inc.29384C108US29384C108006/13/2024Approval of an amendment to the Company's Fourth Amended and Restated Certificate of Incorporation to limit the liability of certain officers of the Company as permitted by Delaware law.CORPORATE GOVERNANCEISSUER1763519.0000000FOR1763519.000000FORS000002106Ingersoll Rand Inc.45687V106US45687V106106/13/2024Election of Directors: Vicente ReynalDIRECTOR ELECTIONSISSUER7343663.0000000FOR7343663.000000FORS000002106Ingersoll Rand Inc.45687V106US45687V106106/13/2024Election of Directors: William P. DonnellyDIRECTOR ELECTIONSISSUER7343663.0000000FOR7343663.000000FORS000002106Ingersoll Rand Inc.45687V106US45687V106106/13/2024Election of Directors: Kirk E. ArnoldDIRECTOR ELECTIONSISSUER7343663.0000000FOR7343663.000000FORS000002106Ingersoll Rand Inc.45687V106US45687V106106/13/2024Election of Directors: Gary D. ForseeDIRECTOR ELECTIONSISSUER7343663.0000000FOR7343663.000000FORS000002106Ingersoll Rand Inc.45687V106US45687V106106/13/2024Election of Directors: Jennifer HartsockDIRECTOR ELECTIONSISSUER7343663.0000000FOR7343663.000000FORS000002106Ingersoll Rand Inc.45687V106US45687V106106/13/2024Election of Directors: John HumphreyDIRECTOR ELECTIONSISSUER7343663.0000000FOR7343663.000000FORS000002106Ingersoll Rand Inc.45687V106US45687V106106/13/2024Election of Directors: Marc E. JonesDIRECTOR ELECTIONSISSUER7343663.0000000FOR7343663.000000FORS000002106Ingersoll Rand Inc.45687V106US45687V106106/13/2024Election of Directors: Julie A. SchertellDIRECTOR ELECTIONSISSUER7343663.0000000FOR7343663.000000FORS000002106Ingersoll Rand Inc.45687V106US45687V106106/13/2024Election of Directors: JoAnna A. SohovichDIRECTOR ELECTIONSISSUER7343663.0000000FOR7343663.000000FORS000002106Ingersoll Rand Inc.45687V106US45687V106106/13/2024Election of Directors: Mark P. StevensonDIRECTOR ELECTIONSISSUER7343663.0000000FOR7343663.000000FORS000002106Ingersoll Rand Inc.45687V106US45687V106106/13/2024Ratification of appointment of Deloitte & Touche LLP as our independent registered public accounting firm for 2024.AUDIT-RELATEDISSUER7343663.0000000FOR7343663.000000FORS000002106Ingersoll Rand Inc.45687V106US45687V106106/13/2024Non-binding vote to approve executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER7343663.0000000FOR7343663.000000FORS000002106Monolithic Power Systems, Inc.609839105US609839105406/13/2024Election of Directors: Eugen ElmigerDIRECTOR ELECTIONSISSUER499577.0000000WITHHOLD499577.000000AGAINSTS000002106Monolithic Power Systems, Inc.609839105US609839105406/13/2024Election of Directors: Eileen WynneDIRECTOR ELECTIONSISSUER499577.0000000WITHHOLD499577.000000AGAINSTS000002106Monolithic Power Systems, Inc.609839105US609839105406/13/2024Election of Directors: Jeff ZhouDIRECTOR ELECTIONSISSUER499577.0000000WITHHOLD499577.000000AGAINSTS000002106Monolithic Power Systems, Inc.609839105US609839105406/13/2024Ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2024.AUDIT-RELATEDISSUER499577.0000000FOR499577.000000FORS000002106Monolithic Power Systems, Inc.609839105US609839105406/13/2024Approve, on an advisory basis, the 2023 executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER499577.0000000FOR499577.000000FORS000002106Monolithic Power Systems, Inc.609839105US609839105406/13/2024Vote on a stockholder proposal to elect each director annually.SHAREHOLDER RIGHTS AND DEFENSESSECURITY HOLDER499577.0000000FOR499577.000000AGAINSTS000002106Pliant Therapeutics, Inc.729139105US729139105706/13/2024To elect three class III directors named in the proxy statement to our Board of Directors: Hoyoung Huh, M.D., Ph.D.DIRECTOR ELECTIONSISSUER2034418.0000000FOR2034418.000000FORS000002106Pliant Therapeutics, Inc.729139105US729139105706/13/2024To elect three class III directors named in the proxy statement to our Board of Directors: Darren Cline, MBADIRECTOR ELECTIONSISSUER2034418.0000000FOR2034418.000000FORS000002106Pliant Therapeutics, Inc.729139105US729139105706/13/2024To elect three class III directors named in the proxy statement to our Board of Directors: David Pyott, MA, MBADIRECTOR ELECTIONSISSUER2034418.0000000FOR2034418.000000FORS000002106Pliant Therapeutics, Inc.729139105US729139105706/13/2024To approve, by non-binding advisory vote, the resolution approving named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER2034418.0000000AGAINST2034418.000000AGAINSTS000002106Pliant Therapeutics, Inc.729139105US729139105706/13/2024To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.AUDIT-RELATEDISSUER2034418.0000000FOR2034418.000000FORS000002106Rocket Pharmaceuticals, Inc77313F106US77313F106606/13/2024Election of Directors: Elisabeth Bjork, M.D., Ph.D.DIRECTOR ELECTIONSISSUER1014464.0000000FOR1014464.000000FORS000002106Rocket Pharmaceuticals, Inc77313F106US77313F106606/13/2024Election of Directors: Carsten BoessDIRECTOR ELECTIONSISSUER1014464.0000000FOR1014464.000000FORS000002106Rocket Pharmaceuticals, Inc77313F106US77313F106606/13/2024Election of Directors: Pedro GranadilloDIRECTOR ELECTIONSISSUER1014464.0000000FOR1014464.000000FORS000002106Rocket Pharmaceuticals, Inc77313F106US77313F106606/13/2024Election of Directors: Gotham Makker, M.D.DIRECTOR ELECTIONSISSUER1014464.0000000FOR1014464.000000FORS000002106Rocket Pharmaceuticals, Inc77313F106US77313F106606/13/2024Election of Directors: Fady Malik, M.D., Ph.D.DIRECTOR ELECTIONSISSUER1014464.0000000FOR1014464.000000FORS000002106Rocket Pharmaceuticals, Inc77313F106US77313F106606/13/2024Election of Directors: Gaurav Shah, M.D.DIRECTOR ELECTIONSISSUER1014464.0000000FOR1014464.000000FORS000002106Rocket Pharmaceuticals, Inc77313F106US77313F106606/13/2024Election of Directors: David P. SouthwellDIRECTOR ELECTIONSISSUER1014464.0000000FOR1014464.000000FORS000002106Rocket Pharmaceuticals, Inc77313F106US77313F106606/13/2024Election of Directors: Roderick Wong, M.D.DIRECTOR ELECTIONSISSUER1014464.0000000FOR1014464.000000FORS000002106Rocket Pharmaceuticals, Inc77313F106US77313F106606/13/2024Election of Directors: R. Keith WoodsDIRECTOR ELECTIONSISSUER1014464.0000000FOR1014464.000000FORS000002106Rocket Pharmaceuticals, Inc77313F106US77313F106606/13/2024Election of Directors: Naveen Yalamanchi, M.D.DIRECTOR ELECTIONSISSUER1014464.0000000FOR1014464.000000FORS000002106Rocket Pharmaceuticals, Inc77313F106US77313F106606/13/2024Ratification of the appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER1014464.0000000FOR1014464.000000FORS000002106Rocket Pharmaceuticals, Inc77313F106US77313F106606/13/2024Approval of the compensation of the Company's named executive officers, on a non-binding, advisory basis.SECTION 14A SAY-ON-PAY VOTESISSUER1014464.0000000FOR1014464.000000FORS000002106Rocket Pharmaceuticals, Inc77313F106US77313F106606/13/2024Approval of an amendment to the Company's Seventh Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock.CAPITAL STRUCTUREISSUER1014464.0000000FOR1014464.000000FORS000002106The Descartes Systems Group Inc.249906108CA249906108306/13/2024Elect Director Deepak ChopraDIRECTOR ELECTIONSISSUER3043647.0000000FOR3043647.000000FORS000002106The Descartes Systems Group Inc.249906108CA249906108306/13/2024Elect Director Deborah CloseDIRECTOR ELECTIONSISSUER3043647.0000000FOR3043647.000000FORS000002106The Descartes Systems Group Inc.249906108CA249906108306/13/2024Elect Director Eric A. DemirianDIRECTOR ELECTIONSISSUER3043647.0000000FOR3043647.000000FORS000002106The Descartes Systems Group Inc.249906108CA249906108306/13/2024Elect Director Sandra HaningtonDIRECTOR ELECTIONSISSUER3043647.0000000FOR3043647.000000FORS000002106The Descartes Systems Group Inc.249906108CA249906108306/13/2024Elect Director Kelley IrwinDIRECTOR ELECTIONSISSUER3043647.0000000FOR3043647.000000FORS000002106The Descartes Systems Group Inc.249906108CA249906108306/13/2024Elect Director Dennis MapleDIRECTOR ELECTIONSISSUER3043647.0000000FOR3043647.000000FORS000002106The Descartes Systems Group Inc.249906108CA249906108306/13/2024Elect Director Chris MuntwylerDIRECTOR ELECTIONSISSUER3043647.0000000FOR3043647.000000FORS000002106The Descartes Systems Group Inc.249906108CA249906108306/13/2024Elect Director Jane O'HaganDIRECTOR ELECTIONSISSUER3043647.0000000FOR3043647.000000FORS000002106The Descartes Systems Group Inc.249906108CA249906108306/13/2024Elect Director Edward J. RyanDIRECTOR ELECTIONSISSUER3043647.0000000FOR3043647.000000FORS000002106The Descartes Systems Group Inc.249906108CA249906108306/13/2024Elect Director John J. WalkerDIRECTOR ELECTIONSISSUER3043647.0000000FOR3043647.000000FORS000002106The Descartes Systems Group Inc.249906108CA249906108306/13/2024Ratify KPMG LLP as AuditorsAUDIT-RELATEDISSUER3043647.0000000FOR3043647.000000FORS000002106The Descartes Systems Group Inc.249906108CA249906108306/13/2024Amend Performance and Restricted Share Unit PlanCOMPENSATIONISSUER3043647.0000000FOR3043647.000000FORS000002106The Descartes Systems Group Inc.249906108CA249906108306/13/2024Advisory Vote on Executive Compensation ApproachCOMPENSATIONISSUER3043647.0000000FOR3043647.000000FORS000002106Xencor, Inc.98401F105US98401F105706/13/2024To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Dr. Bassil I. DahiyatDIRECTOR ELECTIONSISSUER1523315.0000000FOR1523315.000000FORS000002106Xencor, Inc.98401F105US98401F105706/13/2024To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Dr. Ellen G. FeigalDIRECTOR ELECTIONSISSUER1523315.0000000FOR1523315.000000FORS000002106Xencor, Inc.98401F105US98401F105706/13/2024To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Dr. Kevin C. GormanDIRECTOR ELECTIONSISSUER1523315.0000000FOR1523315.000000FORS000002106Xencor, Inc.98401F105US98401F105706/13/2024To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Mr. Kurt A. GustafsonDIRECTOR ELECTIONSISSUER1523315.0000000FOR1523315.000000FORS000002106Xencor, Inc.98401F105US98401F105706/13/2024To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Dr. Barbara KlenckeDIRECTOR ELECTIONSISSUER1523315.0000000FOR1523315.000000FORS000002106Xencor, Inc.98401F105US98401F105706/13/2024To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Dr. A. Bruce MontgomeryDIRECTOR ELECTIONSISSUER1523315.0000000FOR1523315.000000FORS000002106Xencor, Inc.98401F105US98401F105706/13/2024To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Mr. Richard J. RanieriDIRECTOR ELECTIONSISSUER1523315.0000000FOR1523315.000000FORS000002106Xencor, Inc.98401F105US98401F105706/13/2024To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Ms. Dagmar Rosa-BjorkesonDIRECTOR ELECTIONSISSUER1523315.0000000FOR1523315.000000FORS000002106Xencor, Inc.98401F105US98401F105706/13/2024To ratify the selection by the Audit Committee of the Board of Directors of RSM US LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024;AUDIT-RELATEDISSUER1523315.0000000FOR1523315.000000FORS000002106Xencor, Inc.98401F105US98401F105706/13/2024To approve, by non-binding advisory vote, the compensation of the Company's named executive officers, as disclosed in the accompanying Proxy Statement; andSECTION 14A SAY-ON-PAY VOTESISSUER1523315.0000000FOR1523315.000000FORS000002106APi Group Corporation00187Y100US00187Y100106/14/2024To elect nine directors for a one-year term expiring at the 2025 Annual Meeting of Shareholders: Sir Martin E. FranklinDIRECTOR ELECTIONSISSUER752800.0000000FOR752800.000000FORS000002106APi Group Corporation00187Y100US00187Y100106/14/2024To elect nine directors for a one-year term expiring at the 2025 Annual Meeting of Shareholders: James E. LillieDIRECTOR ELECTIONSISSUER752800.0000000FOR752800.000000FORS000002106APi Group Corporation00187Y100US00187Y100106/14/2024To elect nine directors for a one-year term expiring at the 2025 Annual Meeting of Shareholders: Ian G.H. AshkenDIRECTOR ELECTIONSISSUER752800.0000000FOR752800.000000FORS000002106APi Group Corporation00187Y100US00187Y100106/14/2024To elect nine directors for a one-year term expiring at the 2025 Annual Meeting of Shareholders: Russell A. BeckerDIRECTOR ELECTIONSISSUER752800.0000000FOR752800.000000FORS000002106APi Group Corporation00187Y100US00187Y100106/14/2024To elect nine directors for a one-year term expiring at the 2025 Annual Meeting of Shareholders: Paula D. LoopDIRECTOR ELECTIONSISSUER752800.0000000FOR752800.000000FORS000002106APi Group Corporation00187Y100US00187Y100106/14/2024To elect nine directors for a one-year term expiring at the 2025 Annual Meeting of Shareholders: Anthony E. MalkinDIRECTOR ELECTIONSISSUER752800.0000000FOR752800.000000FORS000002106APi Group Corporation00187Y100US00187Y100106/14/2024To elect nine directors for a one-year term expiring at the 2025 Annual Meeting of Shareholders: Thomas V. MilroyDIRECTOR ELECTIONSISSUER752800.0000000FOR752800.000000FORS000002106APi Group Corporation00187Y100US00187Y100106/14/2024To elect nine directors for a one-year term expiring at the 2025 Annual Meeting of Shareholders: Cyrus D. WalkerDIRECTOR ELECTIONSISSUER752800.0000000FOR752800.000000FORS000002106APi Group Corporation00187Y100US00187Y100106/14/2024To elect nine directors for a one-year term expiring at the 2025 Annual Meeting of Shareholders: Carrie A. WheelerDIRECTOR ELECTIONSISSUER752800.0000000FOR752800.000000FORS000002106APi Group Corporation00187Y100US00187Y100106/14/2024To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the 2024 fiscal year.AUDIT-RELATEDISSUER752800.0000000FOR752800.000000FORS000002106APi Group Corporation00187Y100US00187Y100106/14/2024To approve, on an advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER752800.0000000FOR752800.000000FORS000002106Intra-Cellular Therapies, Inc.46116X101US46116X101906/14/2024To elect one director to serve a three-year term expiring in 2027: Joel S. MarcusDIRECTOR ELECTIONSISSUER616698.0000000FOR616698.000000FORS000002106Intra-Cellular Therapies, Inc.46116X101US46116X101906/14/2024To approve the amendment and restatement of the Company's Amended and Restated 2018 Equity Incentive Plan.COMPENSATIONISSUER616698.0000000FOR616698.000000FORS000002106Intra-Cellular Therapies, Inc.46116X101US46116X101906/14/2024To ratify of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER616698.0000000FOR616698.000000FORS000002106Intra-Cellular Therapies, Inc.46116X101US46116X101906/14/2024To approve by an advisory vote the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER616698.0000000FOR616698.000000FORS000002106Kymera Therapeutics, Inc.501575104US501575104406/18/2024To elect three class I directors to our Board of Directors, to serve until the 2027 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Pamela Esposito, Ph.D.DIRECTOR ELECTIONSISSUER2986850.0000000FOR2986850.000000FORS000002106Kymera Therapeutics, Inc.501575104US501575104406/18/2024To elect three class I directors to our Board of Directors, to serve until the 2027 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Gorjan Hrustanovic, Ph.D.DIRECTOR ELECTIONSISSUER2986850.0000000FOR2986850.000000FORS000002106Kymera Therapeutics, Inc.501575104US501575104406/18/2024To elect three class I directors to our Board of Directors, to serve until the 2027 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Victor Sandor, M.D.C.M.DIRECTOR ELECTIONSISSUER2986850.0000000FOR2986850.000000FORS000002106Kymera Therapeutics, Inc.501575104US501575104406/18/2024To approve, on a non-binding advisory basis, the compensation of our named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER2986850.0000000FOR2986850.000000FORS000002106Kymera Therapeutics, Inc.501575104US501575104406/18/2024To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024; andAUDIT-RELATEDISSUER2986850.0000000FOR2986850.000000FORS000002106Kymera Therapeutics, Inc.501575104US501575104406/18/2024To approve an amendment to the Kymera Therapeutics, Inc. 2020 Stock Option and Incentive Plan.COMPENSATIONISSUER2986850.0000000AGAINST2986850.000000AGAINSTS000002106Rivian Automotive, Inc.76954A103US76954A103406/18/2024Election of Class III Directors to serve until the 2027 Annual Meeting of Stockholders: Jay FlatleyDIRECTOR ELECTIONSISSUER3443296.0000000FOR3443296.000000FORS000002106Rivian Automotive, Inc.76954A103US76954A103406/18/2024Election of Class III Directors to serve until the 2027 Annual Meeting of Stockholders: John KrafcikDIRECTOR ELECTIONSISSUER3443296.0000000FOR3443296.000000FORS000002106Rivian Automotive, Inc.76954A103US76954A103406/18/2024Ratification of the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER3443296.0000000FOR3443296.000000FORS000002106Rivian Automotive, Inc.76954A103US76954A103406/18/2024Approval, on an advisory (non-binding) basis, of the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER3443296.0000000FOR3443296.000000FORS000002106Ultragenyx Pharmaceutical Inc.90400D108US90400D108106/18/2024Nominees: Deborah Dunsire, M.D.DIRECTOR ELECTIONSISSUER944542.0000000WITHHOLD944542.000000AGAINSTS000002106Ultragenyx Pharmaceutical Inc.90400D108US90400D108106/18/2024Nominees: Michael NarachiDIRECTOR ELECTIONSISSUER944542.0000000WITHHOLD944542.000000AGAINSTS000002106Ultragenyx Pharmaceutical Inc.90400D108US90400D108106/18/2024Nominees: Corsee D. Sanders, Ph.D.DIRECTOR ELECTIONSISSUER944542.0000000WITHHOLD944542.000000AGAINSTS000002106Ultragenyx Pharmaceutical Inc.90400D108US90400D108106/18/2024Approval of the Amended and Restated 2023 Incentive Plan.COMPENSATIONISSUER944542.0000000FOR944542.000000FORS000002106Ultragenyx Pharmaceutical Inc.90400D108US90400D108106/18/2024Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER944542.0000000FOR944542.000000FORS000002106Ultragenyx Pharmaceutical Inc.90400D108US90400D108106/18/2024Advisory (non-binding) vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER944542.0000000FOR944542.000000FORS000002106Xometry, Inc.98423F109US98423F109306/18/2024Election of Directors: Ranjana ClarkDIRECTOR ELECTIONSISSUER1688962.0000000FOR1688962.000000FORS000002106Xometry, Inc.98423F109US98423F109306/18/2024Election of Directors: Emily RollinsDIRECTOR ELECTIONSISSUER1688962.0000000FOR1688962.000000FORS000002106Xometry, Inc.98423F109US98423F109306/18/2024To approve, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER1688962.0000000FOR1688962.000000FORS000002106Xometry, Inc.98423F109US98423F109306/18/2024To ratify the selection of KPMG, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER1688962.0000000FOR1688962.000000FORS000002106Agios Pharmaceuticals, Inc.00847X104US00847X104606/20/2024To elect each of the four Class II director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: Kaye FosterDIRECTOR ELECTIONSISSUER484995.0000000WITHHOLD484995.000000AGAINSTS000002106Agios Pharmaceuticals, Inc.00847X104US00847X104606/20/2024To elect each of the four Class II director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: Maykin Ho, Ph.D.DIRECTOR ELECTIONSISSUER484995.0000000WITHHOLD484995.000000AGAINSTS000002106Agios Pharmaceuticals, Inc.00847X104US00847X104606/20/2024To elect each of the four Class II director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: Jeffrey CapelloDIRECTOR ELECTIONSISSUER484995.0000000WITHHOLD484995.000000AGAINSTS000002106Agios Pharmaceuticals, Inc.00847X104US00847X104606/20/2024To elect each of the four Class II director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: Catherine OwenDIRECTOR ELECTIONSISSUER484995.0000000WITHHOLD484995.000000AGAINSTS000002106Agios Pharmaceuticals, Inc.00847X104US00847X104606/20/2024To vote, on an advisory basis, to approve the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER484995.0000000FOR484995.000000FORS000002106Agios Pharmaceuticals, Inc.00847X104US00847X104606/20/2024To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER484995.0000000FOR484995.000000FORS000002106C4 Therapeutics, Inc.12529R107US12529R107706/20/2024To elect three Class I directors to our Board of Directors, each to serve until the 2027 Annual Meeting of Stockholders and until his/her successor has been duly elected and qualified, or until his/her earlier resignation or removal: Kenneth Anderson, M.D.DIRECTOR ELECTIONSISSUER1163937.0000000WITHHOLD1163937.000000AGAINSTS000002106C4 Therapeutics, Inc.12529R107US12529R107706/20/2024To elect three Class I directors to our Board of Directors, each to serve until the 2027 Annual Meeting of Stockholders and until his/her successor has been duly elected and qualified, or until his/her earlier resignation or removal: Laura Bessen, M.D.DIRECTOR ELECTIONSISSUER1163937.0000000WITHHOLD1163937.000000AGAINSTS000002106C4 Therapeutics, Inc.12529R107US12529R107706/20/2024To elect three Class I directors to our Board of Directors, each to serve until the 2027 Annual Meeting of Stockholders and until his/her successor has been duly elected and qualified, or until his/her earlier resignation or removal: Owen HughesDIRECTOR ELECTIONSISSUER1163937.0000000WITHHOLD1163937.000000AGAINSTS000002106C4 Therapeutics, Inc.12529R107US12529R107706/20/2024To cast a non-binding, advisory vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1163937.0000000AGAINST1163937.000000AGAINSTS000002106C4 Therapeutics, Inc.12529R107US12529R107706/20/2024To ratify the engagement of KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2024.AUDIT-RELATEDISSUER1163937.0000000FOR1163937.000000FORS000002106Cava Group, Inc.148929102US148929102106/20/2024Election of Class I Directors: Philippe AmouyalDIRECTOR ELECTIONSISSUER2056280.0000000FOR2056280.000000FORS000002106Cava Group, Inc.148929102US148929102106/20/2024Election of Class I Directors: David BossermanDIRECTOR ELECTIONSISSUER2056280.0000000FOR2056280.000000FORS000002106Cava Group, Inc.148929102US148929102106/20/2024Election of Class I Directors: Lauri ShanahanDIRECTOR ELECTIONSISSUER2056280.0000000FOR2056280.000000FORS000002106Cava Group, Inc.148929102US148929102106/20/2024Approval of an amendment and restatement of the CAVA Group, Inc. 2023 Equity Incentive Plan.COMPENSATIONISSUER2056280.0000000AGAINST2056280.000000AGAINSTS000002106Cava Group, Inc.148929102US148929102106/20/2024Ratification of the appointment of Deloitte & Touche LLP as independent registered accounting firm for fiscal year 2024.AUDIT-RELATEDISSUER2056280.0000000FOR2056280.000000FORS000002106EyePoint Pharmaceuticals, Inc.30233G209US30233G209306/20/2024Election of Directors: Goran Ando, M.D.DIRECTOR ELECTIONSISSUER1278824.0000000FOR1278824.000000FORS000002106EyePoint Pharmaceuticals, Inc.30233G209US30233G209306/20/2024Election of Directors: Jay S. Duker, M.D.DIRECTOR ELECTIONSISSUER1278824.0000000FOR1278824.000000FORS000002106EyePoint Pharmaceuticals, Inc.30233G209US30233G209306/20/2024Election of Directors: Nancy LurkerDIRECTOR ELECTIONSISSUER1278824.0000000FOR1278824.000000FORS000002106EyePoint Pharmaceuticals, Inc.30233G209US30233G209306/20/2024Election of Directors: John B. Landis, Ph.D.DIRECTOR ELECTIONSISSUER1278824.0000000FOR1278824.000000FORS000002106EyePoint Pharmaceuticals, Inc.30233G209US30233G209306/20/2024Election of Directors: David Guyer, M.D.DIRECTOR ELECTIONSISSUER1278824.0000000FOR1278824.000000FORS000002106EyePoint Pharmaceuticals, Inc.30233G209US30233G209306/20/2024Election of Directors: Wendy DiCiccoDIRECTOR ELECTIONSISSUER1278824.0000000FOR1278824.000000FORS000002106EyePoint Pharmaceuticals, Inc.30233G209US30233G209306/20/2024Election of Directors: Anthony P. Adamis, M.D.DIRECTOR ELECTIONSISSUER1278824.0000000FOR1278824.000000FORS000002106EyePoint Pharmaceuticals, Inc.30233G209US30233G209306/20/2024Election of Directors: Karen ZaderejDIRECTOR ELECTIONSISSUER1278824.0000000FOR1278824.000000FORS000002106EyePoint Pharmaceuticals, Inc.30233G209US30233G209306/20/2024Election of Directors: Stuart DutyDIRECTOR ELECTIONSISSUER1278824.0000000FOR1278824.000000FORS000002106EyePoint Pharmaceuticals, Inc.30233G209US30233G209306/20/2024To approve an amendment to the EyePoint Pharmaceuticals, Inc. 2023 Long-Term Incentive Plan to (i) increase the number of shares of common stock authorized for issuance thereunder by 4,000,000 shares and (ii) increase the individual non-employee director compensation limit contained therein to $850,000 for ongoing directors in any calendar year and $1,100,000 for new directors in any calendar year.COMPENSATIONISSUER1278824.0000000AGAINST1278824.000000AGAINSTS000002106EyePoint Pharmaceuticals, Inc.30233G209US30233G209306/20/2024To approve an amendment to the EyePoint Pharmaceuticals, Inc. 2019 Employee Stock Purchase Plan to increase the number of shares of common stock authorized for issuance thereunder by 250,000 shares.COMPENSATIONISSUER1278824.0000000FOR1278824.000000FORS000002106EyePoint Pharmaceuticals, Inc.30233G209US30233G209306/20/2024To approve, on an advisory basis, the compensation paid to the Company's named executive officers as disclosed in the accompanying proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER1278824.0000000FOR1278824.000000FORS000002106EyePoint Pharmaceuticals, Inc.30233G209US30233G209306/20/2024To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER1278824.0000000FOR1278824.000000FORS000002106Immatics N.V.N44445109NL001528594106/20/2024Adopt Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER1005689.0000000FOR1005689.000000FORS000002106Immatics N.V.N44445109NL001528594106/20/2024Approve Discharge of DirectorsCORPORATE GOVERNANCEISSUER1005689.0000000FOR1005689.000000FORS000002106Immatics N.V.N44445109NL001528594106/20/2024Reelect M.G. Atieh as Non-Executive Director Class IDIRECTOR ELECTIONSISSUER1005689.0000000FOR1005689.000000FORS000002106Immatics N.V.N44445109NL001528594106/20/2024Reelect P.R. Carter as Non-Executive Director Class IDIRECTOR ELECTIONSISSUER1005689.0000000FOR1005689.000000FORS000002106Immatics N.V.N44445109NL001528594106/20/2024Elect E.R. Forster as Non-Executive Director Class IDIRECTOR ELECTIONSISSUER1005689.0000000AGAINST1005689.000000AGAINSTS000002106Immatics N.V.N44445109NL001528594106/20/2024Grant Board Authority to Issue Shares or to Grant Rights to Subscribe for Ordinary SharesCAPITAL STRUCTUREISSUER1005689.0000000AGAINST1005689.000000AGAINSTS000002106Immatics N.V.N44445109NL001528594106/20/2024Authorize Board to Exclude Preemptive Rights from Share IssuancesCAPITAL STRUCTUREISSUER1005689.0000000AGAINST1005689.000000AGAINSTS000002106Immatics N.V.N44445109NL001528594106/20/2024Authorize Repurchase of Ordinary Shares or Depositary ReceiptsCAPITAL STRUCTUREISSUER1005689.0000000FOR1005689.000000FORS000002106Immatics N.V.N44445109NL001528594106/20/2024Approve 2024 Stock Option and Incentive PlanCOMPENSATIONISSUER1005689.0000000AGAINST1005689.000000AGAINSTS000002106Immatics N.V.N44445109NL001528594106/20/2024Ratify PricewaterhouseCoopers Accountants N.V. as AuditorsAUDIT-RELATEDISSUER1005689.0000000FOR1005689.000000FORS000002106Revolution Medicines, Inc.76155X100US76155X100006/20/2024To elect three Class I directors to hold office until the 2027 Annual Meeting of Stockholders or until his or her successor is elected: Elizabeth McKee AndersonDIRECTOR ELECTIONSISSUER1836025.0000000WITHHOLD1836025.000000AGAINSTS000002106Revolution Medicines, Inc.76155X100US76155X100006/20/2024To elect three Class I directors to hold office until the 2027 Annual Meeting of Stockholders or until his or her successor is elected: Flavia Borellini, Ph.D.DIRECTOR ELECTIONSISSUER1836025.0000000WITHHOLD1836025.000000AGAINSTS000002106Revolution Medicines, Inc.76155X100US76155X100006/20/2024To elect three Class I directors to hold office until the 2027 Annual Meeting of Stockholders or until his or her successor is elected: Lorence Kim, M.D.DIRECTOR ELECTIONSISSUER1836025.0000000WITHHOLD1836025.000000AGAINSTS000002106Revolution Medicines, Inc.76155X100US76155X100006/20/2024To ratify the appointment, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024; andAUDIT-RELATEDISSUER1836025.0000000FOR1836025.000000FORS000002106Revolution Medicines, Inc.76155X100US76155X100006/20/2024To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay").SECTION 14A SAY-ON-PAY VOTESISSUER1836025.0000000FOR1836025.000000FORS000002106Zentalis Pharmaceuticals, Inc.98943L107US98943L107006/21/2024Election of Class I Directors to serve until the 2027 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified, subject to their earlier death, resignation or removal: Kimberly Blackwell, M.D.DIRECTOR ELECTIONSISSUER1256308.0000000FOR1256308.000000FORS000002106Zentalis Pharmaceuticals, Inc.98943L107US98943L107006/21/2024Election of Class I Directors to serve until the 2027 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified, subject to their earlier death, resignation or removal: Enoch Kariuki, Pharm.D.DIRECTOR ELECTIONSISSUER1256308.0000000FOR1256308.000000FORS000002106Zentalis Pharmaceuticals, Inc.98943L107US98943L107006/21/2024To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER1256308.0000000FOR1256308.000000FORS000002106Zentalis Pharmaceuticals, Inc.98943L107US98943L107006/21/2024To approve, on an advisory (non-binding) basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1256308.0000000AGAINST1256308.000000AGAINSTS000002106Centessa Pharmaceuticals Plc152309100US152309100706/25/2024To re-appoint as a director, Francesco De Rubertis, Ph.D., who retires by rotation in accordance with the Company's articles of associationDIRECTOR ELECTIONSISSUER883799.0000000FOR883799.000000FORS000002106Centessa Pharmaceuticals Plc152309100US152309100706/25/2024To re-appoint as a director, Saurabh Saha, M.D., Ph.D., who retires by rotation in accordance with the Company's articles of associationDIRECTOR ELECTIONSISSUER883799.0000000FOR883799.000000FORS000002106Centessa Pharmaceuticals Plc152309100US152309100706/25/2024To re-appoint as a director, Mary Lynne Hedley, Ph.D., who retires by rotation in accordance with the Company's articles of associationDIRECTOR ELECTIONSISSUER883799.0000000FOR883799.000000FORS000002106Centessa Pharmaceuticals Plc152309100US152309100706/25/2024To re-appoint KPMG LLP, a United Kingdom entity, as U.K. statutory auditors of the Company, to hold office until the conclusion of the next meeting at which the Company's annual accounts and reports are laid before the CompanyAUDIT-RELATEDISSUER883799.0000000FOR883799.000000FORS000002106Centessa Pharmaceuticals Plc152309100US152309100706/25/2024To ratify the re-appointment of KPMG LLP, a Delaware limited liability partnership, as the Company's independent registered public accounting firm, for the financial year ending December 31, 2024AUDIT-RELATEDISSUER883799.0000000FOR883799.000000FORS000002106Centessa Pharmaceuticals Plc152309100US152309100706/25/2024To authorize the Audit Committee to determine the Company's auditors' remuneration for the financial year ending December 31, 2024AUDIT-RELATEDISSUER883799.0000000FOR883799.000000FORS000002106Centessa Pharmaceuticals Plc152309100US152309100706/25/2024To receive and adopt our U.K. statutory annual accounts and reports for the financial year ended December 31, 2023 and to note that the Company's directors do not recommend the payment of any dividend for the financial year ended December 31, 2023CORPORATE GOVERNANCEISSUER883799.0000000FOR883799.000000FORS000002106Centessa Pharmaceuticals Plc152309100US152309100706/25/2024To receive and approve on an advisory basis the Company's U.K. statutory directors' remuneration report for the financial year ended December 31, 2023, which is set forth as Annex A to the attached proxy statementCOMPENSATIONISSUER883799.0000000FOR883799.000000FORS000002106Centessa Pharmaceuticals Plc152309100US152309100706/25/2024To authorize the directors of the Company, generally and unconditionally for the purpose of section 551 of the U.K. Companies Act 2006 (the "Act"), to allot shares in the Company or to grant rights to subscribe for or to convert any security into shares in the Company up to a maximum aggregate nominal amount of pounds100,740.CAPITAL STRUCTUREISSUER883799.0000000FOR883799.000000FORS000002106Centessa Pharmaceuticals Plc152309100US152309100706/25/2024Subject to the passing of Resolution 9, to empower the Board of Directors to allot equity securities for cash, under section 570 of the Act as if section 561(1) of the Act did not apply to such allotment up to a maximum aggregate nominal amount of pounds100,740.CAPITAL STRUCTUREISSUER883799.0000000AGAINST883799.000000AGAINSTS000002106Madrigal Pharmaceuticals, Inc.558868105US558868105706/25/2024Re-election of Class II directors: Bill SiboldDIRECTOR ELECTIONSISSUER184949.0000000FOR184949.000000FORS000002106Madrigal Pharmaceuticals, Inc.558868105US558868105706/25/2024Re-election of Class II directors: Rebecca Taub, M.D.DIRECTOR ELECTIONSISSUER184949.0000000FOR184949.000000FORS000002106Madrigal Pharmaceuticals, Inc.558868105US558868105706/25/2024Re-election of Class II directors: Fred B. Craves, Ph.D.DIRECTOR ELECTIONSISSUER184949.0000000FOR184949.000000FORS000002106Madrigal Pharmaceuticals, Inc.558868105US558868105706/25/2024To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER184949.0000000FOR184949.000000FORS000002106Madrigal Pharmaceuticals, Inc.558868105US558868105706/25/2024Advisory vote to approve executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER184949.0000000FOR184949.000000FORS000002106Madrigal Pharmaceuticals, Inc.558868105US558868105706/25/2024To approve an amendment to the Madrigal Pharmaceuticals, Inc. 2015 Amended Stock Plan to increase the total number of shares of our common stock available for issuance by 750,000 shares and extend its duration by 10 years until April 23, 2035.COMPENSATIONISSUER184949.0000000FOR184949.000000FORS000002106MongoDB, Inc.60937P106US60937P106606/25/2024Election of three Class I directors, each to serve until our Annual Meeting of Stockholders in 2027: Roelof BothaDIRECTOR ELECTIONSISSUER466905.0000000FOR466905.000000FORS000002106MongoDB, Inc.60937P106US60937P106606/25/2024Election of three Class I directors, each to serve until our Annual Meeting of Stockholders in 2027: Dev IttycheriaDIRECTOR ELECTIONSISSUER466905.0000000FOR466905.000000FORS000002106MongoDB, Inc.60937P106US60937P106606/25/2024Election of three Class I directors, each to serve until our Annual Meeting of Stockholders in 2027: Ann LewnesDIRECTOR ELECTIONSISSUER466905.0000000FOR466905.000000FORS000002106MongoDB, Inc.60937P106US60937P106606/25/2024Approval, on a non-binding advisory basis, of the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER466905.0000000FOR466905.000000FORS000002106MongoDB, Inc.60937P106US60937P106606/25/2024Ratification of the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending January 31, 2025.AUDIT-RELATEDISSUER466905.0000000FOR466905.000000FORS000002106Structure Therapeutics Inc.86366E106US86366E106406/25/2024Election of the nominee for Class I director named below to serve until the 2027 annual general meeting of shareholders and until her successor is duly elected and qualified, or until her earlier death, resignation or removal: Sharon TetlowDIRECTOR ELECTIONSISSUER480535.0000000FOR480535.000000FORS000002106Structure Therapeutics Inc.86366E106US86366E106406/25/2024To ratify the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER480535.0000000FOR480535.000000FORS000002106Scholar Rock Holding Corporation80706P103US80706P103006/27/2024To elect three Class III directors to our Board of Directors, each to serve until the 2027 Annual Meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation, or removal: Richard BrudnickDIRECTOR ELECTIONSISSUER3942029.0000000FOR3942029.000000FORS000002106Scholar Rock Holding Corporation80706P103US80706P103006/27/2024To elect three Class III directors to our Board of Directors, each to serve until the 2027 Annual Meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation, or removal: Jeffrey S. FlierDIRECTOR ELECTIONSISSUER3942029.0000000FOR3942029.000000FORS000002106Scholar Rock Holding Corporation80706P103US80706P103006/27/2024To elect three Class III directors to our Board of Directors, each to serve until the 2027 Annual Meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation, or removal: Akshay VaishnawDIRECTOR ELECTIONSISSUER3942029.0000000FOR3942029.000000FORS000002106Scholar Rock Holding Corporation80706P103US80706P103006/27/2024To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER3942029.0000000FOR3942029.000000FORS000002106Scholar Rock Holding Corporation80706P103US80706P103006/27/2024To approve an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended to date, to increase the number of authorized shares of common stock from 150,000,000 to 300,000,000.CAPITAL STRUCTUREISSUER3942029.0000000FOR3942029.000000FORS000002106Scholar Rock Holding Corporation80706P103US80706P103006/27/2024To approve an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended to date, to limit the liability of certain officers of the Company as permitted by recent amendments to Delaware law.CORPORATE GOVERNANCEISSUER3942029.0000000FOR3942029.000000FORS000002106Scholar Rock Holding Corporation80706P103US80706P103006/27/2024To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER3942029.0000000FOR3942029.000000FORS000002106Scholar Rock Holding Corporation80706P103US80706P103006/27/2024To approve, on a non-binding, advisory basis, the preferred frequency of future advisory votes on compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER3942029.0000000ONE YEAR3942029.000000FORS000002106Autolus Therapeutics Plc05280R100US05280R100506/28/2024Accept Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER2280916.0000000FOR2280916.000000FORS000002106Autolus Therapeutics Plc05280R100US05280R100506/28/2024Approve Remuneration ReportCOMPENSATIONISSUER2280916.0000000AGAINST2280916.000000AGAINSTS000002106Autolus Therapeutics Plc05280R100US05280R100506/28/2024Reappoint Ernst & Young LLP as Auditors and Authorise Their RemunerationAUDIT-RELATEDISSUER2280916.0000000FOR2280916.000000FORS000002106Autolus Therapeutics Plc05280R100US05280R100506/28/2024Elect Director Linda BainDIRECTOR ELECTIONSISSUER2280916.0000000FOR2280916.000000FORS000002106Autolus Therapeutics Plc05280R100US05280R100506/28/2024Elect Director Cynthia ButittaDIRECTOR ELECTIONSISSUER2280916.0000000FOR2280916.000000FORS000002106Autolus Therapeutics Plc05280R100US05280R100506/28/2024Elect Director Christian ItinDIRECTOR ELECTIONSISSUER2280916.0000000FOR2280916.000000FORS000002106Autolus Therapeutics Plc05280R100US05280R100506/28/2024Elect Director William YoungDIRECTOR ELECTIONSISSUER2280916.0000000FOR2280916.000000FORS000002106Autolus Therapeutics Plc05280R100US05280R100506/28/2024Authorise Issue of EquityCAPITAL STRUCTUREISSUER2280916.0000000FOR2280916.000000FORS000002106Autolus Therapeutics Plc05280R100US05280R100506/28/2024Authorise Issue of Equity without Pre-emptive RightsCAPITAL STRUCTUREISSUER2280916.0000000AGAINST2280916.000000AGAINSTS000002106